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Antibody-based therapeutics are a rapidly expanding class of biopharmaceuticals. The 
number of approved antibody-based therapeutics by the FDA and EMA has more than doubled 
in the last five years, and they are expanding into areas such as antibody-drug conjugates, Fc 
fusions, bispecific antibodies, and biosimilars. Most antibody-based therapeutics use the 
Immunoglobulin isotype G subclass 1 (IgG1) antibody. Some IgG1-based therapeutics obtain 
their therapeutic efficacy by modulating the immune system for the treatment of several disease-
types including cancer, autoimmune disease, and organ transplant rejection. This work further 
explores our understanding of IgG1-mediated immunomodulation by utilizing the fragment 
crystallizable (Fc) region of IgG1 in three research projects.  
In the first project, an IgG1 Fc fusion was prepared as a potential treatment for multiple 
sclerosis, an autoimmune disease that affects > 2.3 million people worldwide. This disease 
involves immune system attack and destruction of the myelin protein surrounding the neurons in 
the central nervous system. One promising class of compounds that selectively prevent the 
activation of immune cells involved in the destruction of myelin are Bifunctional Peptide 
Inhibitors (BPIs). In an effort to further improve the bioactivity of BPIs, the BPI peptides were 
conjugated to the termini of IgG1 Fc to prepare a BPI-Fc fusion. This fusion was tested in a 
mouse model of multiple sclerosis. Compared to the PBS-treated control, mice treated with the 
BPI-Fc fusion showed significantly reduced disease symptoms, did not experience weight loss, 
and showed reduced demyelination. These results demonstrated that the BPI peptides were 
highly active at suppressing the disease when prepared as an Fc fusion.  
In the second project, the N-glycosylation of IgG1 Fc was modified. The N-glycosylation 




immunogenicity. However, recombinant expression of IgG1 results in a mixture of N-
glycoforms. This heterogeneity makes it difficult to understand how N-glycosylation affects 
IgG1 because different N-glycoforms can affect the antibody differently. To solve this problem, 
this work utilized IgG1 Fc as a model system to prepare homogenous IgG1 Fc N-glycoforms, 
and their effects on IgG1 Fc were studied individually. In-vitro enzymatic synthesis was used to 
prepare homogenous oligomannose, hybrid, and complex N-glycoforms. The effect of each non-
fucosylated N-glycoform on IgG1 Fc stability was compared using differential scanning 
calorimetry. The results showed that the complex N-glycoform was more stable than the hybrid 
and oligomannose N-glycoforms. Additionally, the effect of each N-glycoform on IgG1 Fc 
function was compared in an in-vitro receptor-binding assay using FcγRIIIa, the receptor 
involved in activating Antibody-dependent Cellular Cytotoxicity (ADCC). Results showed that 
the binding affinity increased with increased N-glycan processing. Lastly, the hybrid and 
complex IgG1 Fc N-glycoforms were compared for their abilities to accept core-linked fucose. 
Results showed that the complex N-glycoform accepted fucose much more slowly compared to 
the hybrid N-glycoforms.  
In the third project, IgG1 Fc was assembled as a protein-polymer conjugate in order to 
increase its valency. Multivalent display of IgG1 is necessary in order to obtain an avidity effect 
strong enough to activate immune system effector functions, such as ADCC. IgG1 Fc-polymer 
conjugate was prepared using controlled polymerization to first synthesize a water soluble, linear 
poly(acrylamide-peptide) co-polymer. This co-polymer was then used as a scaffold onto which 
multiple IgG1 Fc proteins were site-specifically ligated. The IgG1 Fc-polymer conjugate was 
compared against IgG1 Fc in a receptor binding assay with FcgRIIIa. The results showed that the 




large increase in binding strength was caused by the multimer having a much slower dissociation 
rate.  
The research presented in this dissertation improves our fundamental understanding 
IgG1-mediated immunomodulation and may also help in the development of improved antibody- 
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1.1 Overview of the immune system 
The immune system protects the body from invading pathogens.1 It is roughly divided 
into two categories: innate and adaptive. Innate immunity is the initial response to an invading 
pathogen. Its response is very rapid (hours) because most of the active components are ready 
even before an infection. The mechanisms to clear a pathogen by innate immunity include 
phagocytosis and initiating an inflammatory response. The innate immune system recognizes 
broad classes of molecules such as non-human nucleic acid, glycan, and polypeptide sequences.2 
However, these features are not pathogen-specific, so not all pathogens are detected. On the 
other hand, the adaptive immune system is activated in response to a pathogen, so the response is 
slow (days). However, the response is extremely specific to the pathogens through the 
production of antigen-specific molecules called antibodies (i.e. Immunoglobulins (Ig)). Based on 
the possible genetic combinations that exist, there are theoretically >1011 different antibody 
specificities.3 With that breadth of diversity, antibodies can be tailored to almost any pathogen. 
Although there are differences between the innate and adaptive immune systems, they often 
function cooperativity to rid a pathogen from the body. 
 
1.2 Structure and function of the IgG1 antibody 
There are five isotypes of antibodies: IgA, IgD, IgE, IgG and IgM. Of all isotypes found 
in human serum, IgG accounts for about 80%.1 IgG is divided into 4 subclasses: IgG1, IgG2, 
IgG3, and IgG4. Their DNA sequences are 90-95% homologous but vary in several properties 
including half-life, ability to activate immune system effector functions, and ability cross the 




IgG1 is a Y-shaped structure that is ~150 kDa in size (Figure 1.1A). It is a hetero-
tetramer consisting of two conserved light chains and two conserved heavy chains.5 Each heavy-
light chain pairing are connected by a disulfide bond. The two heavy chains are held together by 
two inter-chain disulfide bonds in the hinge as well as though non-covalent interactions in the 
CH3 domain. In total, IgG1 contains 12 Ig domains that consist of two b-sheet 2º structures that 
are connected by a disulfide bond.6 Furthermore, there are two main regions of the antibody that 
are divided by the hinge. These regions are the fragment antigen binding (Fab) and the fragment 
crystallizable (Fc). They have different functions (Figure 1.1B): The Fab region contains 
complementarity-determining regions (CDR) that recognizes a particular antigen. There are 
billions of possible CDR sequences, which gives IgG1 its extreme specificity.1 The Fc region 
gives IgG1 its biological activity by binding to Fcg receptors (FcgRs). Additionally, IgG1 is a 
glycoprotein. Each heavy chain contains a conserved N-glycosylation site at Asn297. The type of 
biological activity that is elicited depends on the particular FcgR that is engaged as well as the 






Figure 1.1: Representation of the structure and function of an IgG1 antibody. (A) Structure of 
IgG1. Polypeptide colors: grey = heavy chain, orange = light chain, black bars = hinge, magenta 
= CDRs. Glycosylation symbols: blue square = N-acetylglucosamine, green circle = mannose, 
red triangle = fucose. (B) Function of IgG1. Antibodies are responsible for both recognizing the 






1.3 Antibody-mediated effector functions 
IgG1 is capable of eliciting antibody-mediated effector functions that utilize both the 
adaptive and innate branches of the immune system to selectively locate and destroy harmful 
cells. First, the Fab region from an antibody of the IgG subclass recognizes a foreign antigen on 
a target cell and binds to it. Next, the Fc region binds to an activating FcgR (Table 1.1) on an 
effector cell. A single binding event is not enough. Multiple binding events are required in order 
to create an immune complex that activates the effector cell.  
The well-studied effector functions are Complement-dependent Cytotoxicity (CDC), 
Antibody-dependent Cellular Phagocytosis (ADCP), and Antibody-dependent Cellular 
Cytotoxicity (ADCC) (Figure 1.2).4 The CDC pathway involves initial binding of C1q to the Fc. 
C1q contains 6 heads, and each head can bind to an Fc. The binding affinity between a C1q head 
and Fc is very low, but multiple binding events can increase the avidity of binding 100,000-fold.7 
The strong binding upon avidity starts an activation cascade of serum proteins leading to the 
destruction of the target cell’s cell membrane. The ADCP pathway involves recognition of a 
target cell by a phagocyte, such as a macrophage, by binding to the Fc of the bound antibody by 
a FcgR such as FcgRIIa.8 Activation leads to the macrophage engulfing the target cell and 
destroying it by phagocytosis. ADCC works by activating an effector cell to release cytotoxic 
molecules, such as perforin and granzyme, which kill the target cell. The most well-studied 
activating receptor and effector cell type combination for ADCC is FcgRIIIa on natural killer 
(NK) cells. Although, other activating receptors and effector cells have also been shown to elicit 
ADCC.9 There are several ways to influence ADCC activity. For instance, it has been shown that 
ADCC activity can be increased by increasing the affinity of the antibody to the foreign 




target cell.11 Third, ADCC activity can be increased by increasing the affinity of the Fc region of 
the antibody to FcgRIIIa.12 There have been several methods developed to increase affinity of the 
antibody Fc to FcgRIIIa. One such way involved modifying the N-linked glycosylation on the 
Fc. For example, antibodies without core-linked fucose have been shown to increase binding to 
FcgRIIIa and thereby increase ADCC activity.13 In fact, knocking out the gene responsible for 
adding core-linked fucose resulted in antibodies with 100-fold increased ADCC activity.14 
Furthermore, mutating certain residues within the Fc has also been shown to increase binding to 
FcgRIIIa and also increase ADCC activity.15-17 
 
 
Figure 1.2: Antibody-mediated effector mechanisms that lead to death of a target cell. ADCC = 
Antibody-dependent Cellular Cytotoxicity, CDC = Complement-dependent Cytotoxicity, and 




1.4 FcgRs  
FcgRs are part of the Immunoglobulin superfamily.18 They are found on the surfaces of 
immune cells. An immune cell can be either activated or suppressed depending on which FcgR is 
acted upon. An FcgR is acted upon when it binds to the Fc region of an IgG antibody. There are 
three classes of FcgRs (FcgRI, FcgRII, and FcgRIII), some of which are be further divided 
(FcgRIIa/b and FcgRIIIa/b).19 These receptors differ in several ways, such as in their binding 
affinity to antibody Fcs, their activating or inhibitory action, the subclass(es) of IgG that they 
interact with, and the immune cell type(s) they are found on. These differences are summarized 
in Table 1.1. All FcgRs bind to IgG with low affinity except FcgRIa. The low affinity binders 
require multiple binding events in order to activate the immune cell.18 Multiple binding events is 
a regulatory mechanism developed by the immune system in order prevent unnecessary immune 
stimulation, which would cause harm to the body. Another regulatory mechanism used by the 
immune system is the balance between activating and inhibitory FcgRs. All FcgRs are activating 
receptors except FcgRIIb. Activating FcgRs are able to activate proinflammatory responses and 
antibody-mediated effector functions. For example, FcgRIIIa-mediated signaling can activate 
ADCC, and FcgRIIa-mediated signaling can activate ADCP.8, 9 All FcgRs, except FcgRIIIb 
which is attached to the cell membrane by glycosylphosphatidylinositol, are transmembrane 
receptors. The activating FcgRs, except FcgRIIIb, contain an immunoreceptor tyrosine-based 
activation motif (ITAM) in their cytoplasmic regions that leads to intracellular signalizing to 
activate the effector cell. IgG1 and IgG3 are the two IgG subclasses that best bind the activating 
receptors.18 The only inhibitory receptor is FcgRIIb, however, it is found on almost all immune 
cell types.19 FcgRIIb contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) instead 




adaptive an innate immunity as FcgRIIb can induce apoptosis on B cells and down regulate 
dendritic cell activation.20 Furthermore, mice deficient in FcgRIIb saw increased inflammation 
and phagocytosis.20 Both activating and inhibitory FcgRs can be found on the same immune cells 
which helps to regulate the immune response. The binding between FcgRs and IgGs serve as the 
link between innate and adaptive immunity, and that link is influenced by IgG N-glycosylation. 
 
Table 1.1: Properties of Human FcgRs19 
aBinding may only occur during immune complex formation. 
bFound on cell types in spleen and lymph nodes but mostly absent on cell types in blood. 
cMay be present on NK cells in about 20% of the population. 
dRole in neutrophil activation is mainly through facilitating FcgRIIa signaling.21 
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1.5 Effect of IgG N-glycosylation on FcγR binding 
IgG1 contains, in the Fc region on both heavy chains, a conserved N-linked glycosylation 
site, which is critical for FcγR binding. In fact, complete removal of the glycan structure has 
been shown to inhibit binding of IgG1 to any FcγR.16, 22 Modifications to the glycan structure 
affect the strength of binding to Fc receptors, altering the effector response. For instance, 
removal of the fucose residue strengthens binding to FcγRIIIa and has been reported to increase 
binding affinity up to 50-fold and ADCC activity up to 100-fold.13, 14 Furthermore, the addition 
of α-2,6-linked sialic acid to the terminal glycan structure reduces the immunogenicity of the 
antibody by both reducing IgG binding to FcγRIIIa and upregulating presentation of FcγRIIb, the 
FcgR that inhibits effector activity.23, 24 Additionally, the N-glycosylation profile of antibodies 
has been shown to change during disease progression, as shown in HIV and Rheumatoid 
Arthritis.4 The number of ways a glycan structure can be configured is immense (Figure 1.3), so 
further study into the effect of IgG glycan composition on FcγR binding is needed.  
 
 
Figure 1.3: Representation of N-glycan heterogeneity on IgG1. The N-glycoforms presented are 
only the most common from mammalian cell expression of IgG1 and are not a complete 
representation of all possibilities.  Glycosylation symbols: blue square, N-acetylglucosamine; 






1.6 N-glycan biosynthesis and heterogeneity 
 N-glycosylation is a non-template driven process (unlike polypeptide synthesis which is 
blueprinted by the preceding DNA sequence). N-glycosylation occurs on Asn residues that are 
part of the consensus sequence (-Asn-Xxx-Ser/Thr-, where Xxx ≠ Pro).25 The synthesis of N-
glycans occurs in the Endoplasmic Reticulum (ER) and Golgi organelles of a cell (Figure 1.4).26 
First, a Dolichol compound that is membrane-bound on the outside of the ER contains, through a 
pyrophosphate linkage, two N-acetylglucosamine (GlcNAc) and five mannose (Man) residues 
(Dolichol-P-P-GlcNAc2Man5). Then, a flippase enzyme orients this glycan inside the ER. Once 
inside, it is modified by Asn-linked Glycosylation enzymes that add 4 more Man resides to the 
a-1,6 arm and three glucose (Glu) residues to the a-1,3 arm (termed Dolichol-P-P-
GlcNAc2Man9Glu3). This entire 14 sugar structure then transferred by two 
oligosaccharyltransferase enzymes onto the Asn residue of the nascent polypeptide. The glycan 
is b-linked to Asn by an N-glycosidic bond. The protein is then folded with the help of 
chaperones such as Calnexin and Calreticulin. The three Glu residues are important during this 
folding process, and they are sequentially trimmed off during the folding process by a-
glucosidases. Then, an ER a1,2-mannosidase removes a Man residue to create a Man8GlcNAc2-
Asn glycoprotein.  
The glycoprotein is then directed into the Golgi for further N-glycan processing by a 
sequential series of glycosidases and glycotransferases.25 First, Man8GlcNAc2-Asn is trimmed to 
Man5GlcNAc2-Asn by the removal of three a-1,2-linked Man residues by Mannosidase-I. Then, 
Man5GlcNAc2-Asn is converted to GlcNAcMan5GlcNAc2-Asn by the addition of one GlcNAc to 
the a-1,3-arm by N-acetylglucosaminyltransferase-I. Next, GlcNAcMan5GlcNAc2-Asn is 




1,6 arm by Mannosidase-II. Then GlcNAcMan3GlcNAc2-Asn is converted to 
GlcNAc2Man3GlcNAc2-Asn by the addition of one GlcNAc to the a-1,6-arm by N-
acetylglucosaminyltransferase-II. Furthermore, core-linked fucose (Fuc) can be added to the 
innermost GlcNAc by a-1,6-fucosyltransferase to create GlcNAc2Man3GlcNAc2Fuc-Asn. This 
N-glycoform is the most common N-glycoform found on IgG1 in both serum and in monoclonal 
antibody therapeutics.27, 28 The N-glycan can be further decorated by additional glycotransferases 
such as galactosyltransferase which adds galactose, sialyltransferase which adds sialic acid, and 
N-acetylglucosaminyltransferase-III which adds bisecting GlcNAc.  
 
Figure 1.4: Pathway for N-glycan biosynthesis in mammalian cells. The glycoprotein depicted is 
IgG1 for the relevance to this dissertation, but this pathway applies to other proteins. This figure 
is a simplified description of N-glycan biosynthesis. For a more complete description, please see 




N-glycan biosynthesis is an assembly line process, and the substrate specificities of these 
enzymes are very dependent on the processing by earlier enzymes in the assembly line. 
Incomplete processing at a particular step will truncate the process, which, given the numerous 
steps, gives rise to the heterogeneity of N-glycoforms that are observed during expression. There 
are two categories of heterogeneity: Macro and micro. Macroheterogeneity refers to the presence 
or absence of the entire N-glycan at the -Asn-Xxx-Ser/Thr- site. The addition of the STT3D gene 
from Leishmania major has been shown to increase glycan site occupancy of IgG1 expressed in 
the yeast Pichia pastoris.29 Microheterogeneity refers to differences within a glycan, which is 
represented in Figure 1.3. Biantennary N-glycans are divided into three classifications: 
oligomannose, hybrid, and complex (Figure 1.5). All classifications share a penta-saccharide 
core, but the classifications are differentiated by the sugar residue that extends the two antennae 
from the penta-saccharide core. Oligomannose N-glycans are extended on both antennae by Man 
residues. Hybrid N-glycans are extended on one antenna by Man and the other by GlcNAc. 
Complex N-glycans are extend on both antennae by GlcNAc. In the biosynthetic pathway, 
oligomannose N-glycans are processed into hybrid, which are further processed into complex. 
Although complex is the predominant type, IgG1-based therapeutics show the presence of 
oligomannose, hybrid, and complex N-glycoforms.27  
N-glycosylation is a highly variable process that depends on the organism, cell type, 
protein, site within the protein, and even the extracellular conditions.26 In pharmaceuticals, 
glycosylation can have a big effect on product quality, influencing properties such as stability, 
solubility, susceptibility to proteases, susceptibility to aggregation, pharmacokinetics, and 




manufacturing in order to obtain a reproducible N-glycosylation profile from batch to batch. It is 
also a big concern for the production of biosimilars, which is currently an expanding market.31, 32 
 
 
Figure 1.5: Representative examples of oligomannose, hybrid, and complex N-glycoforms. 
 
 
1.7 Production of homogenous N-glycoforms 
N-glycan heterogeneity makes it difficult to understand how N-glycosylation affects 
IgG1 because different N-glycoforms can affect the antibody differently.28 For instance, the 
addition of terminal sialic acid to the N-glycan reduces ADCC activity,33 whereas the addition of 
terminal galactose increases ADCC.34, 35 Therefore, there is a lot of interest to develop antibodies 
with more homogenous glycosylation and then study each N-glycoform individually. To 
accomplish this, several methods have been employed. First, genetically modifying the 
expression cell lines by deleting a particular gene that encodes a particular glyco-processing 
enzyme can truncate the N-glycoform at a particular step. For example, near-homogenous Man5-
GlcNAc2-Asn IgG1 Fc N-glycoforms have been obtained by expressing the protein in HEK293S 




afucosylated antibodies have been produced by expressing the antibodies in cells that are 
deficient in a1,6-fucosyltransferase.14 Second, using in-vitro enzymatic synthesis can be used to 
produce homogenous N-glycoforms post-expression. This method first requires the expression of 
a near-homogenous N-glycoform, which is obtained during in the earlier stages of the 
biosynthetic pathway. Then, enzymatic synthesis is performed in vitro. For example, 
homogenous IgG Fc N-glycoforms have been produced using this method for obtaining a crystal 
structure and for biosimilarity analysis.38, 39 Third, enzyme inhibitors can be added to the culture 
medium during expression to inhibit activity of a particular glyco-processing enzyme, which 
truncates the N-glycoform at a particular step.40 This method has been used to produce somewhat 
homogenous IgG1 Fc N-glycoforms for structural analysis. All three of these methods have been 
used to prepare homogenous IgG1 Fc N-glycoforms in order to better understand the impact of 
N-glycosylation on IgG1. 
 
1.8 IgGs have extended half-lives 
Most peptides and small proteins have short half-lives because their small size makes 
them susceptible to rapid removal from the body by renal clearance. In contrast, most IgG 
subclasses have relatively long half-lives. IgG1 has a reported half-life in humans of 21 days.41 
The long half-life of IgGs is due in part to their large size (150 kDa) but also because of their 
salvation from lysosomal degradation by neonatal Fc receptors (FcRn) (Figure 1.6). This 
receptor is named neonatal because it was initially discovered on neonatal epithelial cells as a 
way to transport IgG antibodies from mother to fetus during gestation.42 However, FcRn has 
since been found on a variety other cell types in adults to prevent degradation of internalized 




for degradation. However, endocytosed IgG are bound by FcRn in the early endosome and 
recycled back into circulation. The acidic pH of the endosome promotes Fc binding to FcRn, 
whereas the neutral pH of the plasma reduces the binding affinity by two orders of magnitude47. 
Mice deficient in FcRn showed approximately a 10-fold increase in IgG elimination over wild-
type mice.48 Conversely, an IgG1 antibody was mutated to increase affinity for FcRn at acidic 
pH but not affect the affinity at neutral pH, and it exhibited an 11-fold increase in half-life.49 An 
increased half-life due to binding FcRn has been correlated to an increased therapeutic efficacy.50  
 
 
Figure 1.6: Neonatal Fc receptor (FcRn) prolongs half-life of circulating of IgGs. 1.) Proteins in 
plasma are endocytosed. 2.) As the endosome matures, the pH in the endosome lowers, which 
causes FcRn bind IgG. 3.) The endosome fuses with lysosome. 4.) IgG bound to FcRn is 
trafficked out of the lysosome. 5.) Endosome buds with plasma membrane and the pH increases, 
which weakens binding of IgG to FcRn, and IgG is released back into circulation. 6.) Proteins 
that did not bind to FcRn are degraded in the lysosome. 
 
 
1.9 Importance of Antibody-based Therapeutics 
 Antibody-based therapeutics are a rapidly expanding class of biopharmaceuticals. The 




in the last five years, and they are expanding into areas such as antibody-drug conjugates, 
bispecific antibodies, and biosimilars.51 Antibodies serve as attractive drug platforms because 
their specificity can be designed, their long half-life, their ability to elicit antibody effector 
functions, and their divalent binding to target. Some antibody-based therapeutics function by 
modifying the immune system. These drugs have been used to treat a variety of disease-types 
including cancer,52 autoimmune diseases,53 and organ transplant rejection.54, 55 Some therapeutics 
are immunostimulants, such as trastuzumab (Herceptin®) and cetuximab (Erbitux®), which have 
been shown activate ADCC.56, 57 On the other hand, some work by suppressing the immune 
system by blocking immune cell activation or upregulating the inhibitory mechanisms.23, 24, 55 
The stimulating or inhibitory activity of antibody-based therapeutics can depend on the particular 
FcgRs that are activated, which can be tailored by modifying the antibody’s subclass and N-
glycosylation. 
 
1.10 IgG1 Fc Fusion Proteins  
IgG1 Fc fusion proteins are a prominent class of biopharmaceutics, exemplified by the 
blockbuster drug etanercept (Enbrel®).58, 59 In 2010, etanercept grossed $7.3 billion in global 
sales, which was more than any monoclonal antibody that year. Seven IgG1 Fc fusions have 
been approved by the FDA for the treatment of several immune disorders including rheumatoid 
arthritis and organ transplant rejection. IgG1 Fc fusions are composed of both a bioactive fusion 
partner, typically a peptide or small protein, and the Fc region of the human IgG1 antibody 
(Figure 1.7). The conjugation of these two species provide the bioactive fusion partner with 
several potential benefits: 1.) Increased half-life. IgG1 has a long half-life, which is mainly due 




proteins have been used to increase the solubility of poorly soluble peptides and proteins.60 IgG1 
is capable of being formulated at very high concentrations (>150 mg/mL).61 3.) The ability to 
elicit antibody-mediated effector functions. The Fc region can bind with FcgRs, which can 
activate antibody-mediated effector functions. 4.) Increased valency. IgG1 Fc fusions are most 
commonly prepared using recombinant DNA technology. The Fc is a homodimer, so 
recombinant fusion to the N- or C-terminus results in 2 bioactive fusion partners per Fc. Fusion 
to both termini results in 4 bioactive fusion partners per Fc. Furthermore, one fusion partner can 
be fused to one terminus and a different fusion partner to the other terminus, resulting in an Fc 
fusion with bi-specificity. A good example of utilizing an IgG1 Fc fusion for increased valency 
is etanercept. Etanercept is an IgG1 Fc fusion protein with two Tumor Necrosis Factor (TNF) 
receptors on its N-termini. Etanercept functions to compete with TNF receptors on immune cells 
for the proinflammatory-inducing cytokine TNF-a. TNF-a is trivalent, so having two TNF 
receptors on etanercept binds TNF-a with 50-1000X stronger avidity than monomeric TNF 
receptor.62  
 
Figure 1.7: Representation of an Fc Fusion. The stars represent the bioactive fusion partners. 
The colors of the stars on the Fc termini are different to represent that two different bioactive 
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Chapter 2  
 
Synthesis of a Bifunctional Peptide Inhibitor–IgG1 Fc Fusion that Suppresses 





Multiple sclerosis (MS) is an autoimmune disease of the central nervous system.1 The 
disease affects approximately 2.3 million people worldwide.2 Those affected experience a wide 
variety of neurological disabilities including impairments in mobility3, cognition4, and 
psychological health5. These neurological disabilities result from the loss of myelin, which is the 
lipoprotein sheath coating the axons of the central nervous system. Demyelination can be 
observed in the brain scans of MS patients as brain lesions.6 The etiology of MS is still unknown 
but suspected reasons include genetic, environmental, geographical, viral, and lifestyle factors.7-
10  The disease is extremely complex and heterogeneous, with involvement by both the humoral 
and cellular immune responses.11-13 The disease involves the activation of autoreactive T-cells 
against myelin proteins that infiltrate the brain to damage the myelin sheath of the neuronal 
axons. 14-16  The myelin proteins that are recognized by the autoreactive T-cells include 
proteolipid protein (PLP), myelin oligodendrocyte protein (MOG), and myelin basic protein 
(MBP). Currently, there is no cure for MS, and the currently available treatments such as beta 
interferons, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, and monoclonal 
antibodies are geared toward reducing symptom severity and frequency of attack.17-19  Some of 
the current treatments suppress general immune responses, which can increase pathogenic 
infections in treated patients. Therefore, there is a need to develop MS treatments that selectively 
suppress autoreactive T-cells against myelin proteins.  
Bifunctional Peptide Inhibitors (BPIs) are a promising new class of peptide conjugates 
that are designed to selectively inhibit the maturation of T-cells specific for myelin protein.20  




derived from lymphocyte function-associated antigen-1 (LFA-1), a protein found on T-cells that 
binds to intercellular adhesion molecule-1 (ICAM-1) (Table 2.1).  
 
Table 2.1: BPI-Fc Fusion Peptides 
aThe active regions of the sequences are shown in bold. 
bSignal-2-blocking peptide derived from LFA-1 that binds ICAM-1.  
cMyelin-derived antigenic peptides.  
dPeptide tag for enzymatic C-terminal protein ligations.  
  
 
For example, a myelin antigenic peptide (e.g., PLP139-15121-26 or MOG38-5025) linked to a LABL 
(CD11a237-246) peptide,21-23, 25 derived from the I-domain of LFA-1, through a short linker is a 
BPI. It is hypothesized that BPIs suppress autoreactive T-cells by blocking the formation of the 
immunological synapse (IS) at the interface of a T-cell and antigen presenting cell (APC) 
because the mechanism of activating T-cells is initiated by the formation of the IS (Figure 
2.1).20, 27, 28 The IS is formed by at least two signals in which the first signal (signal-1) is 
generated via the interactions between the complex of antigen-major histocompatibility complex 
class II (Ag-MHC-II) and a T-cell receptor (TCR). The second signal (signal-2) can be generated 
by ICAM-1/LFA-1 interactions. Initially, signal-2 is formed in the center of the interface 
between an APC and a T-cell while signal-1 is formed at the periphery of the interface to form a 
bullseye-like arrangement. Then, the signal-1 molecules translocate to cluster at the center while 
the signal-2 molecules migrate to peripheral region of the bullseye to form an IS. The IS 
Peptide Name Representation Sequencea 
ICAM-1 Binding Peptide CD11a237–246 (LABL)b  GITDGEATDSGGG 
Proteolipid Protein139-151 (PLP)c  GGGHSLGKWLGHPDKFG 
Myelin Oligodendrocyte Glycoprotein38-50 (MOG)c  GGGWYRSPFSRVVHLGRR 




formation initiates the activation of a naïve T-cell into a proinflammatory T-cell (Figure 2.1). 
This proinflammatory T-cell promotes antigen-specific immune system attack on myelin, 
causing its inflammation and breakdown.15 BPI molecules are hypothesized to bind 
simultaneously to MHC-II and ICAM-1 on the surface of an APC and inhibit the formation of 
the IS.29 As a result, BPIs alter the commitment of naïve T-cells from an inflammatory 
phenotype to regulatory or suppressor phenotypes, and this suppresses autoimmune diseases in 
an antigen-specific manner. While antigenic peptides and signal-2 blocker peptides have been 
shown to have some ability to reduce T-cell activation on their own, Kobayashi et al. have 
demonstrated that linking the two types of peptides to form BPIs results in significantly lower 
clinical scores in an EAE model.21 However, one potential problem with BPIs is the short in vivo 
half-lives of a few hours (2-3 hours) as measured in rat plasma; therefore, there is a need to 








Figure 2.1: Two-signal model of T-cell activation highlighting the role of the ICAM-1–LFA-1 
receptor pairing for both adhesion and costimulation are highlighted as well as the alteration of 
T-cell activation by a BPI. (A) Mechanism of proinflammatory T-cell activation against myelin 
protein. (1) Myelin-specific antigen is internalized by an APC and broken into fragments. (2) 
The antigen fragments are presented on the APC cell surface by MHC-II. (3) A naïve CD4+ T-
cell binds to the APC through the adhesion receptor pairings of ICAM-1 on the APC and LFA-1 
on the T-cell. (4) If the naïve T-cell contains TCRs capable of recognizing the particular antigen 
presented by MHC-II, then the TCR binds the Ag-MHC-II complex to initiate signal-1 on the 
periphery. The ICAM-1–LFA-1 receptor pairings also function as costimulatory molecules to 
constitute signal-2 in a central cluster. (5) The two signals reorganize so that signal-1 pairings 
localize in the central cluster and the signal-2 pairings localize to the periphery of the signal-1 
cluster to form the immunological synapse, which directs the maturation of a naïve T-cell into a 
proinflammatory T-cell against the myelin antigen. (B) Intervention of myelin-specific T-cell 
activation by a BPI. A BPI molecule consists of two peptides, a myelin-specific antigenic peptide 
(PLP) and a signal-2 blocking peptide (LABL), conjugated together. The antigenic peptide of the 
BPI allows formation of Ag–MHC-II pairing with the TCR to form signal-1 but inhibits the 
ICAM-1–LFA-1 receptor pairing to prevent formation of signal-2. Because the BPI peptides are 
conjugated together, the BPI is hypothesized to inhibit formation of the IS and alter the 
maturation of the naïve T-cell into a regulatory T-cell.  
 
In this work, a BPI-Fc fusion was prepared in which the two BPI peptides, a myelin-
specific antigenic peptide and a signal-2-blocking peptide, were conjugated to the N- and C-
termini of the fragment crystallizable (Fc) region of a human IgG1 antibody. This BPI-Fc fusion 




(EAE) in mice. Using the Fc as a platform may increase the half-life of the BPI-Fc due to 
recycling by the FcRn receptor as well as reduced renal clearance because of increased molecular 
weight (4 kDa of traditional BPI compared to 57 kDa of BPI-Fc).30 Additionally, the Fc is a 
homodimer which allows the attachment of two of each of the BPI peptides to the Fc scaffold, 
potentially increasing avidity in binding interactions of the BPI peptides to their respective 
receptors. Furthermore, fusing to the Fc allows for increased solubility of insoluble peptides. 
This work was a proof-of-concept project to determine whether a BPI-Fc fusion could be 
prepared and whether the BPI peptides could still function to protect against EAE when they are 
separated by a 223 amino acid Fc protein.31  
 
2.2 Materials and Methods 
2.2.1 Materials 
DNA primers were ordered from Eurofins (Huntsville, AL). IgG1 cDNA (MGC: 12853) 
was previously purchased from the American Tissue Culture Collection (Manassas, VA).32 
pGAPzαA and pPICzαA vectors were purchased from Invitrogen (USA). All restriction 
enzymes, T4 Polynucleotide Kinase (PNK), T4 DNA Ligase, and protein markers were 
purchased from New England BioLabs (Ipswich, MA). All final DNA constructs were confirmed 
by DNA sequencing. Zeocin was purchased from InvivoGen (San Diego, CA). Tryptone and 
yeast extract were both purchased from Becton, Dickinson and Company (Sparks, MD). Yeast 
nitrogen base was purchased from Sunrise Science Products (San Diego, CA). Fmoc-PAL-PEG-
PS resin and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) were obtained from Applied Biosystems (Foster City, CA) and 




purchased from Peptides International (Louisville, KY), Bachem (Torrance, CA), and Sigma-
Aldrich (St. Louis, MO). Triisopropylsilane (TIPS) and N,N-diisopropylethylamine (DIEA) were 
also purchased from Sigma-Aldrich. Detoxi-Gel Endotoxin Removing Gel was purchased from 
Thermo Scientific (Waltham, MA). All other chemicals were obtained from commercial sources 
without further purification. Protein G resin was prepared in house as previously described.33, 34 
All materials and reagents, except for the protein markers, used for SDS-PAGE were purchased 
from Bio-Rad Laboratories (Hercules, CA), and the experimental method used for SDS-PAGE is 
described in Appendix 1: A.1.1.3.1. All protein mass spectra, except those pertaining to PLP-Fc-
LABL (spinner flask with media change), MOG-Fc, and LABL-Fc-ST (spinner flask) proteins 
were acquired using an Agilent 6520 electrospray ionization time-of-flight liquid 
chromatography mass spectrometer (LC-MS) using a method previously described.34 Mass 
spectra for PLP-Fc-LABL (spinner flask with media change), MOG-Fc, and LABL-Fc-ST 
(spinner flask) proteins were acquired by the KU Mass Spectrometry & Analytical Proteomics 
Laboratory using a Waters Synapt G2 quadrupole time-of-flight LC-MS using a method 
previously described.35 Peptide:N-Glycosidase F (PNGase F) was prepared in house using a 
method previously described.36 Cloning procedures for pPICzαA-PLP-Fc-LABL and pPICzαA-
MOG-Fc and expression procedures for PLP-Fc- LABL (spinner flask, fermentor, and spinner 
flask with media change) are described in Appendix 2: A.1.1.  
2.2.2 Cloning of pPICzαA-LABL-Fc-ST 
A construct consisting of a human IgG1 Fc cDNA (T225àK447) subcloned into pGAPzαA 
with a silent mutation to introduce a SacI restriction site near the 5' end of the Fc coding region 
(termed pGAPzαA-Fc) was produced previously in our laboratory and used as a starting point for 




peptide, was attached C-terminal to the Fc polypeptide sequence. This was accomplished by 
inserting DNA between the NotI site, which occurs after the last human IgG1 Fc encoded amino 
acid, and the XbaI site. Primers containing the ST DNA sequence (5'-
ggccgccttgccagaaactggaggtggataat-3' and 5'-ctagattatccacctccagtttctggcaaggc-3') were designed 
so that when they anneal, they create the proper NotI and XbaI sticky ends. The 5’-termini of the 
primers were phosphorylated by PNK. pGAPzαA-Fc was digested with NotI-HF and XbaI, gel 
purified, and the ST DNA sequence was ligated to the 3’ side of the Fc DNA using T4 DNA 
Ligase to create pGAPzαA-Fc-ST. The LABL DNA sequence was cloned on the 5’ side of the 
Fc DNA in pGAPzαA-Fc-ST. Primers containing the LABL DNA sequence (5'-
tcgagaaaagaggaattactgatggagaagctactgattctggaggtggaacatgcccaccgtgcccagcacctgagct-3' and 5'-
caggtgctgggcacggtgggcatgttccacctccagaatcagtagcttctccatcagtaattcctcttttc-3') were designed so 
that when they anneal, they create the proper XhoI and SacI sticky ends. The 5’-termini of the 
primers were phosphorylated by PNK. pGAPzαA-Fc-ST was digested with XhoI and SacI, gel 
purified, and the digested LABL DNA sequence was ligated into pGAPzαA-Fc-ST on the 5’ side 
of the Fc DNA using T4 DNA Ligase to create pGAPzαA-LABL-Fc-ST. To allow for inducible 
expression under the strong AOX promoter, the LABL-Fc-ST was cut out of pGAPzαA and 
ligated into pPICzαA. To perform this transfer, both pGAPzαA-LABL-Fc-ST DNA and 
pPICzαA were digested with XhoI and XbaI and gel purified. LABL-Fc-ST and pPICzαA 
digested products were ligated together using T4 DNA Ligase to create pPICzαA-LABL-Fc-ST. 
The plasmid was linearized using PmeI and transformed into a strain of P. pastoris with the 
OCH1 gene deleted as previously described.32 




A colony of P. pastoris OCH1 KO transformed with pPICzαA-LABL-Fc-ST was 
inoculated in a culture tube containing 2 mL of YPD media and 100 µg/mL Zeocin. The culture 
was grown in a shaker/incubator at 25°C. After 3 days, the 2 mL culture was transferred to a 
baffled shake flask containing 250 mL of YPD media, 100 µg/mL Zeocin, and 1 drop of 
antifoam. The culture was grown in a shaker/incubator at 25°C. After 3 days, the 250 mL culture 
was transferred to a New Brunswick BioFlo 415 fermentor (Hauppauge, NY) containing 5 L of 
sterilized Buffered Glycerol Complex Medium and PTM1 salts at pH 6.0. The pH was 
maintained by the fermentor-controlled addition of concentrated NH4OH, which also served as 
the nitrogen source. Agitation and gas flow were set under cascade control, which maintained an 
agitation range of 200-1000 rpm and a gas flow range of 1-20 L/min. The cells were grown on a 
carbon source feed of 50% glycerol in water for two days. After which, the carbon source was 
changed to 100% methanol to allow for induction of target protein. After 3 days of induction, the 
culture was harvested by centrifugation at 6,693 x g for 20 min using a Beckman JLA 10.5 rotor 
in a Beckman Avanti J-series centrifuge (USA). The supernatant was collected and filtered using 
a Buon Vino Mini Jet Wine Filter with 0.5 µm filter pads (Cambridge, Ontario). The filtered 
supernatant was then concentrated to 1 L using a Sartorius 30,000 MWCO tangential flow 
concentrator (USA). The LABL-Fc-ST protein was purified from the supernatant using Protein 
G affinity chromatography. First, 10 mL of Protein G resin was packed in a 1.5x20 cm diameter 
Bio-Rad Econo-column (Hercules, CA) and equilibrated with 250 mL of 20 mM Sodium 
Phosphate buffer pH 6.0. Then the concentrated supernatant was loaded onto the column and 
washed with 500 mL of 20 mM Sodium Phosphate buffer and 0.5 M NaCl at pH 6.0. The 
captured protein was eluted using 0.1 M Glycine-Cl buffer, pH 2.7. The column was re-




more protein eluted from the column. The collected protein was dialyzed against 4 L of TBS, pH 
7.5 using Spectra/Por 3500 MWCO dialysis tubing (USA) at 4°C with two buffer changes. 105 
mg of purified protein was obtained as determined by measuring the optical density of the 
solution at 280 nm (MW = 54006.8 Da, ε280 = 71570 M-1cm-1).37 
2.2.4 Preparation of the PLP peptide (GGGHSLGKWLGHPDKFG) 
The PLP peptide used in this work was purchased as 60% pure from Shanghai Mocell 
Biotech Co. (Shanghai, China) and RP-HPLC purified. The peptide was purified on a Thermo 
Separation Products HPLC (preparative run) using a C18 Vydac column 218TP1022 with a 
linear gradient of water/acetonitrile (6 mL/min, detection 220 nm, eluent A is 5% acetonitrile and 
0.1% TFA in water and eluent B is acetonitrile, 14-90% B in 40 min). The fractions were 
analyzed by HPLC on a 5 µm C18 Econosphere column (4.6 x 250 mm) and lyophilized. The 
purity was determined by HPLC analysis using a Shimadzu UFLC and UV detector at 220 nm. 
The mass was determined using a Matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometer (Appendix 1: Figure A.1.1). [M+H]+ mass (Da): Expected = 1749.9 and Observed 
= 1750.0. 
2.2.5 Solid-phase peptide synthesis of the MOG peptide (GGGWYRSPFSRVVHLGRR) 
The MOG peptide was synthesized manually using Fmoc-PAL-PEG-PS resin (0.18 
meq/g) and employing standard Fmoc solid-phase peptide synthesis strategy. Couplings were 
performed using 4-fold molar excess of each Fmoc L-amino acid, 4-fold molar excess of HATU 
and 8-fold molar excess of DIEA. The peptide was then removed from the resin by treatment 
with TFA/TIPS/H2O (95/2.5/2.5 by volume) for 2 hours under nitrogen at room temperature. The 
resin beads were filtered; the filtrate was precipitated in cold diethyl ether, centrifuged, washed 




using the same conditions that were used for purification of the PLP peptide. The mass was 
determined by MALDI mass spectrometry (Appendix 1: Figure A.1.2). [M+H]+ mass (Da): 
Expected = 2087.1 and Observed = 2087.2. 
2.2.6 Expression and purification of Sortase A 
A construct of sortase A (SrtAΔ1-59) cloned with a C-terminal His6 tag into pET23 (a gift 
from Richard DiMarchi, Indiana University) was transformed into Escherichia coli Rosetta 2 
strain. SrtAΔ1-59 was expressed and purified according to a similar procedure previously 
described.38 The enzyme was characterized using intact mass spectrometry and SDS-PAGE 
(Appendix 1: Figure A.1.3). 242 mg/L of purified enzyme was obtained as determined by 
measuring the optical density of the solution at 280 nm (MW = 17719.0 Da, ε280 = 14440 M-1cm-
1).37 
2.2.7 Small-scale sortase-mediated ligations of LABL-Fc-ST + PLP and MOG peptides 
The PLP and MOG peptides were separately ligated to the C-terminus of LABL-Fc-ST 
using sortase-mediated ligations on a sub-milligram scale. In each ligation, 10 µM LABL-Fc-ST 
protein was combined with 6 mM CaCl2, 1 mM GGG-peptide (either PLP or MOG), and 5 µM 
sortase in TBS, pH 7.5 in a 150 µL reaction.39 The ligations were incubated at 35°C for 24 hours. 
After which, they were quenched by the addition of 25 mM EDTA. The ligations were then 
observed by mass spectrometry and SDS-PAGE, which showed a 90% ligation yield for both 
peptides. 
2.2.8 Large-scale sortase-mediated ligation of LABL-Fc-ST + PLP peptide 
On a 60 mg protein scale (the total of 6 pooled reactions), the PLP peptide was ligated to 
the C-terminus of LABL-Fc-ST protein using a sortase-mediated ligation. In total, the ligation 




7 µM SrtAΔ1-59 (3.7 mg). The pH was adjusted to pH 7.5 using 1 M Tris base. The ligation was 
allowed to proceed 24 hours at 35°C and then stored at -20°C until purification. 
2.2.9 Purification of large-scale LABL-Fc-ST-PLP 
The reaction mixture was adjusted to pH 7.0 using 1 N HCl. The Fc-containing protein 
was separated from SrtAΔ1-59 and unreacted PLP peptide using protein G affinity 
chromatography. The column was first equilibrated using TBS, pH 7.0. Then the reaction 
mixture was loaded onto the Protein G column, and the captured Fc protein was washed with 500 
mL of 50 mM Tris and 500 mM NaCl, pH 7.0. Then the Fc-containing protein (unreacted 
LABL-Fc-ST and product LABL-Fc-ST-PLP) was eluted using 0.1 M glycine-HCl buffer pH 2.7 
and immediately dialyzed against TBS, pH 7.5. The protein was then passed through a Detoxi-
Gel endotoxin removal column (Thermo Scientific) to remove endotoxin contaminants that may 
have been introduced during the expression and/or purification steps.40 The flow through from 
the endotoxin removal column was concentrated using an EMD Millipore 10 kDa MWCO 
centrifugal concentrator (USA). Concentration was stopped when the volume of the protein 
solution was 2 mL because precipitation was observed. The concentrated protein was dialyzed 
against 4 L of 1x PBS pH 7.4 with one buffer change at 4°C overnight and then filtered through 
an EMD Millipore 0.2 µm syringe filter. The concentration of the end product was determined to 
be 168 µM (9.6 mg/mL, 19 mg total) by optical density of the solution at 280 nm (MW = 
57128.3 Da, ε280 = 82570 M-1cm-1).37 
2.2.10 Evaluation of BPI-Fc (LABL-Fc-ST-PLP) in EAE mice 
The LABL-Fc-ST-PLP fusion protein was tested in mice induced with EAE using a 
similar protocol that was used by Manikwar et al. to test the I-domain protein, a 197 amino acid 




maintained in the University of Kansas Animal Care Unit and the protocol for this animal work 
had been approved by the Institutional Animal Care and Use Committee (IACUC). Ten 5-7 week 
old Female SJL/J mice (Charles River Labs) were immunized with PLP139-151 peptide in CFA on 
day 0. The PLP/CFA emulsion was injected above the shoulders and flanks of the mice (4 doses 
at 50 µL/dose) by subcutaneous injection. Additionally, on both days 0 and 2, the mice were 
administered 200 ng of pertussis toxin by intraperitoneal injection. On both days 4 and 7, five 
mice were administered 150 µL of 168 µM LABL-Fc-ST-PLP protein (2 doses at 25 nmol/dose) 
and five mice were administered 150 µL of PBS by intravenous injection. During the 25-day 
study, the mice were scored based on the severity of the physical symptoms associated with 
EAE. Scores ranged from 0 to 5 as follows: 0 = no symptoms, 1 = tail weakness, 2 = incomplete 
paralysis of one or two hind limbs, 3 = complete paralysis of one or two hind limbs, 4 = 
complete paralysis of one or two hind limbs plus paralysis one or two fore limbs, and 5 = 
moribund or dead. Additionally, the mice were weighed throughout the study to observe their 
change in weight relative to their weight on day 0. On day 14, one mouse from each group was 
sacrificed and 5 µm slices of each mouse’s brain tissue were prepared as previously described.24 
The brain sections were sent to IHC World (Woodstock, MD) for staining with LFB and cresyl 
violet as previously described.43 The stained tissues were imaged by IHC World using a EPI 
Fluorescence Trinocular Microscope (Model# FM320-9M). IHC World also quantified the 
amount of LFB staining in each brain tissue using ImageJ software. Statistical significance 
between the stained tissue samples was determined using a one-way ANOVA (α=0.05) followed 






2.3 Results and Discussion 
2.3.1 Construction of a BPI-Fc fusion 
The fusion of small, rapidly cleared peptides and proteins to the Fc region of IgG 
antibodies is an effective way to improve their half-lives, and because of this Fc fusion proteins 
have become a prominent class of biopharmaceutics.44, 45 The initial attempt to prepare a BPI-Fc 
fusion used recombinant DNA technology to fuse both the antigenic and signal-2 blocking 
peptides to the human IgG1 Fc. A DNA construct was prepared consisting of the PLP and LABL 
peptides fused to the N- and C-termini of the Fc, respectively (+H3N-HSLGKWLGHPDKFGGG-
Fc-AAAGGGITDGEATDSG); however, recombinant expression of this construct in 
glycosylation-deficient yeast resulted in severe proteolysis of the PLP region as detected by 
intact protein mass spectrometry. Three attempts were performed to express this dual fusion 
construct. The first attempt was performed using a 1 L spinner flask and the conventional 3-day 
induction time (Appendix 1: Figure A.1.4). Mass spectrometry showed that unproteolyzed PLP-
Fc-LABL dual fusion protein was present; however, it was not the major peak. Several other 
peaks of smaller molecular weight were present, all of which corresponded to proteolysis within 
the PLP region. Based on the ratio of peak heights in the mass spectrum, only 33% of the PLP-
Fc-LABL protein was unproteolyzed.  
In a second attempt, the PLP-Fc-LABL dual fusion construct was expressed in a 
fermentor. Expression in a fermentor allows for more precise control over air flow, agitation rate, 
pH, dissolved oxygen concentration, and carbon source feed rate. Having more precise control 
over these expression conditions may help to reduce proteolysis. Expression in a fermentor did 
result in unproteolyzed PLP-Fc-LABL being the major peak in the mass spectrum (Appendix 1: 




species in the fermentor expression compared to the spinner flask expression. Similar to the 
spinner flask expression trial, all of the observed proteolysis occurred within the PLP region. 
Based on the mass spectrometry peak heights, expression of the PLP-Fc-LABL protein in a 
fermentor resulted in only 31% of the protein being unproteolyzed.  
The PLP-Fc-LABL DNA construct was cloned in frame of the Saccharomyces cerevisiae 
alpha factor prepro sequence to allow for secretion of the target protein into the media. During 
protein expression, proteases may also be secreted and can cleave the secreted PLP-Fc-LABL 
protein. In order to reduce the level of proteases present in the media, a third expression was 
attempted. In this attempt, the cells were grown to density in a 1 L spinner flask, pelleted by 
centrifugation under sterile conditions, and transferred to 1 L of fresh media immediately before 
methanol-induced protein expression. Transferring the cells to fresh media before induction 
resulted in fewer proteolysis products. Based on the peak heights in the mass spectrum, 46% of 
unproteolyzed protein was obtained (Appendix 1: Figure A.1.6). Although the third attempt 
produced the most uncut protein (46%), proteolysis was unfortunately still severe. Since IgG1 Fc 
is a dimer linked by inter-chain disulfide bonds, the presence of only 46% uncut monomer in the 
reduced protein detected by mass spectrometry translates to only approximately 21% of the 
disulfide-bonded dimer having two full PLP peptides. It was decided that even with the reduced 
proteolysis, having only 21% full-length dimer would potentially compromise future 
experiments.  
Since changing the expression conditions did not improve the proteolysis observed within 
the PLP region sufficiently, expression of a different antigenic peptide fused to IgG1 Fc was 
attempted to determine if the proteolysis problem was specific to the PLP peptide sequence. The 




expressed as a single Fc fusion. However, expression of this fusion showed that proteolysis was 
even more severe within the MOG region than observed in the PLP fusion (Appendix 1: Figure 
A.1.7). Based on the mass spectrometry peak heights, only 5% of unproteolyzed MOG-Fc was 
obtained. For both the PLP-Fc-LABL and MOG-Fc fusions, proteolysis was observed within the 
antigenic peptide sequence. Fortunately, the LABL peptide sequence showed no proteolysis in 
all three expression attempts of PLP-Fc-LABL. Given these results, an alternative method to 
prepare the BPI-Fc fusion was pursued.  
IgG1 Fc fusions are most commonly prepared by recombinant protein expression.46, 47 
However, the applicability of recombinant expression for the production of peptides and proteins 
is limited by proteolysis and low expression yields. To circumvent these limitations, the fusion 
partners can be prepared separately and conjugated in-vitro using a variety of bioconjugation 
techniques.48, 49 Such bioconjugation techniques can target natural conjugation sites on proteins 
such as the thiol of cysteine residues, the primary amine of lysine residues, and particular sugar 
residues of attached glycans. Additionally, non-native sites can be added to the protein such as 
unnatural amino acid residues, sugar residues, and peptide tags. Peptide tags are attractive, 
because the fusion partners can be conjugated site-specifically, and the conjugation occurs on the 
peptide tag instead of the native protein. A popular method for protein conjugation that requires a 
peptide tag substrate is sortase-mediated ligation.50 Over the past decade, sortase A from 
Staphylococcus aureus has served as an important conjugation tool to attach a variety of 
materials to proteins in a site-specific manner.38, 50-54 In addition to site-specificity, this 
enzymatic conjugation method is very attractive for proteins as it is performed under mild 
conditions and requires only that one species contain the LPXTG recognition motif, where X is 




2.1).39 The mechanism of this reaction is as follows: sortase A recognizes the LPXTG motif, 
cleaving between the threonine and glycine residues using an active site cysteine. The glycine is 
released, and a thioester intermediate is formed between the C-terminal threonine of the sortase-
tagged substrate protein and the active site cysteine of sortase A. Next, a ligand containing an N-
terminal glycine acts as a nucleophile, attacking the thioester to displace sortase A and form an 
amide bond between the protein and ligand (Figure 2.2).50, 53 
 
 
Figure 2.2: Mechanism of sortase-mediated ligations. The ligation requires a substrate to bear a 
LPXTG peptide tag. This peptide tag is recognized by sortase A. The enzyme cleaves between 
threonine and glycine residues to form an acyl-enzyme intermediate. The acyl-enzyme 
intermediate is then susceptible to nucleophilic attack by a ligand bearing an N-terminal glycine 





A new Fc fusion protein was prepared that consisted of the LABL sequence fused to the 
N-terminus of the Fc, and a sortase A recognition tag (AAALPETGGG = ST) fused to the C-
terminus. This construct was named LABL-Fc-ST (+H3N-GITDGEATDSGGG-Fc-
AAALPETGGG). The LABL sequence was capped with an N-terminal glycine so that the 
positively charged N-terminus was not directly part of the LABL sequence. Also, a two glycine 
spacer was added in between the LABL and Fc to reduce the likelihood of the Fc sterically 
hindering the binding activity of the LABL peptide. Similarly, a three alanine spacer was added 
in between the Fc and ST recognition tag to reduce the likelihood of the Fc sterically hindering 
the sortase-mediated ligation. LABL-Fc-ST was expressed in yeast and showed no proteolysis 
(Appendix 1: Figure A.1.8). Furthermore, the 1 L spinner flask expression yield of LABL-Fc-
ST was 5x higher than PLP-Fc-LABL (15 mg vs. 3 mg, respectively). This approach avoids 
expression of the problematic antigenic peptides and instead allows conjugation of antigenic 






Figure 2.3: Sortase-mediated addition of two different antigenic peptides to the C-terminus of 
LABL-Fc-ST. An IgG1 Fc fusion containing an N-terminal LABL peptide and a C-terminal 
sortase A recognition tag was reacted in a sortase-dependent manner with the (A) PLP and (B) 
MOG peptides to produce LABL-Fc-ST-PLP and LABL-Fc-ST-MOG, respectively. 
 
2.3.2 Preparation of antigenic peptides 
The PLP peptide was purchased at ~60% purity and then RP-HPLC purified in our 
laboratory. The peptide was constructed with three glycine residues N-terminal to PLP since at 
least one N-terminal glycine residue was required for this peptide to be a nucleophile in a 
sortase-mediated ligation. The PLP peptide was designed with three sequential N-terminal 




on ligation yield showed that three N-terminal glycine residues gave a higher yield than two or 
one but more than three didn’t result in a much higher yield.55 An additional C-terminal glycine 
was also added to the PLP peptide so that the negative charge of the carboxy terminus of the 
polypeptide backbone was spaced away from the PLP peptide.  
The MOG peptide was chemically synthesized with two N-terminal glycine residues 
instead of three because the native MOG38-50 sequence begins with glycine. However, the MOG 
peptide is very hydrophobic and doesn’t dissolve well in the aqueous buffer required for the 
sortase-mediated ligation. Previously, active BPIs have been produced with linkers and peptides 
attached to the C-terminus of MOG, and therefore we explored increasing the solubility of MOG 
by C-terminal modification.25 In order to increase solubility under aqueous conditions, two 
arginine residues were added to the C-terminus. Additionally, a one glycine spacer was added in 
between MOG and the two arginine residues to reduce the likelihood the positive charges of the 
arginine side changes interfering with binding of MOG38-50 to the MHC-II and TCR. 
2.3.3 Sortase-mediated ligations 
On sub-milligram scales, the two antigenic peptides, PLP and MOG, were enzymatically 
ligated to the C-terminus of LABL-Fc-ST in a sortase-mediated manner to produce the ligation 
products LABL-Fc-ST-PLP and LABL-Fc-ST-MOG, respectively. These reactions were 
performed on small scale to optimize the ligation yields, and because there was no downstream 
application, they were not purified prior to characterization. Based on the peak heights in the 
mass spectra, the ligation yields were both 90% (Figure 2.4B-C). The addition of the antigenic 
peptides to LABL-Fc-ST was also observed by SDS-PAGE, which showed an upward gel shift 
for LABL-Fc-ST-PLP and LABL-Fc-ST-MOG compared to LABL-Fc-ST (Figure 2.4D). The 




enough material to conduct a mouse study to determine whether the BPI-Fc was active in mice 
induced with EAE. A drawback of the sortase-mediated ligation is that the product still contains 
the LPXTG recognition tag, so the product is also a sortase substrate. In order to drive the 
sortase-mediated ligation to near completion, a large excess of peptide was required (≥1 mM). In 
order to prepare enough LABL-Fc-ST-PLP for a mouse study, 52 mg of PLP peptide was 
prepared. Also, the expression of LABL-Fc-ST protein was scaled up from a 1 L spinner flask to 
a 5 L fermentor to produce enough protein for the mouse study. Fermentor expression of LABL-
Fc-ST provided 105 mg of protein and scaling up production of LABL-Fc-ST did not result in 
any proteolysis (Appendix 1: Figure A.1.8 vs. Figure 2.4A).  
 
Figure 2.4: Characterization of LABL-Fc-ST and small-scale sortase-mediated ligations of 
LABL-Fc-ST with the PLP and MOG peptides. Prior to characterization, the proteins were de-
glycosylated with PNGase F and reduced to their monomeric states using dithiothreitol (DTT). 
(A) Mass spectrum of recombinant expression of LABL-Fc-ST. LABL-Fc-ST MW (Da): 




mediated ligation of LABL-Fc-ST + PLP peptide. LABL-Fc-ST-PLP MW (Da): Expected = 
28571.19 and Observed = 28568.53. (C) Mass spectrum of small-scale sortase-mediated ligation 
reactions of LABL-Fc-ST + MOG peptide. LABL-Fc-ST-MOG MW (Da): Expected = 28908.62 
and Observed = 28904.46. (D) SDS-PAGE of LABL-Fc-ST and sortase-mediated ligations of 
LABL-Fc-ST + PLP and MOG peptides. Lanes: 1, 2-212 kDa MW marker; 2, SrtAΔ1-59; 3&5, 
LABL-Fc-ST; 4, sortase-mediated ligation of LABL-Fc-ST + PLP peptide; and 6, sortase-
mediated ligation of LABL-Fc-ST + MOG peptide. 
 
In order to conserve peptide, almost a four-fold higher concentration of LABL-Fc-ST 
was used (10 µM for small scale vs. 37 µM for large scale). Based on the mass spectrometry 
peak height ratio of LABL-Fc-ST-PLP/(LABL-Fc-ST + LABL-Fc-ST-PLP), the large scale 
ligation yield was 87% (Figure 2.5A). This ligation yield was slightly lower than what was 
observed for the small-scale reaction, but it was still nearly complete. The near-completeness of 
the ligation can also be observed by SDS-PAGE (Figure 2.5B) where the LABL-Fc-ST-PLP 
migrated slower (higher) than LABL-Fc-ST. However, SDS-PAGE also showed side products of 
higher molecular weight than the expected product. These products could have been caused by 
the N-terminal glycine that was added to LABL-Fc-ST, which may have caused the N-terminus 
of LABL-Fc-ST to act as a nucleophile in the sortase-mediated ligation to form LABL-Fc-ST–
LABL-Fc-ST dimers. Also, another possibility is that lysine residues have been shown to act as 
nucleophiles in the sortase-mediated ligation because their primary amine side chains can 
compete with the GGG-peptide for thioester attack.56 The LABL-Fc-ST sequence contains 19 
lysine residues in each chain, and SrtAΔ1-59 also contains 19 lysine residues. Additionally, the 
mass spectrum from the large-scale ligation showed that approximately 14% of the product had a 
loss of a terminal glycine. Because the terminal glycines are not part of the active PLP and MOG 
peptides, the loss of this glycine was not seen as a problem that would interfere with the testing 
of this fusion protein. If this loss of glycine variant is included as an active product, then the 




by Protein G affinity chromatography. The TIC overlay of LABL-Fc-ST-PLP before and after 
purification showed that the SrtAΔ1-59 and unreacted PLP peptide were no longer present in the 
purified sample (Appendix 1: Figure A.1.9).  
 
Figure 2.5: Characterization of the large-scale sortase-mediated ligation of LABL-Fc-ST + PLP 
peptide. Prior to characterization, the protein was de-glycosylated with PNGase F and reduced to 
its monomeric state using DTT. (A) Mass spectrum of LABL-Fc-ST + PLP peptide ligation 
reaction. LABL-Fc-ST MW (Da): Expected = 27010.4 and Observed = 27006.7, LABL-Fc-ST-
PLP MW (Da): Expected = 28571.2 and Observed = 28567.5, and LABL-Fc-ST-PLP (-Glycine) 
MW (Da): Expected = 28514.1 and Observed = 28510.5 (B) SDS-PAGE of large-scale LABL-
Fc-ST + PLP peptide ligation. Lanes: 1, 10-200 broad range protein marker; 2, SrtAΔ1-59; 3, 
LABL-Fc-ST; and 4, LABL-Fc-ST-PLP. 
 
2.3.4 Evaluation of the BPI-Fc in EAE mice 
Ten 5-7 week old SJL/J mice were induced with EAE by immunizing them with an 
emulsion of PLP139-151 peptide in CFA as well as pertussis toxin. To test whether the LABL-Fc-
ST-PLP fusion conjugate called BPI-Fc was able to suppress the effects of EAE, on days 4 and 7 
post-immunization, five mice were intravenously injected with 25 nmol of the BPI-Fc and five 
with a PBS control. The study required approximately 15 mg of BPI-Fc. In order to inject two 




to allow for injection volumes of 150 µL per dose. During the course of the study, the mice were 
weighed and their physical symptoms associated with the disease were scored (Figure 2.6). The 
BPI-Fc treated mice showed significantly milder symptoms compared to the PBS control 
(Figure 2.6A). At the height of symptoms, the PBS control mice experienced complete paralysis 
of one or two hind limbs (average score = 3), whereas the BPI-Fc treated mice experienced, at 
most, tail weakness (average score = 0.4). Furthermore, at no point during the study did the BPI-
Fc treated mice weigh less than their respective weights at day 0 (Figure 2.6B). In fact, the 
overall trend in the % change in body weight showed that the BPI-Fc treated mice were gaining 
weight throughout the study. On the other hand, the PBS control mice lost an average of 16% of 
body weight at the height of symptoms (day 12). These results show that the BPI-Fc protected 
the mice against the physical disablements and weight loss caused by EAE.  
 
 
Figure 2.6: Comparison of EAE mice treated with BPI-Fc (LABL-Fc-ST-PLP) vs. PBS control 
(n = 5). (A) EAE clinical score in SJL/J mice after disease induction and treatment. Mice were 
scored during the course of the study from 0-5 based on the physical symptoms observed. (B) % 
change in body weight in SJL/J mice after disease induction and treatment. Each mouse was 
weighed during the course of the study and the weight at each of the measured days compared 





On day 14, one mouse from the BPI-Fc treated and one mouse from the PBS control 
group was sacrificed along with a normal mouse that was neither induced with EAE nor treated. 
A brain slice from each mouse was sent to IHC World for Luxol Fast Blue (LFB) staining 
(Figure 2.7). The amount of staining is representative of the amount of myelin present in the 
brain slice, which is representative of the severity of the disease. A one-way ANOVA showed 
that there was a statistical difference between the three tissue groups (p = 0.0004). A Tukey 
multiple comparisons test showed no statistical difference in the amount of myelin staining 
between the normal control mouse that was neither induced with the EAE disease nor treated and 
the BPI-Fc-treated mouse (p = 0.2288). On the other hand, there was a statistical difference in 
the amount of myelin staining between the normal control mouse and the PBS control mouse (p 
= 0.0004). These results show that the BPI-Fc protected the mice against the demyelination 






Figure 2.7: Luxol fast blue staining of mice brain slices on day 14 after EAE induction. (A) 
Normal: mouse neither induced with EAE nor treated. (B) BPI-Fc: mouse induced with EAE and 
treated with BPI-Fc. (C) PBS: mouse induced with EAE and treated with PBS. (D) 
Quantification of the area stained by LFB in each tissue. The % Area Stained by LFB for each 
tissue was measured in triplicate, and the results between the three tissue samples were compared 
for statistical significance using a one-way ANOVA and Tukey multiple comparisons test. 
 
2.4 Conclusions 
MS is an autoimmune disease that causes demyelination of the neurons in the central 
nervous system. There is currently no cure for MS, and current therapies globally suppress the 
immune system. BPIs are a promising novel approach to treating autoimmune diseases like MS 
and can potentially be designed to specifically prevent the activation of immune cells against a 
particular antigen. They are composed of an antigenic peptide fused to a signal-2 blocking 




the BPI peptides could still work when fused to an IgG1 Fc scaffold. The initial strategy was to 
fuse both peptides (antigenic peptide PLP139-151 and signal-2 blocking peptide LABL) to the Fc 
using recombinant DNA technology. However, this strategy didn’t work because expression in 
yeast resulted in proteolysis of the PLP peptide. Three different expression conditions were 
tested, but severe proteolysis of the PLP peptide was observed in all three expressions. 
Furthermore, a different antigenic peptide (MOG38-50) was tested instead of PLP. However, 
proteolysis of the MOG region was even more severe than PLP.  
Alternatively, a sortase-ligation strategy was developed to conjugate the antigenic 
peptides to a human IgG1 Fc fused to LABL. When IgG1 Fc fused to LABL and a sortase tag 
was expressed in glycosylation-deficient yeast, there was no proteolysis and good yield of the 
protein. The sortase ligation worked well to attach both the PLP and MOG antigenic peptides to 
the LABL-Fc-ST fusion protein in high yields (90% for both ligations). The advantage of this 
approach is that it avoids the proteolysis and expression problems that seem to be associated with 
the antigenic peptides that we have experienced. It also allows a single fusion protein (LABL-Fc-
ST) to be expressed in quantity and then ligated to multiple antigenic peptides, which may be 
helpful to combat antigen spreading.57 Additionally, this method may be used to screen peptides 
for improved BPI-Fcs. The ligation strategy to produce LABL-Fc-ST-PLP was scaled up to 
produce enough material (19 mg) to conduct a mouse study. Scaling up reduced the ligation yield 
some, but not much (90% small scale vs. 87-89% large scale). The mouse study was conducted 
in EAE-induced mice, and it was found that the BPI-Fc worked very well and significantly 
suppressed EAE in a mouse model. BPI-Fc fusions are a promising line of research and will be 
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Chapter 3  
 
b1,2-N-acetylglucosamine On The a1,6-Arm Of The N-glycan Of IgG1 Fc 







Antibody-based therapeutics are a rapidly expanding class of biopharmaceuticals. The 
number of approved antibody-based therapeutics by the FDA and EMA has more than doubled 
in the last five years, and they are expanding into areas such as antibody-drug conjugates, 
bispecific antibodies, and biosimilars.1 Most antibody-based therapeutics use the 
Immunoglobulin isotype G subclass 1 (IgG1) antibody. IgG1 consists of two light chains and 
two heavy chains. Both heavy chains have a conserved N-glycosylation site in the fragment 
crystallizable (Fc) region at Asn297 (Figure 1.1A). The glycosylation at this site can markedly 
affect the antibody’s stability, solubility, susceptibility to proteolysis, pharmacokinetics, and 
immune system function through engagement of C1q and FcgRs.2-5 Therefore, it is important to 
study IgG1 N-glycosylation. However, expression of IgG1, in both natural and recombinant 
systems, results in a mixture of N-glycoforms.6, 7 This heterogeneity makes it difficult to 
understand how N-glycosylation affects IgG1 stability and function because different N-
glycoforms can affect the antibody differently.3 For instance, the addition of terminal sialic acid 
to the N-glycan reduces antibody-dependent cellular cytotoxicity (ADCC),8 a vital effector 
function that contributes to the cell-killing activity of some cancer immunotherapeutics,9, 10 
whereas the addition of terminal galactose increases ADCC.11, 12 
The composition of the N-glycan determines the intramolecular glycan-protein contacts. 
There are contacts between specific sugar residues of the N-glycan and specific amino acid 
residues of the polypeptide. One important contact is a hydrogen bond between the innermost N-
acetylglucosamine (GlcNAc) of the N-glycan and Asp265 of the Fc polypeptide.13 This contact 
helps to stabilize the C’E loop of the Fc. Another important interaction is a hydrophobic 




hydrophobic interaction between GlcNAc on the a1,6-arm of the N-glycan and Phe243 of the Fc 
polypeptide. Abolishing any of these three interactions by mutating the amino acid residues at 
these sites weakens the affinity of the Fc for binding the FcgRIIIa, the primary FcgR on natural 
killer (NK) cells that activates ADCC.13-15 For example, the complete removal of the N-glycan 
prevented binding to FcgRIIIa (highest Fc concentration tested = 20 µM), but the addition of just 
a single GlcNAc allowed for binding at low µM affinity.16 Abolishing these contacts also 
increases the mobility of the N-glycan as observed from solution NMR spectroscopy.15 A more 
mobile N-glycan resulted in a weaker affinity to FcgRIIIa.15 These contacts orient the Fc 
interface to allow for optimal binding to FcgRIIIa.13-15 In general, the longer the glycan, the 
higher the binding affinity because more intramolecular protein-glycan contacts exist.2 
Additionally, removal of these contacts through amino acid mutations causes increased N-glycan 
processing, leading the increased levels of galactose, sialic acid, and bisecting GlcNAc.13, 14 The 
increased dynamics may be allowing the N-glycan to be more accessible to the processing 
enzymes during N-glycan biosynthesis. 
IgG1 is expressed, in both native and recombinant systems, mostly with core-linked 
fucose present on the N-glycan.6, 7 An analysis of 10 FDA-approved monoclonal antibody 
therapeutics showed that the antibodies ranged from 90-98% fucosylated.6 The presence of 
fucosylation on the Fc N-glycan has been shown to dramatically reduce binding affinity for 
FcgRIIIa and decrease ADCC activity.17 However, reported KD values that compare fucosylated 
vs. afucosylated Fc binding to FcgRIIIa vary significantly, with between 2 to 50-fold differences 
being reported.12, 17-21 The reported differences are likely due to several factors such as 
differences in Fc N-glycosylation, differences in FcgRIIIa N-glycosylation, FcgRIIIa valency, 




receptor-binding assay that compares a variety of oligomannose, hybrid, and complex 
homogenous N-glycoforms. Because of the increased ADCC observed by removing core-linked 
fucose, there is interest in the pharmaceutical industry to reduce fucosylation levels in order to 
develop more effective monoclonal antibody-based therapies.22 Furthermore, previous studies 
that observed relative rates of fucosylation between different N-glycoforms did so using the free 
glycan. However, the aforementioned intramolecular contacts between the Fc N-glycan and 
polypeptide may be influencing the affinity of the a1,6-fucosyltranferase (FUT8) for the glycan. 
Therefore, it would be advantageous to observe the rates of fucosylation on N297-bound glycan 
substrates in order to better understand where fucosylation is occurring in the biosynthetic 
pathway. 
This work further investigates the effect of N-glycosylation on IgG1 stability and 
function. IgG1 Fc was used as a model system to prepare several homogenous IgG1 Fc N-
glycoforms, and their effects on IgG1 Fc stability, function, and core-linked fucosylation kinetics 
were studied individually. This was performed by first expressing IgG1 Fc in glycosylation-
deficient yeast to obtain a high mannose N-glycoform. The high mannose N-glycoform was then 
converted, using a stepwise series of glycosidases and glycotransferases, into seven 
oligomannose, hybrid, and biantennary complex N-glycoforms with and without fucose using in-
vitro enzymatic synthesis. The stability of each non-fucosylated N-glycoform was compared 
using differential scanning calorimetry. Next, the function of all seven homogenous IgG1 Fc N-
glycoforms was compared in an in-vitro receptor-binding assay using FcγRIIIa. The receptor 
binding affinity of two previously unreported N-glycoforms is reported. Lastly, the hybrid and 
complex N-glycoforms were compared for their relative abilities to accept core-linked fucose in 





3.2 Materials and Methods 
3.2.1 Materials 
 The pPICzaA and pET28a expression vectors were purchased from Invitrogen (USA) 
and Novagen (Madison, WI), respectively. The QIAprep Spin Miniprep Kit, QIAquick Gel 
Extraction Kit, and Ni-NTA agarose resin were purchased from Qiagen (Germantown, MD). 
Yeast extract, tryptone, and agar were purchased from Becton, Dickinson, and Co. (Franklin 
Lakes, NJ). Zeocin was purchased from Invivogen (San Diego, CA). Yeast nitrogen base was 
purchased from Sunrise Science (San Diego, CA). All molecular biology enzymes and protein 
markers were purchased from New England BioLabs (Ipswich, MA). The protein A-sepharose 
and phenyl-sepharose resins were purchased from GE Healthcare (Waukesha, WI). All dialysis 
tubing was purchased from Spectrum Labs (Rancho Dominguez, CA). Dithiothreitol (DTT) and 
the materials used to prepare the polyacrylamide gels for SDS-PAGE were purchased from Bio-
Rad (Hercules, CA). Protease-free bovine serum albumin was purchased from VWR (USA). 
Streptavidin biosensor tips were purchased from FortéBio (Menlo Park, CA). Pyruvate kinase 
and lactate dehydrogenase were purchased from Millipore-Sigma (St. Louis, MO). An 
expression plasmid for peptide: N-glycosidase F (PNGase F) was gifted by the Lott laboratory at 
Massey University, from which PNGase F was prepared as previously described.23 Additionally, 
an expression plasmid for Staphylococcus aureus sortase A was gifted by the DiMarchi 
laboratory at Indiana University, from which sortase A was prepared as previously described.24 
Standard chemicals were purchased from commercial sources. 
3.2.2 Expression and purification of IgG1 Fc 
 Our laboratory previously cloned the fragment crystallizable region of the heavy chain of 




Fc.16, 25 This plasmid was linearized with the restriction endonuclease SacI-HF and transformed 
using electroporation into a glycosylation-deficient strain of the yeast Pichia pastoris (deleted 
och1, pno1, and bmt 1&2 genes and inserted STT3D gene from Leishmania major in order to 
improve N-glycosylation site occupancy).25-27 The transformed cells were plated on YPD agar 
(1% yeast extract, 2% tryptone, 2% glucose, 1.5% agar) containing 100 µg/mL zeocin and grown 
for 6 days at 30ºC. 
 A colony was selected and transferred to a shake tube containing 2 mL of YPD media 
(1% yeast extract, 2% tryptone, 2% glucose) and 100 µg/mL zeocin, which was grown at 30ºC 
for 3 days and 250 rpm. After 3 days, the 2 mL culture was transferred to a baffled Erlenmeyer 
flask containing 50 mL YPD media and 100 µg/mL zeocin, which was grown at 30ºC and 250 
rpm. After 2 days, the 50 mL culture was transferred to a 1 L spinner flasks containing 1% yeast 
extract, 2% tryptone, 2% glycerol, 100 mM sodium phosphate buffer pH 6.2, 1.34% yeast 
nitrogen base, 0.00004% biotin, and 1 drop antifoam. The culture was stirred on a stir plate at 
r.t., and air flow was maintained at 3 L/min through an in-line sterile filter. The culture was 
grown for 3 days. After which, the pH of the culture was adjusted back to 6.2 using concentrated 
NH4OH. Then, induction was started by adding 0.5% methanol, which was maintained by 
adding 0.5% methanol approximately every 12 hours for 3 days. After induction, the culture was 
harvested by centrifugation at 6693 x g for 20 min using a Beckman JLA 10.5 rotor and 
Beckman Avanti J-series centrifuge (USA). The pellet was discarded, and the pH of the 
supernatant was adjusted to 6.5 using KOH. This expression procedure was repeated eight times 
to produce a total of nine liters.  
The supernatant was filtered through Whatman #1 filter disks using vacuum filtration. 
The IgG1 Fc protein was purified from the supernatant using protein A affinity chromatography. 




mL/min was maintained throughout the purification using a peristaltic pump. A UV detector was 
set up in-line after the column outlet. The column was equilibrated with 10 CV of 20 mM 
sodium phosphate buffer pH 6.5. Then, 2 L of filtered supernatant was passed through the 
column. Next, the column was washed with 25 CV of 20 mM sodium phosphate buffer pH 6.5. 
Lastly, 3 CV of 100 mM glycine-HCl buffer pH 3.0 was passed through the column to elute the 
IgG1 Fc protein. The eluted protein was immediately dialyzed in 2 L of 20 mM sodium 
phosphate buffer pH 7.5 using 3500 MWCO dialysis tubing. The protein was dialyzed at 4ºC 
overnight with one buffer change the following day. This purification procedure was repeated for 
the remaining 6 liters of supernatant in 2 L batches. The IgG1 Fc was characterized by intact 
mass spectrometry and SDS-PAGE (Figure 3.1A&C). The amount of IgG1 Fc obtained after 
protein A affinity chromatography was 243 mg. Observed vs. expected MW (Table 3.1).  
 






The IgG1 Fc was further purified using hydrophobic interaction chromatography (HIC). 
Solid (NH4)2SO4 was dissolved in the IgG1 Fc solution to a final concentration of 1 M, and the 
solution was filtered through a 0.2 µm syringe filter. The purification was performed using 125 
mL of phenyl-sepharose resin and a GE Healthcare ÄKTAmicro FPLC (Waukesha, WI) 
controlled by the UNICORN software (version 5.20). Throughout the purification, the flow rate 
was maintained at 2 mL/min. Elution from the column was monitored using an in-line UV/VIS 
spectrophotometer at 220 nm. All buffers were prepared using Milli-Q water and filtered through 
Species Observed MW (Da) Expected MW (Da) 
Non-glycosylated 25066.4 25066.5 
M8 26770.3 26770.7 
M9 26932.4 26932.1 




a 0.2 µm filter using vacuum filtration prior to use. The column was first washed with 5 CV of 
Milli-Q water. Then the column was equilibrated with 5 CV of buffer A (20 mM sodium 
phosphate pH 7.5 containing 1 M (NH4)2SO4). Next, 40-50 mg of IgG1 Fc protein containing 1 
M (NH4)2SO4 was loaded onto the column using a peristaltic pump. Next, the following 
sequential method was used: 0% buffer B (20 mM sodium phosphate pH 7.5) for 1 CV, a linear 
gradient of 0-27% buffer B for 1 CV, a linear gradient of 27-31% buffer B for 9.5 CV, a linear 
gradient of 31-100% buffer B for 1 CV, and 100% buffer B for 1 CV. During the linear gradient 
of 27-31% buffer B, 10 mL fractions were collected using a fraction collector. The fractions that 
showed a signal at 220 nm were analyzed using intact mass spectrometry in order to determine 
their N-glycan site occupancy. Fractions that contained ≥99% di-glycosylated IgG1 Fc were 
pooled and concentrated using a 10 kDa MWCO centrifugal concentrator and dialyzed using 
3500 MWCO dialysis tubing in 2 L of 20 mM MES buffer pH 6.5 containing 150 NaCl at 4ºC 
with 1 buffer change. This purification method was repeated in 40-50 mg batches. The IgG1 Fc 
was characterized by intact mass spectrometry and SDS-PAGE (Figure 3.1D&F). The amount 
of di-glycosylated IgG1 Fc obtained after HIC was 99 mg (41% yield). Observed vs. expected 
MW (Table 3.2). 
 





3.2.3 In-vitro enzymatic synthesis of homogenous IgG1 Fc N-glycoforms 
3.2.3.1 Synthesis of M5-IgG1 Fc 
Species Observed MW (Da) Expected MW (Da) 
Non-glycosylated Not observed 25066.5 
M8 26770.2 26770.7 
M9 26932.3 26932.1 




Preparation of the a-1,2-mannosidase (Mannosidase-I) and endomannosidase enzymes 
can be found in Appendix 2 (A.2.1.1.1). For the conversion of HM-IgG1 Fc to M5-IgG1 Fc, the 
total reaction consisted of the following: 93 mg HM-IgG1 Fc at 0.5 mg/mL, 6 mg of a1,2-
mannosidase26, 28, and 0.4 mg of endomannosidase26 in 20 mM MES buffer pH 6.5. The reaction 
was mixed and pipetted into dialysis tubing and allowed to react during dialysis at r.t. in 2 L of 
20 mM MES buffer pH 6.5 containing 150 mM NaCl and 5 mM CaCl2. The reaction was 
allowed to proceed for 4 days at r.t. The resulting M5-IgG1 Fc was analyzed by ESI-qTOF MS 
and SDS-PAGE (Figure 3.3A and Figure 3.4 lane 2). ESI-qTOF MS: observed 26285.2 Da, 
expected 26283.5 Da. Total protein yield: 83 mg (89%). 
3.2.3.2 Synthesis of M5H-IgG1 Fc 
Preparation of the b1,2-N-acetylglucosaminyltransferase-I (GnT-I) enzyme can be found 
in Appendix 2 (A.2.1.1.2). For the conversion of M5-IgG1 Fc to M5H-IgG1 Fc, the total 
reaction consisted of the following: 78 mg of M5-IgG1 Fc at 3 mg/mL, 1 mM UDP-GlcNAc, 10 
mM MnCl2, and 0.9 mg of GnT-I29 in 20 mM HEPES buffer pH 7.5. The reaction was incubated 
at 25ºC for one day. The resulting M5H-IgG1 Fc was analyzed by ESI-qTOF MS and SDS-
PAGE (Figure 3.3B and Figure 3.4 lane 3). ESI-qTOF MS: observed 26488.6 Da, expected 
26486.7 Da. Yield: 74 mg (95%). 
3.2.3.3 Synthesis of M3H-IgG1 Fc 
Preparation of the a-1,3/6-mannosidase (Mannosidase-II) enzyme can be found in 
Appendix 2 (A.2.1.1.3). For the conversion of M5H-IgG1 Fc to M3H-IgG1 Fc, the total reaction 
consisted of the following: 45 mg of M5H-IgG1 Fc at 0.5 mg/mL and 3 mg of mannosidase-II in 




M3H-IgG1 Fc was analyzed by ESI-qTOF MS and SDS-PAGE (Figure 3.3C and Figure 3.4 
lane 4). ESI-qTOF MS: observed 26163.0 Da, expected 26162.5 Da. Yield: 42 mg (93%). 
3.2.3.4 Synthesis of G0-IgG1 Fc 
Preparation of the N-acetylglucosaminyltransferase-II (GnT-II) enzyme can be found in 
Appendix 2 (A.2.1.1.4). For conversion of M3H-IgG1 Fc to G0-IgG1 Fc, the total reaction 
consisted of the following: 30 mg of M3H-IgG1 Fc at 3 mg/mL, 1 mM UDP-GlcNAc, 10 mM 
MnCl2, 0.09 mg of GnT-II in 20 mM MES buffer pH 6.5. The reaction was incubated at 25ºC. 
After 2 days, another 0.04 mg of GnT-II was added and the reaction was incubated for another 
day. The resulting G0-IgG1 Fc was analyzed by ESI-qTOF MS and SDS-PAGE (Figure 3.3D 
and Figure 3.4 lane 5). ESI-qTOF MS: observed 26364.0 Da, expected 26365.6 Da. Yield: 26 
mg (87%). 
3.2.3.5 Chemoenzymatic synthesis of GDP-Fucose 
L-fucokinase/guanosine 5'-diphosphate-L-fucose pyrophosphorylase (FKP) was 
expressed by Dr. Khalid Al-Kinani in E. coli Rosetta 2 using a similar procedure as previously 
described.30 FKP concentration was determined using a Pierce BCA Protein Assay Kit (Thermo 
Scientific, Waltham, MA) according to manufacturer’s instructions. On 25 mL scale, the 
following reaction was prepared: 5 mM ATP, 10 mM L-fucose, 10 mM MgCl2 and 104 µg/mL 
FKP in 100 mM HEPES buffer pH 7.5. The reaction was incubated at 28ºC for 18 hrs. After 
which, 70 mg of solid GTP (yielding a final concentration of 5 mM GTP) was added along with 
1 U of yeast inorganic pyrophosphatase (New England BioLabs, Ipswich, MA). The reaction 
was incubated at 28ºC for 22 hrs. After which, 100 U of calf intestinal alkaline phosphatase was 
added. The reaction was allowed to proceed at 28ºC for 71 hrs. 
The progress of the reaction was monitored using ion pair chromatography (IPC) using a 




Thermo Scientific Hypersil C18 column (5 µm, 4.6 mm x 250 mm) was attached to a Shimadzu 
UPLC. The column was equilibrated with 100 mL of buffer A (100 mM potassium phosphate pH 
6.4, 8 mM tetrabutylammonium hydrogen sulfate) A linear gradient consisted of the following: 
0% buffer B (70 mM potassium phosphate pH 6.4, 30% acetonitrile, 8 mM tetrabutylammonium 
hydrogen sulfate) for 8 min, a linear gradient of 0-77% buffer B for 8 min, a linear gradient of 
77-100% buffer B for 4 min, 100% buffer B for 3 min, and finally 100% buffer A for 8 min. The 
flow rate was 1.3 mL/min, and the column oven temperature was 40ºC. Throughout the method, 
UV absorbance at 254 nm was monitored (Appendix 2: Figures A.2.3 and A.2.4) 
 GDP-fucose was purified from the reaction using size exclusion chromatography. A flow 
rate of 0.3 mL/min was maintained using an ÄTKAmicro. A 2.5 cm x 30 cm column was packed 
with 100 mL of Bio-Gel P2 resin (Bio-Rad, Hercules, CA). A peristaltic pump was used to load 
the GDP-fucose reaction mixture. 5 mL of the reaction mixture (1/5th of the total reaction) was 
loaded on to the column. Then, 1.2 CV of Milli-Q water was pumped through during which 1 
mL fractions were obtained. This purification procedure was repeated 4 times for the remaining 
20 mL of reaction mixture. The fractions that corresponded to GDP-fucose were pooled and 
reanalyzed using IPC. After determining that those fractions contained GDP-fucose but no ADP, 
the fractions were lyophilized. In order to remove residual alkaline phosphatase, the lyophilized 
GDP-fucose was dissolved in 50 mM HEPES buffer pH 7.5 and then passed through a Strata 
C18-E solid phase extraction sorbent (Phenomenex, Torrance, CA). The flow through was 
collected. The concentration of purified GDP-fucose was determined using UV 
spectrophotometry at 254 nm using the extinction coefficient for GDP (e254 = 13,800 M-1cm-1).32 
Based on the starting amount of GTP, the GDP-fucose yield was 42%.  




Preparation of the a1,6-fucosyltransferase (FUT8) enzyme can be found in Appendix 2 
(A.2.1.1.5). For conversion of M5H-IgG1 Fc to M5HF-IgG1 Fc, the following reaction was 
performed: 16 mg of M5H-IgG1 Fc at 1 mg/mL, 1 mM of impure GDP-fucose, 0.1 mg FUT8 in 
20 mM MES buffer pH 7.0. The reaction was incubated at 25ºC for 2 days. The resulting M5HF-
IgG1 Fc was analyzed by ESI-qTOF MS and SDS-PAGE (Figure 3.3E and Figure 3.4 lane 6). 
ESI-qTOF MS: observed 26629.0 Da, expected 26632.8 Da. Yield: 14 mg (87%). 
3.2.3.7 Synthesis of M3HF-IgG1 Fc 
Preparation of the Mannosidase-II enzyme can be found in Appendix 2 (A.2.1.1.3). For 
conversion of M5HF-IgG1 Fc to M3HF-IgG1 Fc, the following reaction was performed: 12 mg 
of M5HF-IgG1 Fc at 0.5 mg/mL and 0.7 mg mannosidase-II in 20 mM MES buffer pH 6.0. The 
reaction was incubated at 25ºC for 1 day.  The resulting M3HF-IgG1 Fc was analyzed by ESI-
qTOF MS and SDS-PAGE (Figure 3.3F and Figure 3.4 lane 7). ESI-qTOF MS: observed 
26304.0 Da, expected 26306.5 Da. Yield: 10 mg (83%). 
3.2.3.8 Synthesis of G0F-IgG1 Fc 
Preparation of the GnT-II enzyme can be found in Appendix 2 (A.2.1.1.4). For 
conversion of M3HF to G0F, the following reaction was performed: 8 mg of M3HF at 3 mg/mL, 
1 mM of UDP-GlcNAc, 10 mM of MnCl2, 0.02 mg of GnT-II in 20 mM MES buffer pH 6.5. 
The reaction was incubated at 25ºC. After 2 days, another 0.01 mg of GnT-II was added and the 
reaction was incubated for another day. The resulting G0F-IgG1 Fc was analyzed by ESI-qTOF 
MS and SDS-PAGE (Figure 3.3G and Figure 3.4 lane 8). ESI-qTOF MS: observed 26508.0 
Da, expected 26511.7 Da. Yield: 6 mg (75%). 
3.2.3.9 General procedures for reaction analysis and purification 
The progress of each reaction was monitored using intact mass spectrometry under 




purified from the reaction using protein A affinity chromatography. First, the reaction was 
diluted 5X with 20 mM MES buffer pH 6.5. A column containing 20 mL of Protein A resin was 
equilibrated with 25 CV of 20 mM MES buffer pH 6.5. Then, the diluted reaction mixture was 
loaded. Next, the column was washed with 25 CV of 20 mM MES buffer pH 6.5 containing 500 
mM NaCl. Lastly, the IgG1 Fc glycoprotein was eluted using 2-3 CV of 100 mM Gly-Cl buffer 
pH 3.0. The eluted protein was immediately pipetted in 3500 Da MWCO dialysis tubing and 
dialyzed into 2 L of buffer needed for the next enzymatic step. All dialyses occurred at 4ºC with 
1 buffer change. The purified IgG1 Fc N-glycoforms were analyzed using intact mass 
spectrometry by injecting 6 µg of each non-fucosylated N-glycoform under reducing conditions, 
11 µg for each fucosylated N-glycoform under reducing conditions, and 11 µg for all N-
glycoforms under non-reducing conditions. The N-glycoforms were also analyzed using SDS-
PAGE according to a method previously described.24  
3.2.4 Intact protein mass spectrometry 
An Agilent 6520 Quadrupole Time-Of-Flight LC/MS with an electrospray ionization 
source was used (Santa Clara, CA). All samples were prepared with a pH between 6-8. For 
samples analyzed under reducing conditions, 10 mM DTT was added. For samples analyzed 
under reducing conditions, no DTT was added. The samples were centrifuged for 5 min at 
16,100 x g using an Eppendorf 5415D centrifuge (Hauppauge, NY). The supernatant was 
pipetted into an autosampler vial containing a glass insert. 6-11 µg of each IgG1 Fc N-glycoform 
was injected onto the LC column (Vydac 214 MS C4, 50 mm length x 2.4 mm ID, 300 Å particle 
size, 5 µm pore size). The two LC mobile phases were composed of the following: A = Milli-Q 
water and B = 99.9% acetonitrile, 0.02% LC/MS-grade trifluoroacetic acid, 0.08% LC/MS-grade 
formic acid. The following sequential LC method was employed: 5% mobile phase B at 1.0 




mobile phase B for 3.0 min at 0.5 mL/min, a linear gradient of 90-5% mobile phase B for 0.5 
min at 1.0 mL/min, and 5% mobile phase B for 1.5 min at 1 mL/min. Data was collected using 
the Agilent MassHunter Acquisition software (version B.02.00) and processed using the Agilent 
MassHunter Qualitative Analysis software (version B.03.01). 
3.2.5 Analytical size exclusion chromatography 
 The non-fucosylated N-glycoforms were characterized using SEC according to a method 
previously described.16 Briefly, 30 µg of each non-fucosylated N-glycoform (40 µL at 0.75 
mg/mL) were injected on a TSKgel G3000SWXL column (5 µm, 7.8 mm ID x 30 cm) (TOSOH 
Bioscience, King of Prussia, PA). An isocratic gradient of 0.2 M sodium phosphate buffer pH 
6.8 was used at a flow rate of 0.7 mL/min for 30 minutes per run. Each IgG1 Fc N-glycoform 
was performed in triplicate. Monomer and soluble aggregate values were quantified using the 
Shimadzu LC Solutions Software (Kyoto, Japan). 
3.2.6 Thermal stability assessed by turbidity measurements at 350 nm 
 The non-fucosylated N-glycoforms were characterized using OD350 nm measurements 
at various temperatures using a method previously described.2 Briefly, 250 µL of 0.2 mg/mL in 
20 mM MES buffer pH 7.0 of each non-fucosylated N-glycoform was analyzed using a Cary 100 
Bio UV-Visible Spectrophotometer (Agilent, Santa Clara, CA). The temperature parameters 
were as follows: temperature range of 10-100ºC, ramp of 1ºC/min, and a measurement was taken 
every 1.25ºC with a 2 min hold before each measurement. The sample was monitored using 
UV/VIS spectrophotometry at 350 nm. Each IgG1 Fc N-glycoform was measured in triplicate.  
3.2.7 Differential Scanning Calorimetry (DSC)  
 Approximately 1 mg of each non-fucosylated IgG1 Fc N-glycoform was dialyzed in 2 L 
of 20 mM MES buffer pH 7.0 overnight at 4ºC with 1 buffer change the following day. Each N-




concentration, the N-glycoforms were filtered using 0.2 µm syringe filters. Then, the 
concentration of each N-glycoform was adjusted to 0.5 mg/mL by measuring the absorbance at 
280 nm using UV/VIS spectrophotometry (e280 = 71570 M-1cm-1)33 and diluting as necessary. 
Each IgG1 Fc N-glycoform was analyzed using DSC. A MicroCal VP-Auto DSC (Northampton, 
MA) was used. 200 µL of 0.5 mg/mL of each sample was injected. The samples were analyzed 
from 10-100ºC with a temperature ramp of 1ºC/min. Each sample was measured in triplicate. 
Also, a reference sample containing 20 mM MES buffer pH 7.0 was analyzed in triplicate. A 
water blank was injected between each sample. Samples were stored in an autosampler at 4ºC 
until injection. Data was processed using Origin 7 software containing a MicroCal LLC DSC 
plug in. The data for each sample was subtracted against the reference sample. The data were 
also normalized for concentration and adjusted to a consistent baseline. The data were fitted to a 
three-transition model to calculate Tm1, Tm2, and Tm3, which corresponded to the temperature that 
correlated with the maximum heat capacity. Tonset was determined as the earliest temperature to 
cause the heat capacity to reach 0.5 kcal/mol/ºC.  
3.2.8 Production of FcgRIIIa  
3.2.8.1 Molecular cloning 
 The extracellular region of human FcgRIIIa (accession# BC017865) V158 polymorph 
was cloned with a C-terminal ST tag followed by a hexahistidine (His6) tag. This modification 
was performed using PCR with primers (forward 5’- ggcgccgctagctatgcggactgaagatctcccaaaggc 
and reverse 5’-gccgcgcgcgcggccgcttaatgatgatggtggtggtgtccacctccagtttctggcaatccaccaccttg 
agtgatggtgatgttcac), and pPICzaA-FcgRIIIa, produced previously in our laboratory,25 was used 
as a template to amplify the FcgRIIIa-ST-His6 PCR product. This PCR product was purified 




and NotI-HF. A pPICzA plasmid containing the a-factor secretion peptide (but not the a-factor 
protein) followed by an NheI restriction site was designed by Dr. Tolbert. This plasmid was 
digested with the same restriction endonucleases. Both were gel purified and then ligated 
together using T4 DNA Ligase. The construct was then transformed into electrocompetent E. 
coli Top10f’ cells, which were plated on low salt LB agar (0.5% yeast extract, 1% tryptone, 
0.5% NaCl, 1.5% agar) containing 25 µg/mL zeocin and grown overnight at 37ºC. To confirm 
the correct sequence, the plasmid DNA was extracted using a QIAprep Spin Miniprep Kit 
(Germantown, MD) and sequenced by the UC-Berkeley DNA Sequencing Facility (Berkeley, 
CA). The plasmid DNA with a confirmed sequence was then linearized using the restriction 
endonuclease SacI and transformed into electrocompetent, glycosylation-deficient P. pastoris 
(deleted och1, pno1, and bmt 1&2 genes and inserted STT3D gene from L. major in order to 
improve N-glycosylation site occupancy)25-27 cells using electroporation. The cells were then 
plated on YPD agar containing 100 µg/mL zeocin and grown at 30ºC for 6 days.  
3.2.8.2 Expression and purification 
 A colony was transferred to a shake tube containing 2 mL YPD media and 100 µg/mL 
zeocin and grown at 30ºC and 250 rpm. After 3 days, the culture was transferred to a 250 mL 
baffled Erlenmeyer flask containing 50 mL YPD media and 100 µg/mL zeocin and grown at 
30ºC and 250 rpm. After 2 days, the culture was transferred to a 1 L spinner flask containing 1% 
yeast extract, 2% tryptone, 100 mM sodium phosphate buffer pH 6.2, 2% glycerol, 1.34% yeast 
nitrogen base, 0.00004% biotin, and 1 drop of Antifoam 204. Each culture was stirred on a stir 
plate at r.t. The air flow was maintained at 3 L/min and contained an in-line sterile filter. After 3 
days of growth, the pH of the culture was adjusted back to 6.2 using concentrated NH4OH. The 




hours for 3.5 days. After induction, the cultures were centrifuged at 6,693 x g for 20 min using a 
Beckman Avanti J-series centrifuge (USA). The supernatant was collected, and the pH of the 
supernatant was raised to 7.5 using KOH. The precipitate was allowed to settle at 4ºC for 4 hrs. 
This procedure was repeated three times for a total of four liters.  
The supernatant was filtered through Whatman #1 filter disks using vacuum filtration. 
The FcgRIIIa-ST-His6 protein was purified from the supernatant using Ni-NTA affinity 
chromatography. A 2.5 x 20 cm column was packed with 10 mL of Ni-NTA-Agarose resin. The 
flow rate was maintained at 15 mL/min using a peristaltic pump. A UV detector was installed in-
line post-column. The column was first equilibrated with 30 CV of 50 mM sodium phosphate 
buffer pH 7.5. Then, 1 L of supernatant was passed through. Then the column was washed with 
50 CV of wash buffer (50 mM sodium phosphate buffer pH 7.5, 500 mM NaCl, 5% glycerol, 20 
mM imidazole). Finally, the FcgRIIIa-ST-His6 was eluted using 2 CV 50 mM sodium phosphate 
buffer pH 7.5 containing 250 mM imidazole. The eluted protein was pipetted into 3500 Da 
MWCO dialysis tubing and dialyzed in 2 L of 20 mM sodium phosphate buffer pH 7.5 at 4ºC 
with 1 buffer change. It was observed that passing the supernatant through the column stripped 
much of the Ni2+ off the column. The Ni2+ was re-loaded by passing 2 CV of 100 mM NiSO4 
through the column, with 5 CV dH2O passed through before and after. This purification method 
was repeated for the remaining 3 L of supernatant in 1 L batches. The amount of FcgRIIIa-ST-
His6 protein obtained was determined by measuring the absorbance at 280 nm using UV 
spectrophotometry (MW = 21683.2 Da, e280 = 39670 M-1cm-1).33 The final yield was 40 mg (10 
mg/L). 
 Solid (NH4)2SO4 was dissolved in the solution of 40 mg of FcgRIIIa-ST-His6 to a final 




used in the purification were pre-filtered through a 0.22 µm filter using vacuum filtration. The 
flow rate was maintained at 2 mL/min. An GE Healthcare ÄKTAmicro was used throughout this 
purification. A UV/VIS detector was installed in-line post-column, and absorbance at 220 nm 
was observed. A GE Healthcare column was packed with 125 mL phenyl-sepharose resin. The 
column was first washed with 5 CV of Milli-Q water. Then, the column was equilibrated with 5 
CV of buffer A (20 mM sodium phosphate pH 7.5 containing 2 M (NH4)2SO4). Next, 40 mg of 
FcgRIIIa-ST-His6 was loaded onto the column using a peristaltic pump. Finally, the following 
sequential method was employed: a linear gradient of 33-40% buffer B (20 mM sodium 
phosphate pH 7.5) for 1 CV, a linear gradient of 40-70% buffer B for 9.5 CV, a linear gradient of 
70-100% buffer B for 1 CV, 100% buffer B for 2 CV. During the linear gradient of 40-70% 
buffer B, 10 mL fractions were collected using a fraction collector. Fractions were analyzed for 
N-glycan site occupancy using intact mass spectrometry. Fractions that showed receptor with all 
5 N-linked glycosylation sites occupied were pooled, concentrated using a 10.5 kDa MWCO 
centrifugal concentrator, and dialyzed in 2 L of tris-buffered saline (TBS, 50 mM tris buffer 
containing 150 mM NaCl) pH 7.5 at 4ºC with 2 buffer changes. The amount of FcgRIIIa-ST-
His6 protein obtained was determined by measuring the absorbance at 280 nm using UV 
spectrophotometry (MW = 21683.2 g/mol, e280 = 39670 M-1cm-1).33 The final yield was 10 mg 
(25% yield). 
3.2.8.3 Sortase-mediated biotinylation 
A sortase-mediated ligation was performed to C-terminally biotinylate the FcgRIIIa. For 
this reaction, Dr. Shaofeng Duan synthesized a compound containing triglycine with a free 
amino terminus conjugated to biotin via an ethylenediamine linker (Gly3-EDA-Biotin), similar 




performed on a 10 mL scale as follows: 8 µM FcgRIIIa-ST-His6 (1.8 mg), 2 mM CaCl2, 1 mM 
Gly3-EDA-Biotin, and 8 µM sortase A24 in TBS pH 7.5. The reaction was allowed to proceed at 
37ºC for 40 hrs. After which, FcgRIIIa-Biotin was purified from the reaction using Ni-NTA 
affinity chromatography to remove unreacted FcgRIIIa-ST-His6. This purification was 
performed with gravity flow. First, 2 mL of Ni-NTA agarose resin was equilibrated with 15 CV 
of TBS pH 7.5. Then the sortase-mediated biotinylation reaction was loaded onto the column. 
Then the column was washed with 15 CV of TBS pH 7.5 containing 500 mL NaCl, 5% glycerol, 
and 20 mM imidazole. Finally, the elution buffer was passed through the column (TBS pH 7.5 
containing 250 mM Imidazole). The purification steps were analyzed by SDS-PAGE, which 
showed that the majority of the FcgRIIIa-biotin eluted during the wash step. The collected wash 
step was pipetted into 3500 MWCO dialysis tubing and dialyzed in 2 L of PBS pH 7.4 at 4ºC 
with 2 buffer changes. The amount of FcgRIIIa-biotin obtained was determined by measuring the 
absorbance at 280 nm using UV spectrophotometry (MW = 21128.7 g/mol, e280 = 39670 M-1cm-
1).33 The final yield was 1.4 mg (78% yield from biotinylation). 
3.2.9 Bio-Layer Interferometry for FcgRIIIa binding assay 
The concentration of each IgG1 Fc N-glycoform was measured in triplicate (e280 = 71570 
M-1cm-1). First, a biosensor tip coated with streptavidin was hydrated in PBS pH 7.4 for 10 
minutes. The tip was further hydrated in kinetic buffer (PBS pH 7.4 containing 1 mg/mL BSA) 
overnight. Then, the tip was inserted in to a FortéBio BLItz instrument (Menlo Park, CA). The 
tip was placed in kinetic buffer and shaken for 30 sec, which was repeated 3 times to obtain a 
steady baseline. Next, 0.01 µM FcgRIIIa-biotin in kinetic buffer was loaded onto the tip to a 
response level of 0.3 nm. The tip was then placed in kinetic buffer for 6 minutes. After loading 




(the total time to complete an experiment). Next, each IgG1 Fc N-glycoform was tested in a 
series of concentrations from low to high. For each concentration, the following steps were 
performed: 1.) a baseline was established by placing the tip in kinetic buffer for 30 sec, 2.) an 
association phase was performed by placing the tip in IgG1 Fc N-glycoform solution for 180 sec 
for non-fucosylated N-glycoforms (360 sec for fucosylated N-glycoforms), and 3.) a dissociation 
phase was performed by placing the tip in kinetic buffer for 360 sec. The tip was regenerated 
after each dissociation step by placing the tip in 1 mM NaOH for 30 sec followed by kinetic 
buffer for 60 sec and repeating once. The following IgG1 Fc concentrations were analyzed (nM): 
M5, M5H, and M3H = 4, 8, 16, 31, 63, 125, 250, 500; G0 = 2, 4, 8, 16, 31, 63, 125, 250; M5HF 
= 35, 70, 141, 281, 563, 1125, 2250, 4500; M3HF and G0F = 18, 35, 70, 141, 281, 563, 1125, 
2250. This method was performed for all IgG1 Fc N-glycoforms in triplicate. The data for each 
set of IgG1 Fc measurements were fitted using a 1:1 binding model with reference correction (no 
Fc loading) using the BLItzPro Software. The kinetic rate constants (ka and kd) and the 
dissociation constant (KD) were determined and their averages ± standard deviations were 
reported. Additionally, an equilibrium KD for each N-glycoform was measured by plotting the 
binding response at the end of the association phase (206.0-208.0 sec for the non-fucosylated N-
glycoforms and 386.0-388.8 sec for the fucosylated N-glycoforms) against the respective IgG1 
Fc concentration, which was fitted to a non-linear regression using the “one site-specific 
binding” model in Prism 7 software. The equilibrium KD for each N-glycoform was reported as 
the average ± standard deviation. Statistical significance (p < 0.05) of the ka, kd, and kinetic KD 
values were determined by performing a one-way ANOVA followed by a Tukey’s Multiple 
Comparisons test using the Prism 7 software. 
3.2.10 Fucosylation kinetics 




The coupled enzyme assay was performed using a Thermo Scientific Evolution 260 Bio 
UV/VIS Spectrophotometer with a Peltier Control and Cooling Unit (Waltham, MA). The assay 
was monitored at 340 nm. Each assay was performed in a Starna 100 µL quartz, low head space, 
µ-cuvette (Atascadero, CA) at 37°C in HBS pH 7.5. The assay was performed in 125 µL total 
reaction volume according to the following steps: 1.) the N-glycoform or glycan was mixed with 
0.75 mM phosphoenolpyruvate, 2.5 mM MgCl2, 50 mM KCl, 1.25 U pyruvate kinase, 1.75 U 
lactate dehydrogenase, and 175 µU FUT8, 2.) the spectrophotometer was blanked and 0.15 mM 
NADH was added, 3.) a baseline was established for 10 min, and 4.) the fucosylation reaction 
was started by adding 0.36 mM of GDP-fucose. The slope from the initial 4% of the reaction 
was measured, which was reference-corrected from the average slope of triplicate runs 
containing no N-glycoform/glycan. 
3.2.10.2 Determination of FUT8 activity 
The activity of FUT8 was determined using free M3H glycan, which was performed 
according to the FUT8 activity assay (3.2.10.1) procedure with 80 µM free M3H glycan 
substrate. The slope from the initial 4% of the reaction was measured, which was converted to 
µmol fucosylation/min.  
3.2.10.3 KM and Vmax determination of free glycans 
The concentration of each glycan tested (M5H, M3H, and G0) was determined by 
measuring the concentration of IgG1 Fc dimer at 280 nm (e280 = 71570 M-1cm-1)33 and 
multiplying that concentration by 2 (2 N-linked glycans per Fc dimer). After measuring the 
concentration, the free glycans were obtained by treating the IgG1 Fc N-glycoforms with 
PNGase F. Complete de-glycosylation was confirmed using intact mass spectrometry. The free 
glycans were tested in a FUT8 coupled enzyme assay according to the FUT8 activity assay 




The slopes from the initial 4% of each concentration was measured in triplicate. The slopes were 
plotted against their respective free glycan concentrations and fitted to the Michaelis-Menton 
model using the Prism 7 software to obtain KM and Vmax values. 
3.2.10.4 KM and Vmax determination of IgG1 Fc N-glycoforms 
The concentration of each IgG1 Fc N-glycoform tested (M5H, M3H, and G0) was 
determined by measuring the concentration of IgG1 Fc dimer at 280 nm (e280 = 71570 M-1cm-1)33 
and multiplying that concentration by 2 (2 N-linked glycans per Fc dimer). The IgG1 Fc N-
glycoforms were tested in a FUT8 coupled enzyme assay according to the FUT8 activity assay 
(3.2.10.1) procedure. The IgG1 Fc N-glycoform concentrations tested for M5H and M3H were 9, 
18, 36, 75, 150, and 300 µM and for G0 were 25, 50, 100, 200, 400, and 800 µM. The slope from 
the initial 4% of each concentration was measured in triplicate. The slopes were plotted against 
their respective free glycan concentrations and fitted to the Michaelis-Menton model using the 
Prism 7 software to obtain KM and Vmax values. 
3.2.10.5 Analysis of IgG1 Fc N-glycoform fucosylation kinetics by LC/MS 
The IgG1 Fc N-glycoforms were also compared for their relative abilities to accept 
fucose using intact mass spectrometry. For each IgG1 Fc N-glycoform (M5H, M3H, and G0), 
the following reaction was prepared: 0.15 mg/mL IgG1 Fc, 19 µg/mL of FUT8, and 1 mM of 
impure GDP-fucose in 20 mM MES buffer, pH 7.0. The total volume of each reaction was 400 
µL, and the reactions were incubated at 25ºC. The time point was determined by the time of 
injection onto the LC/MS. At each time point, 7.5 µg of IgG1 Fc N-glycoform was injected. The 
% fucosylation at each time point was determined by observing the ratio in peak heights: % 
Fucosylated = Fucosylated/(Fucosylated + Non-fucosylated) x 100. 
 




3.3.1 Expression and purification of HM-IgG1 Fc 
The Fc region of IgG1 was used as a model system for studying the effect of N-
glycosylation on IgG1 stability, function, and core-linked fucosylation. Using IgG1 Fc as a 
model system eliminated the variability within the Fab region. IgG1 Fc was expressed in a 
glycosylation-deficient yeast strain of P. pastoris.16, 26 Preparing a genetically modified strain 
was necessary in order to create an active glycan substrate for the in-vitro glycosidases and 
glycotransferases. The deletion of the PNO1 gene helped to eliminate phosphomannose residues 
observed in yeast.34 Additionally, deletion of the BMT 1 & 2 genes helped to eliminate beta-
linked mannose.35, 36 b-1,2 mannose linkages have been shown to not be substrates for the a-1,2-
mannosidases.37 Lastly, the deletion of the OCH1 gene prevents initiation of an a-1,6-mannose 
linked branch point that produces non-human like N-glycans, allowing for IgG1 Fc to be 
expressed as high mannose N-glycoforms with 8 to 10 mannose residues (Figure 3.1).38, 39 This 
N-glycoform set was labeled high mannose (abbreviated “HM”) and used as a starting substrate 
for the in-vitro enzymatic synthesis of the homogenous oligomannose, hybrid, and complex N-







Figure 3.1: Characterization of di-glycosylated IgG1 Fc. (A) Intact mass spectrum of IgG1 Fc 
after purification by protein A affinity chromatography. (B) Representation of the observed 
incomplete N-glycan site occupancy. (C) SDS-PAGE of IgG1 Fc after purification by protein A 
affinity chromatography. Lanes: 1, 10-200 kDa MW protein marker and 2, IgG1 Fc. (D) Intact 
mass spectrum of IgG1 Fc after purification by HIC. (E) Representation of complete N-glycan 
site occupancy. (F) SDS-PAGE of IgG1 Fc after purification by HIC. Lanes: 1, 10-200 kDa MW 
protein marker and 2, IgG1 Fc. (G) Table showing expected MWs of observed IgG1 Fc N-
glycoforms. All samples were reduced with DTT prior to analysis.  
 
The STT3D gene from L. major was added to improve the N-glycosylation site 
occupancy of proteins produced in P. pastoris.27 However, it did not completely eliminate site-
occupancy heterogeneity during expression of IgG1 Fc. This observation was shown in the intact 
mass spectrometry where there was the presence of a non-glycosylated peak under reducing 




which translated to 86% di-glycosylated, 13% mono-glycosylated, and <1 % non-glycosylated. 
The presence of incomplete N-linked site occupancy was also observed on SDS-PAGE (Figure 
3.1C), which showed two bands that corresponded to glycosylated and non-glycosylated IgG1 
Fc under reducing conditions. It has been shown that mono-glycosylated IgG1 reduces thermal 
stability and binding affinity to FcgRs.40 Because this work focused on modifying the N-linked 
glycosylation, it was desirable to obtain fully di-glycosylated protein. This was accomplished 
using HIC as a purification step as previously performed.16 After purification by HIC, purely di-
glycosylated HM-IgG1 Fc was obtained as shown by intact mass spectrometry by the absence of 
the non-glycosylated peak (Figure 3.1D) under reducing conditions as well as by the SDS-
PAGE showing only one band (Figure 3.1F). The yield after HIC was 40%. A higher yield 





Figure 3.2: Representation of in-vitro enzymatic synthesis of homogenous oligomannose (M5), 
hybrid (M5H, M3H, M5HF, and M3HF), and complex (G0 and G0F) IgG1 Fc N-glycoforms 
from HM-IgG1 Fc. The IgG1 Fc protein structure was not depicted in order to emphasize 




3.3.2 In-vitro enzymatic synthesis of homogenous IgG1 Fc N-glycoforms 
In order to study the effect of N-glycosylation on IgG1 Fc function and stability, a series 
of homogenous IgG1 Fc N-glycoforms were produced. In-vivo, the N-glycosylation is assembled 
as the protein passes through the endoplasmic reticulum and Golgi organelles.41 In these 
organelles, there is an assembly-line series of glycosidases and glycotransferases that modify the 
glycan. These enzymes require specific processing by the enzymes earlier in the pathway to be a 
substrate. Incomplete conversion at a particular step truncates the N-glycoform, which, given the 
multitude of steps in this process, results in the mixture of N-glycoforms that is observed during 
recombinant expression.6  
In this work, a series of homogenous N-glycoforms were produced by reproducing the 
glyco-processing that occurs in mammalian cells in vitro. This required the production of the 
mammalian glyco-processing enzymes. These enzymes were not commercially available, so they 
were cloned, expressed, and purified in house. Mannosidase-I from Bacteroides 
thetaiotaomicron was cloned in a pET28a vector and expressed in Escherichia coli Rosetta 2 
cells (Novagen) by Dr. Ishan Shah (Appendix 2, A.2.1.1.1).26, 28 GnT-I from Homo sapiens was 
cloned into E. coli Rosetta gami2(DE3) (Novagen) by Dr. Mark Pawlicki and expressed and 
purified by Dr. Khalid Al-Kinani (Appendix 2, A.2.1.1.2).29 Mannosidase-II from mouse was 
cloned in pPICzaA by Dr. Brian Hamilton, expressed in P. pastoris KM71H (Invitrogen) and 
purified (Appendix 2, A.2.1.1.3). GnT-II mammalian gene sequence was codon optimized for 
expression in yeast then cloned into the pPICzaA vector by Dr. Tolbert and expressed and 
purified by Dr. Khalid Al-Kinani (Appendix 2, A.2.1.1.4). FUT8 from mus musculus was 




In-vitro enzymatic synthesis allowed us to perform one step at a time, obtain complete 
conversion, and then move on to the next step. This stepwise scheme was performed in the 
following order (Figure 3.2): HM → M5 → M5H → M3H → G0. Additionally, the M5H N-
glycoform was fucosylated to produce M5HF, which was then converted to other fucosylated N-
glycoforms: M5H →	M5HF → M3HF → G0F. Each enzymatic step was monitored using intact 
mass spectrometry. Based on the peak heights, the yield at each enzymatic step was >98% under 





Figure 3.3: Intact mass spectra of homogenous IgG1 Fc N-glycoforms prepared by in-vitro 
enzymatic synthesis. Also shown are the glycan representations and expected MWs of each IgG1 
Fc N-glycoform. N-glycoforms: (A) M5, (B), M5H, (C) M3H, (D) G0, (E) M5HF, (F) M3HF, 
(G) G0F. All samples were reduced with DTT prior to analysis. Glycosylation symbols: blue 




In order to produce the non-fucosylated N-glycoforms, four in-vitro enzymatic steps were 
performed. The first step was to convert HM to M5. For this step, two enzymes were used: 
mannosidase-I to cleave terminal a1,2-mannose residues28 and an endomannosidase in case 
some of the higher-order +162 peaks were glucose.42 After removal of the a1,2-mannose 
residues, there was still a small peak of +162 from the expected M5 molecular weight. This was 
determined to not be part of the N-linked glycan because treating the protein with PNGase F, 
which removes N-linked glycans, did not remove the small +162 peak from the de-glycosylated 
IgG1 Fc mass spectra (Appendix 2: Figure A.2.2). Based on literature, this peak is likely O-
linked mannose.43, 44 The next step was to convert M5 to M3H. For this step, M5 was treated 
with GnT-I, which adds the b1,2-GlcNAc to the a1,3-arm of the N-glycan.45 The next step was 
to convert M5H to M3H. For this step, M5H was treated with mannosidase-II, which 
sequentially cleaves the a1,6-linked followed by the a1,3-linked mannose residues from the 
a1,6-arm of the N-glycan.46 The last step was to convert M3H to G0. This was performed by 
treating M3H with GnT-II, which adds the b1,2-GlcNAc to the a1,6-arm of the N-glycan.47, 48 
Furthermore, three fucosylated N-glycoforms were produced. This required the use of GDP-
fucose. It is expensive to purchase commercially, so it was produced in-house from less 
expensive materials using chemoenzymatic synthesis. FKP is a bifunctional enzyme that was 
used to convert fucose and ATP into fucose-1-phosphate, which was then converted, in the 
presence of GTP, into GDP-fucose.49 The reaction was monitored using ion pair chromatography 
(Appendix 2: Figures A.2.3 and A.2.4). After synthesis, alkaline phosphatase was added to 
convert the ADP byproduct into adenosine to make it smaller so that it could be removed using 
SEC. GDP-fucose was then purified from the reaction mixture using SEC and lyophilized. GDP-




converted to M5HF. For this step, M5H was treated with FUT8, which adds an a1,6-fucose 
residue onto the GlcNAc that is closest to Asn297.50-53 The next steps were to convert MH5F to 
M3HF and M3HF to G0. These steps were performed using the same enzymes that were used for 
the synthesis of their non-fucosylated counterparts.  
After completion of each enzymatic step, the IgG1 Fc N-glycoform was purified from the 
enzymes using protein A affinity chromatography. The protein yield after each enzymatic step 
and subsequent purification using protein A affinity chromatography was 75-97%. After which, 
the IgG1 Fc N-glycoforms were analyzed by SDS-PAGE (Figure 3.4). SDS-PAGE result did 
not show any proteolyzed bands nor contaminant bands coming from the enzyme preps after 
purification. Each N-glycoform showed only a single band. The production of homogenous N-
glycoforms using this strategy produced one oligomannose N-glycoform (M5), four hybrid N-






Figure 3.4: SDS-PAGE of homogenous IgG1 Fc N-glycoforms prepared by in-vitro enzymatic 
synthesis. Lanes: 1 & 9, 10-200 kDa MW protein marker; 2, M5; 3, M5H; 4, M3H; 5, G0; 6, 
M5HF; 7, M3HF; and 8, G0F. All samples were reduced with DTT prior to loading.   
 
3.3.3 Comparison of IgG1 Fc N-glycoform stability 
 The non-fucosylated N-glycoforms were compared against one another using DSC 
(Figure 3.5). DSC has been used by other researchers to compare the thermal stability of 
different IgG1 Fc variants.2, 54-56 The fucosylated N-glycoforms were not tested because previous 
results in the Tolbert laboratory by Dr. Al-Kinani comparing IgG2 Fc M5H vs. M5HF did not 
show any differences (unpublished results). Additionally, Mimura et al. reported DSC results 
from homogenous non-fucosylated N-glycoforms of IgG1 Fc in one manuscript55 and their 
fucosylated counterparts in another56. Comparing the results didn’t show any significant 
differences upon fucosylation. Therefore, it was suspected that fucosylation would not have 




M3H IgG1 Fc N-glycoforms were very similar, with a Tonset of 54.6ºC and Tm1 of 67.6ºC. 
However, G0-IgG1 Fc showed a significant difference from the other N-glycoforms. The G0 N-
glycoform showed a Tonset of 61.3ºC and Tm1 of 71.4ºC. Compared to the other N-glycoforms, 
this is an increase the Tonset of unfolding by almost 7ºC and the Tm1 by almost 4ºC. The Tm1 
corresponds to unfolding of the CH2 domain, which is where the N-glycan is located. The Tm2, 
which corresponds to unfolding of the CH3 domain, didn’t show any mentionable differences. 
 
 
Figure 3.5: DSC thermograms of non-fucosylated homogenous IgG1 Fc N-glycoforms. Samples 
were analyzed in triplicate. Each thermogram represents the average values from triplicate 
measurements after correction from a buffer reference. Table shows average Tonset, Tm1, Tm2, and 




It has been reported from crystal structures as well as from NMR studies that there is an 
interaction with the GlcNAc on the a-1,6-arm on the N-glycan with Phe243 of the Fc (Figure 
3.6).57-59 It has also been reported that this interaction results in a stability benefit by researchers 
who compared homogenous IgG1 Fc N-glycoforms by DSC.55, 56, 58 These reports compared 
M5H to G0 and M3F to G0F. However, these comparisons still left ambiguity as to which sugar 
residue, or absence of sugar residue, is causing the stability difference. The stability difference 
could have been caused by loss of either the a1,3- and/or a1,6-mannose residues on the a1,6 
arm and/or the addition of the b1,2-GlcNAc on the a1,6 arm. In this work, the N-glycoforms 
used provided a more conclusive determination because M3H was compared to G0. The only 
difference between these two N-glycoforms was the addition of the b1,2-GlcNAc on the a1,6 
arm. Therefore, the results in this work showed clearly that the b1,2-GlcNAc on the a1,6 arm 
was causing the increase in stability.  
 The non-fucosylated N-glycoforms were also compared to one another using analytical 
SEC to check for the presence of soluble aggregates (Appendix 2: Figure A.2.5). The results 
showed that all N-glycoforms showed a very high percentage (>97.7%) of monomer, with the 
G0 N-glycoform showing the highest percentage of monomer (99.5%). Furthermore, the non-
fucosylated N-glycoforms were compared to one another using OD350 to measure aggregation 
propensity as a function of temperature (Appendix 2: Figure A.2.6). Results showed that the 
M5 N-glycoform showed the earliest Tonset of turbidity (72.3ºC). Both hybrid N-glycoforms 
showed very similar Tonset values (74.1-74.2ºC). Lastly, the G0 showed the highest Tonset, 






Figure 3.6: Representation of GlcNAc on the a1,6-arm interacting with the IgG1 Fc backbone. 
(A) Representation of G2F-IgG1 Fc. (B) Crystal structure of G2F-IgG1 Fc highlighting the 
interaction between GlcNAc on the a-1,6 arm of the N-glycan and Phe243 (PDB: 4KU1). 
Glycosylation symbols: blue, GlcNAc; green, mannose; red, fucose; yellow, galactose. 
 
 
3.3.4 Comparison of IgG1 Fc N-glycoform binding to FcgRIIIa 
The function of the IgG1 Fc N-glycoforms were compared in a receptor binding assay 
with FcgRIIIa. This receptor was chosen for the comparability assessment because it is the 
primary FcgR receptor found on NK cells that is involved in activating ADCC.60 IgG1 Fc is a 
symmetric homodimer, but FcgRIIIa binds to the Fc asymmetrically in a 1:1 ratio.61 More 
specifically, FcgRIIIa interacts with the BC, C’E, and FG loops in the CH2 domain of one Fc 
chain and residues S239 and L235 on both Fc chains.62 These regions are put into proper 
orientation by intramolecular contacts between the Fc N-glycan and Fc polypeptide, which 
restrict the dynamics of the Fc protein-glycan.13-15 The type of glycosylation determines which 
contacts occur and therefore affect the binding affinity to FcgRIIIa.  
In this work, seven homogenous N-glycoforms were compared in a receptor binding 




fucosylated N-glycoforms showed an overall trend of increasing affinity with increasing N-
glycan processing (M5 ≈ M5H < M3H < G0) (Table 3.3). This trend is somewhat apparent in 
the progressively faster association rate constants (ka) (M5 < M5H < M3H < G0), and more 
significant trend differences are present in the progressively slower dissociation rate constants 
(kd) (M5 ≈ M5H > M3H > G0) (Figure 3.8). The results did not show a significant difference in 
KD between the M5 and M5H N-glycoforms. However, there was a significant difference 
between the M5H and M3H N-glycoforms, showing that the removal of the a-1,3/6 mannose 
residues improved binding affinity. Furthermore, there was a significant difference between the 
M3H and G0 N-glycoforms, indicating that the addition of the GlcNAc on the a1,6-arm of the 
Fc N-glycan increased binding affinity. This difference could be due to the additional interaction 
between the GlcNAc on the a1,6-arm of the Fc N-glycan interacting with Phe243 (Figure 3.6). 
These trends also hold true when comparing the N-glycoforms’ affinities from equilibrium 
binding (Figure 3.9).  
Furthermore, comparing the non-fucosylated N-glycoforms to their fucosylated 
counterparts showed about a 10-fold lower affinity upon fucosylation from analysis of the 
kinetic KD results and a 25-fold difference from equilibrium KD results (Figure 3.8 and Figure 
3.9). Comparing the kinetic rate constants showed that fucosylation caused a decrease in ka and 
increase in kd, with the biggest difference coming from the ka. This result is in agreement with 
Subedi and Barb (2016), who also reported these trends in kinetic rate constants when comparing 
non-fucosylated vs. fucosylated homogenous N-glycoforms.19 In literature, there are a large 
range of values reported for the reduced affinity of binding to FcgRIIIa upon fucosylation. The 
differences range from 2 to 50-fold.12, 17-21 The differences in KD between fucosylated and non-




N-glycosylation as well.18 Falconer et al. (2018) showed that comparing G2 vs G2F N-
glycoforms of the Fc using homogenous M5 N-glycosylation of FcgRIIIa, the affinity upon Fc 
fucosylation decreased 17.5-fold. However, when comparing these same Fc N-glycans using 
FcgRIIIa with N-glycosylation containing only a single GlcNAc, the affinity upon fucosylation 
only decreased 2-fold. In our work, a homogenous M8-10 N-glycosylation for the FcgRIIIa was 
used (Appendix 2: Figure A.2.7). Using this receptor, comparing homogenous N-glycoforms 
with and without fucose showed about a 10-fold (kinetic) and 25-fold (equilibrium) weaker 







Figure 3.7: Representative sensorgrams of FcgRIIIa binding to homogenous IgG1 Fc N-
glycoforms. Shown below each sensorgrams is the set of IgG1 Fc concentrations that were 
tested. N-glycoforms: (A) M5, (B) M5H, (C) M3H, (D) G0, (E) M5HF, (F) M3HF, and (G) G0F. 
Reported KD is the average value of triplicate runs ± standard deviation. 
 
Table 3.3: Kinetic Values For IgG1 Fc N-glycoforms Binding To FcgRIIIa* 
*Reported values are the average of triplicate runs ± standard deviation. 
#Standard deviations were calculated by taking into account the error of propagation.  
N-glycoform KD (nM)# ka x 105 (1/Ms) kd x 10-2 (1/s) 
M5 33.9 ± 3.6 4.20 ± 0.28 1.42 ± 0.12 
M5H 29.8 ± 4.6 4.77 ± 0.49 1.42 ± 0.17 
M3H 16.4 ± 1.4 5.07 ± 0.42 0.83 ± 0.02 
G0 10.4 ± 1.1 5.50 ± 0.05 0.57 ± 0.06 
M5HF 318.8 ± 33.1 0.39 ± 0.01 1.24 ± 0.12 
M3HF 159.1 ± 9.8 0.81 ± 0.04 1.28 ± 0.05 





Figure 3.8: Bar graphs comparing kinetic values of IgG1 Fc N-glycoforms in binding assay with 
FcgRIIIa. (A-C) Comparison of non-fucosylated N-glycoforms. (A) Kinetic dissociation value 
(KD), (B) kinetic association rate constant (ka), and (C) kinetic dissociation rate constant (kd). (D-
F) Comparison of non-fucosylated (solid bars) vs. fucosylated (hatched bars) N-glycoforms. (D) 
KD, (E) ka, and (F) kd. The top of each bar represents the average value of triplicate runs and the 
error bar represents standard deviation. Significance: ** = p < 0.01, *** = p < 0.001, and **** = 





Figure 3.9: Equilibrium binding curves of homogenous IgG1 Fc N-glycoforms binding to 
FcgRIIIa. (A) M5, (B) M5H, (C) M3H, (D) G0, (E) M5HF, (F) M3HF, (G) G0F. KD values 




Most FcgRIIIa binding assays were done using FcgRIIIa from recombinant expression in 
mammalian cell lines, which produces FcgRIIIa with mostly complex-type N-glycosylation. 
However, an analysis of the N-glycosylation of FcgRIIIa from donor NK cells showed that 
almost a quarter of N-glycosylation was hybrid and almost another quarter was oligomannose.63 
Furthermore, in a comparison between FcgRIIIa with complex vs. oligomannose N-
glycosylation, IgG1 Fc with G0F N-glycosylation bound the oligomannose-containing receptor 
with 12-fold greater affinity than the complex. It was shown that the N-linked glycosylation 
affected the conformation of FcgRIIIa differently when the glycosylation was complex vs M5. 
The FcgRIIIa used in this study was M8-10 and showed a KD using G0F-IgG1 Fc as 97.9 nM, 
which is in between the KD results reported by Patel et al. (2018) using the M5 and complex 
FcgRIIIa, which showed 25 nM and 310 nM, respectively.  
One hypothesis for the effects of IgG1 fucosylation on FcgRIIIa binding that is supported 
by crystal structures of complexed Fc-FcgRIIIa is that there are intermolecular glycan-glycan 
contacts between the Asn297 glycan of the Fc Asn162 glycan of the FcgRIIIa,21, 64 and the 
addition of core-linked fucose on the Fc N-glycan inhibits these contacts, thereby weakening the 
binding affinity. When the Fc Asn297 glycan is afucosyated, the two N-glycans are in close 
proximity. However, when the Fc Asn297 glycan is fucosylated, the distance between the 
glycans increases. The contacts that are involved in the Fc are mainly in the core 
pentasaccharide, especially the innermost GlcNAc residue. However, it was observed that 
trimming all N-glycans of FcgRIIIa down to single GlcNAc, which should have abolished the 
some of the proposed glycan-glycan contacts, actually increased binding affinity.18 Falconer et 
al. (2018) recently proposed a second hypothesis whereby the amount of volume sampled by the 




support for this second hypothesis because, when comparing non-fucosylated N-glycoforms, the 
biggest difference in binding was between the M3H and M5H. Removing the two mannoses may 
have allowed for more volume to be sampled by the Asn162 glycan of FcgRIIIa. Also, these two 
mannose residues were not involved in any of the intermolecular glycan-glycan or glycan-
polypeptide contacts that were reported from the crystal structure data.21, 64 Furthermore, 
comparison of M3H to G0 showed that the addition of GlcNAc improved binding. It allowed for 
the Phe243 contact, which may have help to orient the Fc interface to allow for optimal binding 
by restricting the mobility of the Fc Asn 297 glycan15 and also possibly increasing the sampling 
volume of the FcgRIIIa Asn162 glycan. 
3.3.5 Comparison of core-linked fucosylation. 
 The rates of the core-linked fucosylation of the different homogenous N-glycoforms by 
FUT8 were compared by measuring initial rate kinetics in a coupled enzyme assay (Figure 
3.10). FUT8 adds an a1,6-fucose residue to the innermost GlcNAc of the N-glycan of IgG1 Fc. 
In order for the N-glycan to be a substrate for FUT8, the presence of GlcNAc on the a1,6 arm of 
the biantennary N-glycan is required.65 The FUT8-catalyzed transfer of fucose to IgG1 Fc was 
detected using a coupled enzyme assay in which GDP produced by the FUT8 reaction was 
phosphorylated to GTP using pyruvate kinase and PEP. The resulting pyruvate was then reduced 
to lactic acid by NADH in a reaction catalyzed by lactate dehydrogenase. Loss of NADH was 
detected by monitoring absorbance at 340 nm.  Large excesses of pyruvate kinase and lactate 
dehydrogenase were utilized such that the FUT8 reaction was the rate-limiting step of the 





Figure 3.10: Representation of coupled enzyme assay. FUT8 was coupled to PK/LDH enzymes. 
Fucose transfer by FUT8 produces GDP as a byproduct. GDP is accepted as a substrate for PK 
which transfers phosphate from PEP to GDP to form GTP and pyruvate. Pyruvate is reduced by 
LDH and NADH to form lactate and NAD+. NADH absorbs light at 340 nm, whereas NAD+ 




The KM of FUT8 for the M5H, M3H, and G0 N-glycoforms were determined for both 
free glycans and glycans N297-bound to IgG1 Fc. The free glycan was obtained by treating the 
corresponding IgG1 Fc N-glycoform with PNGase F with completion of the de-glycosylation 
being confirmed using intact mass spectrometry (Appendix 2: Figure A.2.8). The M5 N-
glycoform was not tested because it was previously reported that M5 is not a substrate for 
FUT8,53 except under unique conditions.14, 66 The results showed that the KM for the free glycans 
were all in the low µM range and were within 2-fold of one another (17 µM for M5H, 13 µM for 
M3H, and 25 µM for G0) (Figure 3.11A-C and Table 3.4). These data are near the KM 




biantennary glycan, which was 12.9 ± 1.2 µM. The results showed that the affinities for the 
different N-glycoforms  (glycan types) were relatively similar when the glycans were free in 
solution. However, when the glycans were Asn297-bound to IgG1 Fc, the KM values of M5H 
and M3H were relatively similar at 244 µM and 189 µM, respectively, while the G0 N-
glycoform had a significantly larger KM of 3437 µM (Figure 3.11D-F and Table 3.4). 
Compared to the corresponding free glycans, the KM values for the bound M5H and M3H N-
glycoforms increased approximately 14-fold while the KM for G0 increased 137-fold. For both 
the free glycan and glycoprotein bound states, the M3H N-glycoform showed a slightly higher 
affinity for FUT8 than M5H. The loss of the 2 mannose residues may be making the innermost 
GlcNAc and/or the GlcNAc on the a1,3-arm more accessible, although the difference in 
affinities between M3H and M5H substrates was not dramatic. The trends between M5H, M3H, 
and G0 bound to IgG1 Fc were also observed using intact mass spectrometry (Appendix 2: 






Figure 3.11: Michaelis-Menton plots for fucosylation by FUT8 of glycans either free or bound 
to IgG1 Fc. Free glycans were produced from IgG1 Fc N-glycoforms using PNGase F, whereas 
the bound N-glycoforms were Asn297-linked to IgG1 Fc. Free N-glycoforms: (A) M5H, (B) 
M3H, and (C) G0. IgG1 Fc-bound N-glycoforms: (D) M5H, (E) M3H, (F) G0. The reported KM 









Bound KM (µM)* 
KM Ratio 
(Bound/Free) Vmax (µmol/min) x10
-3* 
M5H Free 17 ± 3 14 0.17 ± 0.01 Bound 244 ± 15 0.25 ± 0.01 
M3H Free 13 ± 2 14 0.21 ± 0.01 Bound 189 ± 12 0.25 ± 0.01 
G0 Free 25 ± 4 137 0.20 ± 0.01 Bound 3437 ± 735 0.22 ± 0.04 
*The reported KM and Vmax values are the fitted values of triplicate runs ± standard error. 
 
The extremely high KM for the G0 N-glycoform when bound to IgG1 Fc could be caused 
by the interaction between the GlcNAc on the a1,6-arm of the N-glycan and Phe243 of the IgG1 
Fc polypeptide (Figure 3.6). This interaction could be reducing the accessibility of FUT8 to the 
glycan. Mutations at the 243 position have been shown to lead to more highly-processed types of 
glycosylation such as increased levels of galactose, sialic acid, and bisecting GlcNAc.14, 15, 67 
This suggests that disrupting this interaction increased the glycan processing activities of 
galactosyltransferase, sialyltransferase, and N-acetylglucosaminyltransferase-III, respectively. 
Based on this work, the glycan-protein contact at position 243 may also be affecting the activity 
of FUT8. Interestingly, the reports that showed increased bisecting GlcNAc upon Phe243 
mutation also observed that the fucosylation levels were maintained. Increasing bisecting 
GlcNAc usually decreases fucosylation levels.22 Perhaps the fucosylation levels were maintained 
because removing the Phe243 interaction made the N-glycan more accessible to FUT8. In the 
literature, Calderon et al. (2016) showed that fucosylation of free glycans is occurring 
throughout the hybrid and complex-type glycans.53 Even glycans with terminal galactose and 
sialyation are capable of being fucosylated. However, this work showed that when the glycans 
were N-linked to IgG1 Fc, only hybrid glycans were fucosylated to any practical extent. This 




primarily during the hybrid stages (Figure 3.12). Therefore, this work allowed us to make new 
insights into the fucosylation during N-glycan biosynthesis IgG1. 
 
 
Figure 3.12: Representation of N-linked glycan processing of IgG1 in the Golgi of mammalian 
cells. Shown is the most prominent pathway for N-linked glycan processing after taking into 
account the FUT8 kinetic studies reported herein. For the fucosylation step, the thick arrows 




IgG1-based therapeutics are important biomolecules for the treatment of a variety of 
complex diseases including cancer, autoimmune disease, and organ-transplant rejection. Their 
bioactivity can engage immune system function through interaction with FcgRs. FcgRs can 
activate both pro- and anti-inflammatory pathways. The specific type of activation can be 
influenced by the N-glycosylation of IgG1. Subtle differences in N-glycosylation can have large 
influences on the immune response. However, these differences are difficult to determine 
because expression of IgG1 results in a mixture of N-glycoforms and different N-glycoforms can 




In this work, IgG1 Fc was used as a model system to prepare seven homogenous IgG1 N-
glycoforms. IgG1 Fc was expressed in glycosylation-deficient yeast to obtain a relatively 
homogenous high mannose N-glycoform. This N-glycoform was then used as a starting substrate 
to for in-vitro enzymatic synthesis to produce a series of oligomannose, hybrid, and complex 
type N-glycoforms with and without fucose. At each step, >98% conversion was obtained as 
determined by intact mass spectrometry.  
The influence of the different N-glycoforms on IgG1 Fc stability were compared using 
DSC. Compared to the other non-fucosylated N-glycoforms, the G0 N-glycoform showed a large 
increase in thermal stability in the CH2 domain. This stability is likely due to an intramolecular 
glycan-protein interaction between the GlcNAc on the a1,6-arm and the Phe243 residue of the 
IgG1 Fc polypeptide. This is the first report of a comparison between M3H and G0 N-
glycoforms, which is the most direct comparison to demonstrate this stability effect.  
Furthermore, the seven homogenous IgG1 Fc N-glycoforms were compared in a binding 
assay with FcgRIIIa. In literature, there is a big range in reported values for IgG1 Fc binding to 
FcgRIIIa. The measured affinity can depend on several factors such as N-glycosylation of the 
IgG1, the N-glycosylation of FcgRIIIa, and the methodology. This work attempted to clarify the 
variation by comparing all seven N-glycoforms in a consistent assay. The results showed an 
increased affinity for M3H compared to M5H. This could be due to reduced sterics of M3H 
compared to M5H, which may be have increased the freedom within the Fc-FcgRIIIa interface. 
Results also showed an increased affinity for G0 compared to M3H. This could be due to the 
interaction between GlcNAc on the a1,6-arm of the N-glycan and the Phe243 that is present for 
G0 but not M3H. Additionally, comparing the non-fucosylated N-glycoforms to their 




difference in affinity upon fucosylation. To the best of our knowledge, this is the first report of a 
binding affinity of FcgRIIIa to IgG1 Fc using homogenous M3H and M3HF N-glycoforms.  
Lastly, the M5H, M3H, and G0 N-glycoforms were compared in a FUT8 kinetic coupled 
enzyme assay. The N-glycoforms were measured in both their free and Asn-297 bound states. In 
their free states, the N-glycoforms were relatively similar. However, when bound to IgG1 Fc, the 
G0 N-glycoform showed much lower affinity to FUT8. This could be due to the GlcNAc on the 
a1,6-arm of the N-glycan interacting with Phe243 on the Fc. Previous reports showed that both 
hybrid and complex N-glycoforms were acceptable substrates for FUT8 when the glycan is free. 
Our work supports this data. However, our work also shows that when the G0 N-glycoform is 
bound to the Fc, the glycan has a much weaker affinity for the FUT8 active site compared to the 
hybrid N-glycoforms. This suggests that, during N-glycan biosynthesis, fucosylation is likely 
occurring at the hybrid stages. These studies improve our fundamental understanding of IgG1 N-
glycosylation and may also help in the development of improved antibody-based therapeutics. 
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Chapter 4  
 
Controlled Assembly Of Multivalent IgG1 Fc – Polyacrylamide Conjugates 







Multivalent display of active molecules serves important roles in several biological 
processes such as bacterial invasion into a host, cell-cell adhesion, DNA transcription, and in the 
removal of foreign pathogens.1 In medicine, they have been used to neutralize anthrax toxin2, 
inhibit bacterial entry3, alter antigen-specific immune responses4, and in the design of 
therapeutics5. One benefit to the multivalent display of active molecules is the increased avidity 
of binding.6 For instance, etanercept (Enbrel®), the blockbuster therapeutic for the treatment of 
several diseases including rheumatoid arthritis, is an IgG1 Fc fusion protein with two tumor 
necrosis factor (TNF) receptors on its N-termini. Etanercept functions to compete with TNF 
receptor on immune cells for binding to the proinflammatory-inducing cytokine TNF-a. TNF-
a is trivalent, so having two TNF receptors on etanercept binds TNF-a with 50-1,000X stronger 
avidity than monomeric TNF receptor.7  
Previously, the production of multivalent active molecules sometimes utilized 
polymerization methods that were uncontrolled.8 This lack of control can be problematic because 
it creates a heterogenous polymer. It has been shown that the biological activity of the polymer 
can be affected by the polymer’s size, shape, and density.9, 10 For example, polymerization of 
IgG has been shown to activate Complement-dependent Cytotoxicity (CDC),9, 11, 12 an important 
effector function of the immune system to clear foreign pathogens, at much lower concentrations 
than required for monomeric IgGs.9, 12 However, Smith et al. (1995) showed that the size of the 
IgG polymer affected the strength of the CDC response.9 Therefore, there is a need to develop 
polymers with controlled properties.  
While dimers and trimers have been made in a controlled fashion,13, 14 producing larger 




large polymers in a controlled fashion include using dendrimers with “click” handles on the 
termini of the arms,15 fusing the 18 amino acid tail piece of IgM to IgG molecules as a way to 
make hexameric IgGs,9, 12, 16 and expressing proteins with non-native amino acids that contain 
click functional goups17. Another method to control polymerization is to use a controlled radical 
polymerization method such as atom transfer radical polymerization (ATRP). ATRP allows for 
control the polymer length, polymer size, and density of incorporated monomers by controlling 
the ratios of the reaction components.18 ATRP has been used previously by Appel et al. (2011) to 
incorporate two different acrylamide-containing monomers with controlled ratios into the 
production of high molecular weight, water-soluble co-polymers.19 
In this work, a novel method to ligate multiple proteins together in a controlled manner is 
presented that combines both ATRP and sortase-mediated ligation. This work utilized the 
controlled polymerization reaction of ATRP to synthesize a water-soluble, linear 
poly(acrylamide-peptide) co-polymer (Scheme 1). The versatility of this polymerization method 
was demonstrated by synthesizing several different co-polymer scaffolds with controlled size, 
shape, and density of peptides. The co-polymer was used as a scaffold to site-specifically attach 
the Fc region of the human IgG1 antibody (IgG1 Fc) to the incorporated peptides using a sortase-
mediated ligation (Scheme 2). Over the past twenty years, sortase has served as a valuable 
biotechnology tool for the site-specific ligation of a variety of molecules.20 This mechanism for 
this ligation is as follows (Figure 2.2):21-23 It requires one species contain a C-terminal sortase 
polypeptide sequence LPXTG, where X can be any amino acid. The sortase enzyme recognizes 
this sequence and cleaves between the threonine and glycine to form a thioester intermediate. 
Next, any species that contains an N-terminal glycine can theoretically act as a nucleophile to 
displace the sortase and form a new peptide bond between the two species. After sortase-




compared to IgG1 Fc in a receptor binding assay to FcgRIIIa, the receptor involved in activating 
antibody-dependent cellular cytotoxicity (ADCC). Lastly, the versatility of this controlled 
protein ligation method was further demonstrated by applying it to a different protein, 
interleukin-1 receptor antagonist (IL1ra). 
 
 
4.2 Materials and Methods 
4.2.1 Materials 
DNA primers were purchased from Eurofins (Huntsville, AL). pGAPzaA and pPICzaA 
plasmids were purchased from Invitrogen (USA). All molecular biology enzymes and protein 




and QIAquick Gel Extraction Kits were purchased from Qiagen (Germantown, MD). Zeocin was 
purchased from InvivoGen (San Diego, CA). Agarose was purchased from Lonza (Allendale, 
NJ). Agar, tryptone, and yeast extract were purchased from Becton, Dickinson and Company 
(Sparks, MD). Yeast Nitrogen Base was purchased from Sunrise Science Products (San Diego, 
CA). Antifoam 204 was purchased from Millipore-Sigma (St. Louis, MO). Protein A and 
phenyl-sepharose resins were purchased from GE Healthcare (Waukesha, WI). Dithiothreitol 
(DTT) was purchased from Bio-Rad (Hercules, CA). Bio-layer Interferometry biosensor tips 
were purchased from Forté Bio (Menlo Park, CA). Protease-free bovine serum albumin (BSA) 
was purchased from VWR (USA). Centrifugal concentrators and syringe filters were purchased 
from EMD-Millipore (USA). An expression plasmid for Peptide: N-glycosidase F (PNGase F) 
was gifted by the Lott laboratory at Massey University, from which PNGase F was prepared as 
previously described.24 Additionally, an expression plasmid for sortase A was gifted by the 
DiMarchi laboratory at Indiana University, from which sortase A was prepared as previously 
described.25 All other chemicals were obtained from commercial sources without further 
purifications. The methods for Gly3-IL1ra cloning, expression, purification, and ligation to the 
AM-ST co-polymers can be found in Appendix 3: A.3.1.   
4.2.2 Preparation of AM-ST co-polymer 
A series of co-polymers were synthesized, purified, and characterized by Dr. Zahra 
Khedri. The co-polymers were comprised of acrylamide (abbreviated “AM”) and a sortase 
recognition peptide (GGLPETGGG) functionalized with an acryloyl group on the N-terminus 
(abbreviated “ST”), which were polymerized in varying ratios using ATRP to produce the 
poly(acrylamide-GGLPETGGG) co-polymers (abbreviated “AM-ST co-polymer”) (Table 4.1). 
Dr. Khedri synthesized three AM-ST co-polymers, which varied in molecular weight as well as 




gel permeation chromatography (GPC) with polyacrylamide standards. The polydispersity index 
(PDI) was also determined using GPC. The number of ST peptides per polymer was determined 
using 1HNMR. A more detailed synthesis, purification, and characterization of these AM-ST co-
polymers are currently being written for publication in combination with the work described in 
this chapter.  
4.2.3 Molecular cloning of pPICzaA-Gly5-IgG1 Fc 
The Fc region of the human IgG1 heavy chain (T225-K447) cDNA (MGC-12853) was 
previously cloned into the pGAPzaA plasmid to form pGAPzaA-IgG1 Fc with a silent mutation 
to produce a SacI site near the N-terminus of the Fc and used previously in our laboratory.25 In 
order to add the five glycine residues to the N-terminus, the construct was digested with the 
restriction endonucleases XhoI and SacI-HF and gel purified. DNA primers consisting of 5'-
tcgagaaaagaggtggtggaggtggaacatgcccaccgtgcccagcacctgagct (forward) and 5'-
caggtgctgggcacggtgggcatgttccacctccaccacctcttttc (reverse) were designed to anneal together with 
the proper XhoI and SacI sticky ends. The primers were mixed together and phosphorylated 
using T4 Polynucleotide Kinase. They were then ligated into the digested pGAPzaA-IgG1 Fc 
plasmid using T4 DNA Ligase to create pGAPzaA-Gly5-IgG1 Fc. The plasmid was then 
transformed into Escherichia coli Top10f’ using electroporation and grown on low salt LB agar 
(0.5% yeast extract, 1% tryptone, 0.5% NaCl, 1.5% agar) containing 25 µg/mL zeocin. To 
confirm the correct sequence, the plasmid DNA was extracted using a Qiagen QIAprep Spin 
Miniprep Kit and sequenced by the UC-Berkeley DNA Sequencing Facility (Berkeley, CA). For 
methanol-induced expression in Pichia pastoris, the Gly5-IgG1 Fc DNA was transferred from 
pGAPzaA into pPICzaA. This transfer was accomplished by digesting the pGAPzaA-Gly5-




Fc DNA, which was gel purified. pPICzaA was digested with the same restriction enzymes and 
also gel purified. The digested Gly5-IgG1 Fc DNA and pPICzaA were ligated together using T4 
DNA Ligase to create pPICzaA-Gly5-IgG1 Fc. The plasmid was transformed into E. coli 
Top10f’ using electroporation, and the cells were plated on low salt LB agar containing 25 
µg/mL zeocin and grown at 37°C overnight. To confirm the correct sequence, the plasmid DNA 
was extracted using a Qiagen Miniprep Kit and sequenced by the UC-Berkeley DNA 
Sequencing Facility (Berkeley, CA). The pPICzaA-Gly5-IgG1 Fc plasmid was linearized in the 
AOX1 promoter region using the restriction endonuclease PmeI and transformed using 
electroporation into a glycosylation-deficient strain of the yeast Pichia pastoris that was 
prepared previously in our laboratory (deleted och1, pno1, and bmt 1&2 genes and inserted 
STT3D gene from Leishmania major in order to improve N-glycosylation site occupancy).26-28 
The cells were plated on YPD agar (1% yeast extract, 2% tryptone, 2% glucose, 1.5% agar) 
containing 100 µg/mL zeocin and grown at 30°C for 6 days. 
4.2.4 Expression of Gly5-IgG1 Fc 
A colony was selected and grown in a shake tube containing 2 mL YPD media (1% yeast 
extract, 2% tryptone, 2% glucose) and 100 µg/mL zeocin at 30°C and 250 rpm. After 3 days, the 
culture was transferred to a 250 mL baffled Erlenmeyer flask containing 50 mL YPD media and 
100 µg/mL zeocin and grown at 30°C and 250 rpm. After 2 days, the culture was transferred to a 
1 L spinner flask containing 2% tryptone, 1% yeast extract, 2% glycerol, 1.34% yeast nitrogen 
base, 0.00004% biotin, 100 mM potassium phosphate buffer pH 6.2, and 1 drop of Antifoam 
204. The spinner flask was stirred at room temperature with an air flow of 3 L/min. After 3 days 
of growth, the pH of the culture was adjusted back to 6.2 using concentrated NH4OH. Expression 




12 hours. After 3 days of induction, the culture was centrifuged at 6,693 x g for 20 min using a 
Beckman Avanti J-series centrifuge (USA). The supernatant was collected, and the pH was 
adjusted to 6.5 using KOH. This expression procedure was repeated three times to produce a 
total of four liters. 
4.2.5 Purification of Gly5-IgG1 Fc 
The supernatant was then filtered using vacuum filtration through Whatman #1 filter 
disks. The IgG1 Fc protein was then purified from the supernatant using protein A affinity 
chromatography. A 2.5 cm x 20 cm column was packed with 20 mL of protein A-sepharose 
resin. A flow rate of 15 mL/min was used throughout the purification using a peristaltic pump. 
The column was equilibrated with 15 CV of 20 mM sodium phosphate buffer pH 6.5. 2 L of the 
filtered supernatant was passed through the column followed by 25 CV of 20 mM sodium 
phosphate buffer pH 6.5 containing 500 mM NaCl. The IgG1 Fc protein was eluted from the 
column using 3 CV of 100 mM glycine-Cl buffer pH 3.0. The eluted protein was immediately 
dialyzed in 2 L of 20 mM sodium phosphate buffer pH 7.5 at 4°C with 1 buffer change. This 
protein A affinity chromatography procedure was repeated for the remaining 2 L of supernatant. 
After purification by protein A affinity chromatography, the yield was 19 mg/L (76 mg total for 
the 4 L). 
After dialysis, the Gly5-IgG1 Fc protein was further purified by hydrophobic interaction 
chromatography (HIC). The protein was mixed with solid (NH4)2SO4 crystals at a final 
concentration of 1 M (NH4)2SO4. An ÄKTA micro (GE Healthcare, Waukesha, WI) was used 
throughout this purification at a flow rate of 2 mL/min. A column containing 125 mL of phenyl-
sepharose resin was first washed with 5 CV of Milli-Q H2O and then equilibrated with 5 CV of 
buffer A (20 mM sodium phosphate buffer pH 7.5 containing 1 M (NH4)2SO4). Half of the 




Fc, the following stepwise purification method was employed: 0% buffer B (20 mM sodium 
phosphate pH 7.5) for 1 CV, a linear gradient of 0%-27% buffer B for 1 CV, a linear gradient of 
27%-31% buffer B for 9.5 CV, a linear gradient of 31%-100% buffer B for 1 CV, and finally 
100% buffer B for 1 CV. During the linear gradient of 27-31% buffer B, 10 mL fractions were 
collected. The fractions were analyzed for N-glycan site occupancy using intact protein mass 
spectrometry. The fractions containing ≥99% di-glycosylated Gly5-IgG1 Fc were pooled, 
concentrated to about 20 mL using a 10 kDa MWCO centrifugal concentrator, and dialyzed in 2 
L of 20 mM MES buffer pH 6.5 containing 150 mM NaCl at 4°C with 1 buffer change. This 
purification method was repeated for the remaining half of Gly5-Fc protein. At this stage, the N-
linked glycosylation was high mannose (abbreviated “HM”). After secondary purification by 
HIC, the yield was 22 mg.  
4.2.6 Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Polyacrylamide gels that were prepared with a uniform acrylamide concentration were 
done so in house.29 The gel that was prepared with a gradient concentration of 4-20% acrylamide 
was purchased from Bio-Rad (Hercules, CA). For the small-scale, sortase-mediated ligation 
reactions, 80 µg of protein was loaded. For the large-scale ligation, 10 µg of protein was loaded. 
For screening fractions after size exclusion chromatography, 10 µL of each fraction was loaded. 
For all other samples, 2 µg of protein was loaded. Samples that were analyzed under reducing 
conditions contained 50 mM DTT. The preparation of the samples, electrophoresis, and 
visualization of protein by Coomassie staining were all performed as previously described.25  
4.2.7 Intact protein mass spectrometry 
 The proteins were analyzed by intact protein mass spectrometry as previously described 
(3.2.4). 




a-1,2-mannosidase from Bacteroides thetaiotaomicron and an endomannosidase from rat 
were prepared previously.27, 30 The concentrations of these enzyme preparations were determined 
using a Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA) according to 
manufacturer’s instructions. 22 mg of Gly5-IgG1 Fc with the HM N-glycoform at approximately 
0.5 mg/mL was mixed with 1.6 mg of a-1,2-mannosidase and 0.09 mg of rat endomannosidase. 
The reaction mixture was transferred to 3.5 kDa MWCO dialysis tubing and dialyzed at r.t. in 2 
L of 20 mM MES buffer pH 6.5 containing 150 mM NaCl and 5 mM CaCl2. Conversion of HM 
into the M5 N-glycoform was monitored using intact protein mass spectrometry. After 4 days, 
the reaction was stopped by purifying the Gly5-IgG1 Fc protein from the enzymes using protein 
A affinity chromatography according to the purification procedure described in section 4.2.5. 
After elution, the protein was immediately dialyzed in 2 L of tris-buffered saline (TBS, 50 mM 
Tris, 150 mM NaCl) pH 7.5 at 4°C with 1 buffer change. At this stage, Gly5-IgG1 Fc protein 
contains the homogenous M5 N-glycoform, and this protein is abbreviated as “Fc”.  
4.2.9 Sortase-mediated ligation of Fc to AM-ST co-polymer 
The Fc was concentrated using a 30 kDa MWCO centrifugal concentrator and filtered 
through a 0.22 µm syringe filter. After concentration and filtration, the final concentration was 
265 µM. The AM-ST co-polymer concentration was based on the number of ST sites. A series of 
30 µL, small-scale, sortase-mediated ligation reactions were prepared using the following: 242 
µM Fc, 2 µM CaCl2, 10 µM sortase A, and a series of 0, 0.02, 0.04, 1, and 5 µM AM-ST co-
polymer in TBS pH 7.5. The reactions were allowed to proceed at 37ºC for 24 hours. After 
which, they were analyzed using SDS-PAGE. Based on the SDS-PAGE data, the reaction using 
5 µM of co-polymer showed the best balance between obtaining the largest size Fc-polymer 




860 µL. The reaction was again analyzed using SDS-PAGE. Fc ligated to the AM-ST co-
polymer was abbreviated as “Fc-polymer conjugate”.  
The Fc-polymer conjugate was purified from the free protein (sortase and un-ligated Fc) 
using size exclusion chromatography. A 2.5 cm x 30 cm column containing 100 mL of Bio-Gel 
P100 resin (Bio-Rad, Hercules, CA) was equilibrated using 5 CV of TBS pH 7.5 at 0.3 mL/min. 
850 µL of the reaction were pipetted on the top of the resin bed. Then TBS pH 7.5 was pumped 
through the column at a rate of 0.3 mL/min. 1 mL fractions were collected. Every 3rd fraction 
was manually checked for protein using UV/VIS spectrophotometry at 280 nm. The fractions 
that indicated protein were analyzed using SDS-PAGE. 5 fractions showed Fc-polymer 
conjugate with very little un-ligated Fc. These fractions were pooled, concentrated to 2 mL using 
a 30 kDa MWCO centrifugal concentrator, and dialyzed in PBS pH 7.4. 
4.2.10 Analytical size exclusion chromatography 
 A Phenomenex Yarra (3µm, 7.8 mm ID x 300 mm) SEC-3000 column (Torrance, CA) 
was attached to a Shimadzu UFLC (Kyoto, Japan). The column was equilibrated with 200 mM 
sodium phosphate buffer pH 6.8. 50 µL of 0.3 mg/mL of each sample was injected. The method 
consisted of an isocratic gradient of 200 mM sodium phosphate buffer pH 6.8 for 40 minutes at a 
flow rate of 0.4 mL/min and column temperature of 30ºC. A blank was injected between each 
sample.  
4.2.11 BioLayer interferometry of Fc and Fc-polymer conjugate binding to FcgRIIIa 
The concentration for both the Fc and Fc-polymer conjugate were determined by 
measuring the absorbance at 280 nm using UV/VIS spectrophotometry in quintuplicate and then 
using the average value to solve for concentration using Beer’s law using an extinction 




signal at 280 nm. After determining the concentration, BSA was added to both the Fc and Fc-
polymer conjugate to a final concentration of 1 mg/mL. The samples were prepared using two-
fold serial dilutions for the Fc and four-fold serial dilutions for the Fc-polymer conjugate. The 
extracellular region of human FcgRIIIa was cloned, expressed, purified, and biotinylated as 
described in the previous chapter (3.2.8). All binding samples and reagents were incubated at 
25ºC prior to analysis, and all analyses were performed at 25ºC.   
For analysis of the Fc, a biosensor tip coated with streptavidin was first hydrated at r.t. in 
PBS pH 7.4 for 10 min and then further hydrated at r.t. in kinetic buffer (PBS pH 7.4 containing 
1 mg/mL BSA) overnight to ensure adequate hydration. Then, the biosensor tip was fixed in the 
Forté Bio BLItz instrument (Menlo Park, CA). Next, FcgRIIIa was immobilized on to the 
biosensor tip according to the following steps: 1.) a baseline was established for 30 sec using 
kinetic buffer, 2.) the biosensor tip was loaded with biotinylated FcgRIIIa to a response level of 
0.3 nm, and 3.) a baseline was re-established using kinetic buffer for 360 sec. After the FcgRIIIa 
was immobilized, a reference (with no Fc present) was performed using kinetic buffer for the 
duration of an experiment (30 sec baseline, 180 sec association, and 360 sec dissociation). Then, 
the following series of Fc concentrations were tested from low to high: 4, 8, 16, 31, 63, 125, 250, 
and 500 nM on the same biosensor tip according to the following steps: 1.) a baseline was 
established for 30 sec using kinetic buffer, 2.) association was performed by placing the tip in the 
Fc solution for 180 sec, and 3.) dissociation was performed by placing the tip in kinetic buffer 
for 360 sec. Between each Fc concentration, the tip was regenerated according to the following 
steps: 1.) the tip was placed in 1 mM NaOH for 30 sec, 2.) the tip was placed in kinetic buffer for 
60 sec, and 3.) both steps were repeated. The entire procedure was performed in triplicate. Each 




kinetic rate constants (ka and kd) and the kinetic dissociation constant (KD). Additionally, the 
response values from 206.0-208.8 sec were averaged and plotted against their respective Fc 
concentrations. These data were fitted using a non-linear regression, and an equilibrium KD was 
determined using a “one site--specific binding” model in the Prism 7 software. 
For analysis of the Fc-polymer conjugate, a biosensor tip coated with streptavidin was 
hydrated and immobilized with biotinylated FcgRIIIa using the same procedure described for the 
Fc. After the FcgRIIIa was immobilized, a reference (with no Fc-polymer conjugate present) was 
performed using kinetic buffer for the duration of an experiment (30 sec baseline, 1800 sec 
association, and 3600 sec dissociation). Then, the following series of Fc-polymer conjugate 
concentrations were tested from low to high: 0.1, 0.5, 2, and 8 nM according to the following 
steps: 1.) a baseline was established for 30 sec using kinetic buffer, 2.) association was 
performed by placing the tip in the Fc-polymer conjugate solution for 1800 sec, and 3.) 
dissociation was performed by placing the tip in kinetic buffer for 3600 sec. Multiple 
regeneration strategies were attempted, but no regeneration procedure was found that completely 
dissociated the polymer from the tip without inactivating FcgRIIIa. Therefore, a new tip was 
used for each Fc polymer-conjugate concentration. Only 4 concentrations of Fc-polymer 
conjugate were tested because each concentration required a 10x increase in time for each 
analysis (compared to the Fc), a new reference, and a fresh tip. The entire procedure was 
performed in triplicate. Each series of concentrations was fitted to a 1:1 binding model in the 







4.3 Results and Discussion 
4.3.1 Expression and purification of Gly5-IgG1 Fc 
Gly5-IgG1 Fc was expressed in a glycosylation-deficient strain of the yeast P. pastoris. 
The yield after protein A affinity chromatography was 19 mg/L (76 mg total). The 5 glycine 
residues on the N-terminus were initially chosen in order to allow enough space between the Fc 
and the AM-ST co-polymer. However, based on the peak heights from the intact mass spectrum 
(Figure 4.1A), about 2% of the Gly5-IgG1 Fc was proteolyzed to Gly3. This was not seen as a 
problem for two reasons: 1.) 2% does not constitute a large amount of the total Fc and 2.) ligands 
with 3 glycine residues on the N-terminus are still accepted as nucleophilic substrates by sortase 
A and so can be utilized in sortase ligations.25  
Based on the peak heights of the intact mass spectrum after protein A affinity 
chromatography, 8% of the total Fc chains were non-glycosylated at the conserved N-linked 
glycosylation site (Figure 4.1A). This translated to the site occupancy being 85% di-
glycosylated, 15% mono-glycosylated, and <1% non-glycosylated. Additionally, SDS-PAGE 
showed two bands near the 30 kDa MW marker, wherein the more intense band corresponded to 
glycosylated Gly5-Fc and the less intense band corresponded to non-glycosylated Gly5-Fc 
(Figure 4.1B). To simplify the analysis of the Fc-polymer conjugate, the mono-glycosylated and 
non-glycosylated Fc forms were removed using HIC (Figure 4.1C). After secondary purification 
by HIC, the Mass Hunter software could not quantify a peak height for the non-glycosylated Fc 
single chain, so it was concluded that all Fc was di-glycosylated. However, after HIC, only 22 
mg of fully di-glycosylated Gly5-Fc was obtained (29% yield). A higher yield could have been 
obtained if the criteria for di-glycosylated were less stringent. However, in order to make the 





Figure 4.1: Characterization of Gly5-IgG1 Fc. (A) Intact mass spectrum and (B) SDS-PAGE of 
Gly5-IgG1 Fc after purification by protein A affinity chromatography, Lanes: 1, 10-200 kDa 
MW Marker; 2, Gly5-IgG1 Fc after purification. (C) Mass spectrum of Gly5-IgG1 Fc after 
secondary purification by HIC. (D) Representation of di-glycosylated Gly5-IgG1 Fc. 
Glycosylation symbols: Blue squares, N-acetylglucosamine; Green circles, mannose. (E) Table 
showing observed and expected molecular weights of Gly5-IgG1 Fc species in mass spectrum 
after protein A affinity chromatography. All samples were reduced with DTT before analysis. 
 
4.3.2 Conversion of Gly5-IgG1 Fc from the HM to the M5 N-glycoform 
To further improve the homogeneity of the Gly5-Fc, the N-glycoform was converted 
from HM to M5. HM was a mixture of N-glycoforms ranging from M8-M11. The heterogenous 
HM N-glycoform was converted to a homogenous M5 N-glycoform to remove the heterogeneity 




4.2A). Gly5-IgG1 Fc with HM N-glycoform was treated with a bacterial a-1,2-mannosidase30 
and well as a rat endomannosidase27. The endomannosidase was added to help improve 
conversion to M5 by removing any terminal glucose residues that may be present on the N-
glycan due to incomplete processing during N-glycan biosynthesis.32 After treatment for 4 days 
at r.t., the conversion was 98% based on the peak heights from intact protein mass spectrometry 
(Figure 4.2B and Appendix 3: Figure A.3.1). The calculation of 98% was performed by 
dividing the peak height for the M5 N-glycoform by the sum of the peak heights for the M5, M6, 
M7 N-glycoforms after subtracting the contribution of O-linked glycosylation. O-linked 
glycosylation was determined by observing the glycosylation peaks that remained after treatment 
with PNGase F, which removed the N-linked glycosylation (Appendix 3: Figure A.3.2). Based 
on the literature, the remaining glycosylation peaks were likely O-linked mannose,32, 33 which 
accounted for about 5% of the total N-glycoform peak heights. Additionally, SDS-PAGE 
showed just one band (Figure 4.2 D), which provided further evidence that the HIC purification 
step was successful in obtaining the completely di-glycosylated N-glycoform. The gel also 
suggested that the a-1,2-mannosidase and endomannosidase enzymes were not present after 
Protein A affinity purification. Having only one band for the Fc during SDS-PAGE analysis 





Figure 4.2: Characterization of the conversion of Gly5-IgG1 Fc from the HM to M5 N-
glycoform. (A) Representation of the in-vitro enzymatic conversion. (B) Intact mass spectrum, 
(C) Representation, and (D) SDS-PAGE of Gly5-IgG1 Fc after conversion to the M5 N-
glycoform. Samples for (B) and (D) were reduced with DTT before analysis. Expected MW: 
Gly5-IgG1 Fc with the M5 N-glycoform = 26568.8 Da. Lanes: 1, 10-200 kDa MW protein 




4.3.3 Sortase-mediated ligation of Fc to AM-ST co-polymers 
Dr. Khedri synthesized a series of AM-ST co-polymers using ATRP that were used as 
scaffolds for attaching multiple Fc proteins (Table 4.1). The polymers varied in size as well as in 
the number of ST peptides incorporated. These parameters were controlled by adjusting the 
relative ratios of reaction components, such as the ratio of acrylamide to acrylamide-ST 




average of 20.5 ST peptides/polymer (co-polymer #3) as determined by 1H NMR (unpublished 
data). This co-polymer was chosen for use in the Fc ligation because it would allow for the most 
Fcs to be attached, which would potentially allow for the largest avidity effect when compared to 
free Fc in a receptor-binding assay.  The Fc was ligated to the AM-ST co-polymer #3 (Table 
4.1) using a sortase-mediated ligation. This ligation was utilized to ligate multiple Fc’s to interior 
sites in the co-polymer (Figure 4.3).   
 
Table 4.1: Properties of synthesized AM-ST co-polymers 
Polymer M:MCP:L:CuCl , pH, time (hr), 
(AM:ST), %EtOH in H2Oa 
# ST/Polymer AM/ST 
Ratio 
MW (Da) PDI 
1 15:1:1:1, 7, 12 
(10:1), 30 
2.8 13.1 4798 1.13 
2 16.8:1:1:1, 9, 17 
(4.7:1), 30 
6.6 9.5 9778 1.12 
3 17:1:1:1, 9, 24,  
(3:1), 16 
20.5 6.0 25000 1.13 





Figure 4.3: Representation of the controlled assembly of an Fc-polymer conjugate. (A) ATRP 
reaction using acrylamide (AM) and an acrylamide-containing sortase recognition tag (ST) as 
monomers to form the AM-ST co-polymer. (B) Sortase-mediated ligation of Fcs to the ST 






A series of small-scale sortase-mediated ligation reactions were performed to find the 
optimal AM-ST co-polymer concentration that balanced obtaining the most Fcs attached per co-
polymer with highest yield of Fc-polymer conjugate (Figure 4.4). Based on the SDS-PAGE 
data, the optimal AM-ST co-polymer concentration for this ligation was 5 µM (co-polymer:Fc 
ratio of 1:42, 210 µM Fc). At this concentration, large Fc polymers were observed as shown by 
Coomassie staining in the stacking layer. Additionally, there may have been even larger 
polymers because a Coomassie stained band was observed in the bottom of the loading well 
when the samples were analyzed under non-reducing conditions, suggesting that there were 
polymers so large that they did enter the stacking layer (Appendix 3: Figure A.3.3). This may 
have been because the Fc is a dimer, which may have caused cross-linking of multiple polymers. 
Adding a reducing agent broke-up the cross linking in the presence of SDS and resulted in the 





Figure 4.4: SDS-PAGE of small-scale, sortase-mediated ligations of Fc to the AM-ST co-
polymer. Lanes: 1, 10-200 kDa MW protein marker; 2, Fc, 3, sortase A, 4, AM-ST co-polymer; 
5-9, sortase-mediated ligations of Fc to AM-ST co-polymer: [AM-ST co-polymer] (µM): Lane 5 
= 0, Lane 6 = 0.02, Lane 7 = 0.04, Lane 8 = 1, Lane 9 = 5. In order to obtain resolution in 
different size ranges, the samples were analyzed on gels prepared with both (A) 6% and (B) 12% 
acrylamide. All samples were reduced with DTT prior to loading. 
 
The Fc-ligation using 5 µM AM-ST co-polymer was chosen for scale-up, which was 
performed with the remaining Fc protein (29 times larger scale) (Figure 4.5). Scaling up the 
reaction did not hurt the formation of large Fc-polymer conjugates. Based on the SDS-PAGE the 




10 Fc/co-polymer. Although, it is difficult to determine the largest size Fc-polymer conjugates 
formed because band intensity becomes poor after >10 Fc/co-polymer are attached. There are 
two sites of attachment because the Fc is a homodimer, and the majority of the Fcs attached to 
the polymer twice. This result is shown by analysis of the protein-polymer conjugate after SEC 
purification with SDS PAGE under reducing conditions, which showed ~20% corresponding to 
Fc (This band is of similar intensity to lane 3 in which 2 µg of Fc was loaded. In lane 4, the 
amount of Fc polymer conjugate loaded was 10 µg). This implies that the majority of ligated Fcs 
are attached to the polymer at both N-termini.  
 
 
Figure 4.5: SDS-PAGE showing large-scale ligation of Fc to AM-ST co-polymer. Samples were 
analyzed using a 4-20% acrylamide gradient gel. Lanes: 1, 10-190 kDa MW protein marker; 2, 
sortase A; 3, Fc; and 4, Fc-polymer conjugate after purification by SEC. All samples were 




4.3.4 Purification of the Fc-polymer conjugate 
In order to perform a comparison between the free Fc and Fc-polymer conjugate, the 
excess free Fc was removed from the ligation reaction using size exclusion chromatography 
(SEC). Bio-Gel P100 resin, with a typical fractionation range of 5-100 kDa, was used for this 
separation. This range allowed for separation of the free Fc (~50 kDa) from the Fc-polymer 
conjugates. However, fractionation of different Fc-polymer conjugates was not achieved with 
this resin. Based on the SEC results, almost all of the un-ligated Fc was removed (Appendix 3: 
Figure A.3.4).  
After the sortase ligation and purification of the Fc-polymer conjugate, the amount of Fc-
polymer conjugate obtained was 0.6 mg (5% yield of Fc). The low yield was caused by the 
sortase product also being a sortase substrate, which hindered formation of the Fc-polymer 
conjugate. In order to drive the reaction toward polymer formation, an excess of nucleophile is 
needed. In this ligation method, the nucleophile is the Fc. The Fc was concentrated to 260 µM, 
(~15 mg/mL), as practical limitations of protein precipitation at high concentrations limited 
concentrating the Fc further. For sortase-mediated ligations, the glycine-containing nucleophile 
is typically used in mM concentrations to obtain a high ligation yield.34 The ligation yield could 
theoretically be improved by formulating the Fc to make it more stable at higher concentrations 
or by using a more soluble protein.  
After purification, the Fc and Fc-polymer conjugates were analyzed by analytical SEC 
(Figure 4.6). The Fc showed a single peak, whereas the Fc-polymer conjugate showed multiple 
peaks that all eluted earlier than the Fc. The earlier elution suggested that the Fc-polymer 
conjugate was larger in size than the Fc. The multiple peaks were caused by the heterogeneity in 
polymer size. Additionally, the Fc-polymer conjugate did not show any peaks corresponding to 




ST co-polymer showed an elution peak using UV/VIS spectrophotometry at 220 nm (Figure 
4.6A) but not at 280 nm (Figure 4.6B). The observed signal at 220 nm was due to the amide 
bonds in the polyacrylamide backbone of the AM-ST co-polymer. The absence of a signal at 280 
nm for the polymer allowed us to use absorbance at 280 nm to calculate the Fc concentration of 
the Fc-polymer conjugate during binding studies. The Fc and Fc-polymer conjugate showed 
signal at both wavelengths because they contain both amide bonds and aromatic residues.  
 
 
Figure 4.6: Characterization of Fc polymer components by analytical size exclusion 
chromatography. Elution from the SEC column was observed at both (A) 220 nm and (B) 280 
nm. Black = AM-ST co-polymer #3 (Table 4.1), Pink = Fc, and Blue = Fc-polymer conjugate. 
The three components were analyzed separately, and their chromatograms were overlaid.  
 
 
4.3.5 Comparison of the Fc and Fc-polymer conjugate binding to FcgRIIIa  
For a comparison of the binding affinity, FcgRIIIa was used. This receptor was chosen 
because FcgRIIIa is the primary Fcg receptor found on NK cells that is necessary for IgG to 
activate ADCC.35 It has been shown that ADCC activity can be increased by increasing the 
affinity of the antibody to the foreign antigen.36, 37 For example, aglycosylated IgG1, which is 
believed to not bind most FcgRs even at low µM concentrations when tested in monomeric 




that allowed for avidity of binding.38 In another example, formation of IgG1 Fc hexamers has 




Figure 4.7: Comparison of binding response to FcgRIIIa of Fc and Fc-polymer conjugate. 
Representations of binding of (A) Fc and (B) Fc-polymer conjugate. (C) BioLayer 
interferometry sensorgram comparing the binding response of the Fc and Fc-polymer conjugate. 
The Fc (green) and Fc-polymer conjugate (blue) were both tested at the same protein 
concentration (8 nM) on the same biosensor. 
 
FcgRIIIa was site-specifically biotinylated on the C-terminus using a sortase-mediated 
ligation with a triglycine-biotin compound that was synthesized in house as previously 




biosensor tip at the same concentration (Figure 4.7). Performing the comparison on the same 
biosensor ensured that the same amount of receptor was present. This result showed that Fc-
polymer conjugate provided about 10 times more signal at the end of the association phase 
compared to the Fc. This observation suggested that the FcgRIIIa bound to the Fc-polymer 
conjugate with greater strength than to the Fc. Additionally, the Fc had reached equilibrium at 
the end of the association phase of 180 sec, whereas the polymeric Fc had not even after 1800 
sec. If the Fc-polymer conjugate had been allowed to reach equilibrium (assuming equilibrium 




Figure 4.8: Representative biolayer interferometry sensorgrams of the (A) Fc and (B) Fc-






Table 4.2: Kinetic Binding Results Of Fc vs. Fc-polymer Conjugate Binding To FcgRIIIaa 
Species ka ± SD x 105 (1/Ms) kd ± SD x 10-2 (1/s) KD ± SD (nM)b 
Fc 5.0 ± 0.4 1.6 ± 0.1 32 ± 3 
Fc-polymer conjugate 4.2 ± 0.2 0.002 ± 0.001 0.04 ± 0.03 
aShown are the average values of triplicate runs ± the standard deviation (SD). 
bThe SD for the KD was calculated taking into account the error of propagation. 
 
 
For a quantitative analysis, several concentrations of Fc and Fc-polymer conjugate were 
tested in triplicate. The binding results from the Fc showed a KD value of 32 ± 3 nM (Figure 
4.8A). This result was similar to what was observed for the M5-IgG1 Fc measured in the 
previous chapter (Table 3.3) and in literature.39 This observation suggested that the addition of 5 
glycine residues to the N-terminus did not affect the binding between IgG1 Fc and FcgRIIIa 
significantly. Additionally, the kinetic binding and equilibrium binding results did not show any 
statistically significant differences (Figure 4.8A vs. Appendix 3: Figure A.3.5). Compared to 
the Fc, the Fc-polymer conjugate showed a KD of 0.04 ± 0.03 nM (Figure 4.8B). The KD of the 
Fc-polymer conjugate was 800 times lower than the Fc. Interestingly, the ka rate constants were 
quite similar, with the Fc-polymer conjugate showing only a 1.2-fold slower association rate 
than the Fc (Table 4.2). On the other hand, the kd rate constants were very different, with the Fc-
polymer conjugate showing a 800 times slower dissociation rate. This was likely due to the 
increase in avidity of the Fc-polymer conjugate having multiple Fc-FcgRIIIa interactions. In the 
free Fc, when the Fc and receptor dissociated, the Fc diffused away. However, in the Fc-polymer 
conjugate, if one Fc-receptor interaction dissociated, then there were still other binding events 
that kept the polymer associated with the receptor. The binding for the Fc was complete in 180 
sec association and 360 sec association. However, the Fc-polymer analysis association and 




association was 1800 sec and the dissociation was 3600 sec. However, even after an association 
time of 1800 sec, the Fc-polymer conjugate samples had not reached binding equilibrium.  
4.3.6 Sortase-mediated ligation of IL1ra to AM-ST co-polymers 
 To demonstrate the versatility of this controlled ligation method, another protein was 
attached to the same co-polymers (Table 4.1). Interluekin-1 receptor antagonist (IL1ra) plays an 
important role in the immune system by working to downregulate the proinflammatory response 
invoked by interleukin-1.40 Its biological role makes it a useful therapeutic, as it is FDA 
approved under the name Anakinra (Kineret®) for the treatment of several diseases including 
rheumatoid arthritis. IL1ra was chosen for ligation to AM-ST co-polymers because it is a single 
chain protein, so it has only one ligation site per protein. Therefore, the IL1ra-polymer conjugate 
didn’t show the heterogeneity that was observed with the Fc-polymer conjugate, which had 2 
ligation sites per protein, when analyzed by SDS-PAGE under non-reducing conditions 
(Appendix 3: Figure A.3.3). IL1ra was expressed as a fusion protein with an N-terminal hexa-
histidine tag, followed by a Tobacco Etch Virus (TEV) cleavage tag, followed by two N-terminal 
glycine residues on its N-terminus. The TEV cleavage site is (Glu-Asn-Leu-Tyr-Phe-Gln-Xxx), 
where Xxx can be many different amino acids.41 TEV protease is a cysteine protease that cleaves 
between the Gln and Xxx. In this work, a glycine residue was used for the Xxx, so that cleavage 
by TEV protease produced an IL1ra with an N-terminal glycine (Appendix 3: Figure A.3.6A). 
TEV cleavage was complete as shown by SDS-PAGE wherein the band corresponding to the 
IL1ra fusion migrated a greater distance after cleavage compared to before (Appendix 3: Figure 
A.3.6B). Also, there was just a single band after cleavage, which corresponded to a single peak 
on the intact mass spectrum (Appendix 3: Figure A.3.6C).  
 Sortase-mediated ligation of IL1ra to AM-ST co-polymers was performed using several 




similar to what was observed for sortase-mediated ligation of IgG1 Fc to the co-polymer when 
analyzed under reducing conditions. This result provided further evidence that the less defined 
bands of the Fc-polymer conjugate under non-reducing conditions was due to the fact that there 
were two ligation sites per IgG1 Fc (Appendix 3: Figure A.3.3). Increasing the AM-ST co-
polymer concentration led to smaller sized protein-polymer conjugates because the Gly3-IL1ra 
nucleophile became less in excess. Additionally, Gly3-IL1ra was ligated to the AM-ST co-
polymers #1 and #2. It was observed by SDS-PAGE that AM-ST co-polymer #1 produced the 
smallest size IL1ra-polymer conjugates, followed by #2, and lastly #3 produced the largest 
IL1ra-polymer conjugates. This trend was consistent with the relative sizes of the polymer 
scaffolds (Table 4.1). The Gly3-IL1ra-polymer conjugate was purified from the free Gly3-IL1ra 
using SEC, just like the Fc-polymer conjugate. SDS-PAGE results showed separation of most of 
the Gly3-IL1ra from the Gly3-IL1ra-polymer conjugate (Appendix 3: Figure A.3.8). These 
results showed that this method for the controlled assembly of multivalent protein-polymer 
conjugates was not limited to just IgG1 Fc.  
 
4.4 Conclusions 
The multivalent display of protein ligands is important in a variety of biological 
processes. The ability to produce multivalent protein-polymer conjugates is potentially very 
useful in studying such biological processes as well as in designing improved therapeutics. 
However, the activity of the synthesized protein-polymer conjugates is dependent on being able 
to control the physical characteristics of the initial polymer. Therefore, a combination of 
controlled polymerization with selective protein ligation holds promise for producing well 
defined protein-polymer conjugates. In this work, a novel method for the controlled assembly of 




soluble poly(acrylamide-peptide) co-polymers. Three co-polymers were prepared with controlled 
length and peptide density. The largest and most peptide-dense co-polymer was used as a 
scaffold for the site-specific attachment of protein to the peptide using a sortase-mediated 
ligation. This was demonstrated using IgG1 Fc by preparing IgG1 Fc with 5 N-terminal glycine 
residues. The N-linked glycosylation was modified to a di-glycosylated, homogenous M5 N-
glycoform in order to make the Fc as homogenous has possible. This Fc was ligated to the co-
polymer and then compared against the Fc alone in a kinetic receptor-binding assay with 
FcgRIIIa. The results showed that the Fc-polymer conjugate bound FcgRIIIa 800 times stronger 
than the Fc. This large increase in binding strength was caused by the large difference in 
dissociation rates, wherein the Fc-polymer conjugate dissociated 800-fold more slowly than the 
Fc.  
This method of producing protein-polymer conjugates allows the researcher to control 
many of the polymer’s characteristics. First, this method allows for control of the size of the 
polymer. In this work, the three poly(acrylamide-ST peptide) scaffolds ranged in size from ≈ 
5,000-25,000 Da. Second, it allows the researcher to control the density of the protein by 
adjusting the ratio of acrylamide to the ST peptide. In this work, the three poly(acrylamide-ST 
peptide) scaffolds contained an antigen density ranging from ≈ 3-20 ST peptides/polymer. Third, 
the protein is attached site-specifically, which allows for a more uniform protein-polymer and 
also prevents the heterogeneity in protein activity that may result with other polymerization and 
ligation methods where the site of attachment is less specific. In this work, the proteins were 
covalently attached to the co-polymer scaffold on their N-termini. And fourth, this method could 
be used to ligate a variety of proteins to water soluble co-polymer scaffolds. In this work, both 




have to be the same as this technique could be used to ligate a mixture of proteins as long as they 
contain an N-terminal glycine.  
Many different molecules can be ligated to the co-polymer scaffold using a sortase-
mediated ligation. Sortase-mediated ligations have been used to ligate a variety of molecules 
onto the ST recognition peptide including proteins, peptides, sugars, nucleic acids, molecular 
probes, and small molecule cytotoxic drugs.20 These types of molecules could be ligated to the 
co-polymer scaffold to increase their valency. Therefore, this method of producing co-polymers 
containing internal sortase ligation sites may be used in combination with other, peptide-, 
protein- and glyco-engineering strategies for a variety of applications. 
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Chapter 5  
 







Antibody-based therapeutics have the ability to treat a variety of different diseases 
including cancer, autoimmune disease, and organ transplant rejection. Some work by modulating 
the immune system. This work further explored the use of antibody-mediated 
immunomodulation by utilizing the Fc region of the human IgG1 antibody. In Chapter 2, an 
IgG1 Fc fusion was prepared with the Bifunctional Peptide Inhibitor (BPI) as a potential 
treatment for multiple sclerosis (MS). In a mouse-model of MS, BPIs have been shown to 
selectively prevent the activation of T-cells that are involved in causing the symptoms of MS.1 In 
this proof-of-concept study, a BPI-Fc fusion was successfully prepared, and, when tested in a 
mouse model of MS, the BPI-Fc fusion was highly active. BPI-Fc fusions are a promising 
research avenue in the development of antigen-specific immunotherapy for the potential 
treatment of multiple sclerosis. In Chapter 3, the effect of IgG1 N-glycosylation was explored. 
Different N-glycoforms can have different IgG1-mediated immunomodulatory effects. However, 
these differences are difficult to determine because expression of IgG1 results in a mixture of N-
glycoforms, so the production of homogenous N-glycoforms was needed. Using IgG1 Fc as a 
model system, seven homogenous N-glycoforms were prepared to near complete yield. 
Comparing the thermal stability of the IgG1 Fc N-glycoforms showed that IgG1 Fc stability can 
be altered based on the particular N-glycoform. Furthermore, comparing the binding affinity of 
the IgG1 Fc N-glycoforms to FcgRIIIa showed that binding affinity can also be altered based on 
the particular N-glycoform. Lastly, comparing the substrate specificity of a1,6-fucosyltranferase, 
the enzyme responsible for adding core-linked fucose, for different IgG1 Fc N-glycoforms 
showed that fucosylation kinetics can be altered based on the particular N-glycoform. These 




Additionally, these results improve our fundamental understanding of N-glycan biosynthesis by 
providing us with additional information about the occurrence of fucosylation during the 
process. In Chapter 4, IgG1 Fc was ligated to multiple sites on a polymer scaffold to simulate the 
multivalent binding event that is needed to activate ADCC. An IgG1 Fc-polymer conjugate was 
prepared using a novel method by combining atom transfer radical polymerization (ATRP) with 
sortase-mediated ligation. The polymerized IgG1 Fc was then compared to the monomer in a 
binding assay with FcgRIIIa. Compared to IgG1 Fc, the Fc-polymer conjugate showed an 800-
fold increase in binding affinity. This increased binding affinity was caused by an 800-fold 
decrease in the dissociation rate. These results suggest that the multivalent binding mechanism 
needed to activate ADCC may involve slowing the dissociation rate of Fc-FcgR interactions. The 
research presented in this dissertation improves our fundamental understanding of IgG1-
mediated immunomodulation and may also help in the development of improved antibody-based 
therapeutics. 
 
5.2 Future Directions 
Building off the results presented in Chapter 2, there are many research avenues that 
could be explored. For instance, other antigenic peptides could be tested. It was already shown in 
Chapter 2 that the BPI-Fc fusion can be successfully synthesized using the MOG antigenic 
peptide. Testing this peptide in a BPI-Fc fusion in-vivo would demonstrate the applicability of 
the synthesis because the LABL-Fc-ST scaffold can be used again instead of having to perform 
the cloning, expression, and purification for each BPI-Fc fusion. Additionally, BPI-Fc fusions 
can be tested in a different disease model, such as diabetes. The Siahaan laboratory has shown 




blocking peptide is LABL, just like in the MS model. Therefore, the LABL-Fc-ST protein 
scaffold would work well during the synthesis. A peptide derived from glutamic acid 
decarboxylase could be used as the diabetes-specific antigenic peptide. Furthermore, a BPI-Fc 
fusion could be prepared using multiple antigenic peptides to combat the threat of antigen 
spreading.4-6 This synthesis could be performed in a variety of ways: 1.) by performing a sortase-
mediated ligation on the LABL-Fc-ST scaffold with a mixture of antigenic peptides, or 2.) by 
synthesizing a long peptide that contains multiple antigenic sequences within one peptide, or 3.) 
by using the controlled assembly of multivalent active molecules strategy that was presented in 
Chapter 4 (To attach the AM-ST co-polymer to LABL-Fc-ST, a triglycine-containing functional 
group that would allow linking of LABL-Fc-ST to the terminus of a AM-ST co-polymer could 
be used.). Furthermore, measuring the in-vivo half-life of the BPI-Fc would be useful. 
Theoretically, the BPI-Fc has a longer half-life then the BPI peptides because it has a slower 
renal clearance and can be rescued from lysosomal degradation by FcRn.7 This half-life study 
could be analyzed using a western blot by quantifying the band intensity over time. The western 
blot could be useful because it would also show an approximate size of the BPI-Fc fusion, which 
would allow us to see if proteolysis is occurring. Additionally, the western blot could be detected 
using different detection antibodies that recognize different regions of the molecule: the Fc, the 
signal 2-blocking peptide, and the antigenic peptide. Similarly, a dose-response study could be 
performed. If the Fc is promoting an increased half-life, then perhaps a lower dose could be 
given to achieve similar results. Lastly, the N-linked glycosylation of IgG1 Fc could be modified 
in order to better suppress the disease. For instance, adding sialic acid to the termini of the 
glycan branches has been suggested to promote anti-inflammatory activity.8 Combining this anti-
inflammatory activity with the immunosuppressive activity of the BPI peptides could produce a 




 Building off the results presented in Chapter 3, additional homogenous IgG1 Fc N-
glycoforms could be tested. For instance, terminal galactose or sialic acid could be prepared, 
with and without fucose. Also, the substrate specificities of the N-glycoforms could be tested 
using other glyco-processing enzymes, such as N-acetylglucosaminyltransferase-III which adds 
bisecting N-acetylglucosamine (GlcNAc). Bisecting GlcNAc is important because its presence 
reduces fucosylation levels.9 Reduced fucosylation has been shown to increase ADCC activity, 
and ADCC activity is important for the cell-killing ability of some cancer immunotherapies.10 
Additionally, Hydrogen-Deuterium exchange could be performed on the IgG1 Fc N-glycoforms 
produced in this chapter. Hydrogen-Deuterium exchange was previously performed using a 
different series of homogenous IgG1 Fc N-glycoforms produced in the Tolbert laboratory.11 The 
results presented in Chapter 3 and findings in the literature would lead us to hypothesize that the 
G0 N-glycoform would show less flexibility compared to the M5, M5H, and M3H N-glycoforms 
because the G0 N-glycoform contains an additional intramolecular glycan-polypeptide 
interaction that the other N-glycoforms do not contain.12-14 Furthermore, the IgG1 N-glycoforms 
produced in this chapter could be tested in a binding assay FcgRIIIa using different N-
glycoforms of FcgRIIIa. Falconer et. al (2018) showed an increase in binding affinity for IgG1 
Fc by changing the N-glycosylation of FcgRIIIa from complex to oligomannose.15 
Building off the results presented in Chapter 4, the IgG1 Fc-polymer conjugate could be 
tested in an ADCC assay to see if it can stimulate ADCC without needing to bind a target cell. 
Promega sells an ADCC reporter bioassay assay that induces luciferase expression upon effector 
cell activation.16 If successful, then IgG1 Fc-polymer conjugates of different N-glycoforms could 
be prepared and compared for their relative abilities to induce ADCC. This work would build off 




N-glycosylation of Gly5-IgG1 Fc could be modified with terminal sialic acid using in-vitro 
enzymatic synthesis, and the sialylated IgG1 Fc could be prepared as an Fc-polymer conjugate. 
This sialylated IgG1 Fc-polymer conjugate could be tested to see if it increased binding for DC-
SIGN, a receptor involved in promoting anti-inflammatory activity.8 If successful, this concept 
may have use as a potential immunosuppressant.  
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Synthesis of a Bifunctional Peptide Inhibitor–IgG1 Fc Fusion that Suppresses 








A.1.1.1 DNA cloning 
A.1.1.1.1 Cloning of pPICzαA-PLP-Fc-LABL 
DNA primers were designed that allowed for the C-terminal addition of the LABL 
peptide to IgG1 Fc with a three alanine residue spacer (5'-
ggccgccggaggtggaattactgatggagaagctactgattctggataat-3’ and 5'-
ctagattatccagaatcagtagcttctccatcagtaattccacctccggc-3’) and for the proper NotI and XbaI sticky 
ends when mixed together. The primers were phosphorylated on the 5’-termini using PNK. 
pGAPzαA-Fc with no stop codon after the Fc, as described in the “Cloning of pPICzαA-LABL-
Fc-ST” experimental section, was digested using NotI-HF and XbaI and gel purified. The LABL 
DNA primers and digested pGAPzαA-Fc with complimentary NotI and XbaI sticky ends were 
ligated together using T4 DNA Ligase to create pGAPzαA-Fc-LABL.  
DNA primers were designed that allowed for the N-terminal addition of the PLP peptide 
to IgG1 Fc with a three glycine residue spacer (5'-
ggcgccctcgagaaaagacattctttgggaaaatggttgggacatccagataaatttggaggtg-3’ and 5'-
cgccgcgagctcaggtgctgggcacggtgggcatgttccacctccaaatttatctggatgtccc-3’). The primers were 
extended using PCR. The PCR product was purified using the Qiagen QIAquick Gel Extraction 
Kit (USA). The PLP PCR product and pGAPzαA-Fc-LABL were digested using XhoI and SacI-
HF and gel purified. The digested pGAPzαA-Fc-LABL and PLP DNA were ligated together 
using T4 DNA Ligase to create pGAPzαA-PLP-Fc-LABL. In a separate reaction, pGAPzαA-Fc-
LABL was digested using XhoI and XbaI and gel purified. pPICzαA was also digested using 
XhoI and XbaI and gel purified. The digested Fc-LABL and pPICzαA DNA were ligated 
together using T4 DNA Ligase to produce pPICzαA-Fc-LABL. pGAPzαA-PLP-Fc-LABL and 




PLP-Fc and pPICzαA-Fc-LABL DNA were gel purified and then ligated together using T4 DNA 
Ligase to create pPICzαA-PLP-Fc-LABL. 
A.1.1.1.2 Cloning of pPICzαA-MOG-Fc 
DNA primers were designed that allowed for the N-terminal addition of the MOG 
peptide to IgG1 Fc with a three glycine spacer (5'-
ggcgccctcgagaaaagaggatggtatagatctccattttctagagttgttcatttgggagg-3’ and 5'-
cgccgcgagctcaggtgctgggcacggtgggcatgttccacctcccaaatgaacaactctagaaaatgg-3’). The primers were 
annealed and extended using PCR. The PCR product was purified using the Qiagen QIAquick 
Gel Extraction Kit and digested with XhoI and SacI-HF. pGAPzαA-Fc with a stop codon after 
the Fc (prepared similarly to pGAPzαA-Fc with no stop codon as described in the “Cloning of 
pPICzαA-LABL-Fc-ST” experimental section) was also digested with XhoI and SacI-HF. Both 
digests were gel purified, and the digested MOG and pGAPzαA-Fc DNA were ligated together 
using T4 DNA Ligase to produce pGAPzαA-MOG-Fc. pGAPzαA-MOG-Fc and pPICzαA were 
digested with XhoI and NotI-HF. The digested MOG-Fc and pPICzαA DNA were gel purified 
and ligated together using T4 DNA Ligase to produce pPICzαA-MOG-Fc. 
A.1.1.2 Protein expression 
A.1.1.2.1 Expression of PLP-Fc-LABL (Spinner Flask)  
P. pastoris OCH1 KO cells transformed with pPICzαA-PLP-Fc-LABL were inoculated 
in a shake tube containing 2 mL of YPD media and 100 µg/mL Zeocin. The culture was shaken 
at 250 rpm and 25°C. After 3 days, the 2 mL culture was transferred to a 250 mL baffled shake 
flask containing 50 mL YPD media and 100 µg/mL Zeocin. The culture was shaken at 250 rpm 
at 25°C. After 2 days, the 50 mL culture was transferred to a 1 L spinner flask containing 
Buffered Glycerol-complex (BMGY) media, 0.004% histidine, and 1 drop of Antifoam 204 




After 70 hours of growth, 25 mL of 20%(v/v) methanol was added every 12 hours. After 60 
hours of induction, the culture was centrifuged at 6000 rpm for 20 min. The supernatant was 
collected and the pH was adjusted to 7.0 and placed in the 4°C refrigerator for 4 hours. The 
supernatant was vacuum filtered using Whatman #1 filter. PLP-Fc-LABL protein was purified 
from the supernatant using Protein G affinity chromatography. The Protein G column was 
equilibrated using 200 mL of 20 mM Sodium Phosphate buffer, pH 7.0. The 1 L of supernatant 
was loaded and then the column was washed using 200 mL of 20 mM Sodium Phosphate buffer, 
pH 7.0. The Fc-containing protein was eluted from the column using 200 mL of 100 mM glycine 
pH 2.7. The protein was immediately dialyzed against 2 L of 20 mM Sodium Phosphate buffer, 
pH 7.0 at 4 °C with 1 buffer change.  The yield of purified protein obtained was measured to be 
3.0 mg as determined by measuring the optical density of the solution at 280 nm (MW = 56133.2 
Da, ε280 = 82570 M-1cm-1). 
A.1.1.2.2 Expression of PLP-Fc-LABL (Fermentor)  
In order to avoid adding histidine to the fermentor media, P. pastoris OCH1 KO cells 
containing pPICzαA-PLP-Fc-LABL was transformed with pPIC9K. First, pPIC9K was 
linearized using SalI. The transformation of SalI-linearized pPIC9K into P. pastoris OCH1 KO 
cells containing pPICzαA-PLP-Fc-LABL was performed using electroporation. The 
electroporated cells were plated on Minimal Dextrose plates and incubated for 5 days at 25°C. 
After which, a colony was inoculated into 2 mL YPD media and 100 µg/mL Zeocin. The culture 
was shaken at 250 rpm and 25°C. After 3 days, the culture was transferred to a baffled shake 
flask containing 250 mL YPD media, 100 µg/mL Zeocin, and 1 drop of Antifoam 204. After 4 
days, the 250 mL culture was transferred to a New Brunswick BioFlo 415 fermentor using a 
fermentation basal salts medium and PTM1 trace salts. 50% glycerol was added as a carbon 




addition of NH4OH.  The culture was centrifuged at 6000 rpm for 15 minutes. Approximately 6 
L of supernatant was collected and stored at 4°C overnight. The supernatant was filtered, 
concentrated, and then subjected to Protein G affinity chromatography using a similar 
purification procedure as described in Chapter 2, 2.2.3 “Expression and purification of LABL-
Fc-ST (Fermentor)”. The yield of purified protein obtained was 150 mg as determined by 
measuring the optical density of the solution at 280 nm (MW = 56133.2 Da, ε280 = 82570 M-1cm-
1). 
A.1.1.2.3 Expression of PLP-Fc-LABL (spinner flask, media change)  
P. pastoris OCH1 KO cells transformed with pPICzαA-PLP-Fc-LABL was inoculated in 
a shake tube containing 2 mL of YPD media and 100 µg/mL Zeocin. The culture was shaken at 
250 rpm and 25°C. After 3 days the 2 mL culture was transferred to a baffled shake flask 
containing 50 mL YPD media and 100 µg/mL Zeocin. The culture was shaken at 250 rpm and 
25°C. After 3 days, the 50 mL culture was transferred to a 1 L spinner flask containing BMGY 
media, 0.004% histidine, and 1 drop of Antifoam 204 (Sigma). The culture was stirred at room 
temperature with an air flow rate of 3 L/min. After 3 days of growth, the culture was centrifuged 
at 4500 rpm for 15 minutes. The supernatant was discarded, and the cell pellet was re-suspended 
in approximately 60 mL of YPD media. The re-suspended cells were transferred to a spinner 
flask containing 1 L of fresh Buffered Methanol-complex (BMMY) media, 0.004% histidine, 
and 1 drop of Antifoam 204. The culture was stirred at room temperature with an air flow rate of 
3 L/min. Every 12 hours, 25 mL of 20%(v/v) methanol was added. After 47 hours of induction, 
the culture was centrifuged at 6000 rpm for 20 min. The supernatant was collected and the pH 
was adjusted to 7.0 and placed in the 4°C refrigerator for 1.5 hours. The supernatant was vacuum 
filtered using a Whatman #1 filter. PLP-Fc-LABL protein was purified from the supernatant 




“Expression of PLP-Fc-LABL (spinner flask)” experimental section. The yield of purified 
protein obtained was measured to be 2.1 mg as determined by measuring the optical density of 
the solution at 280 nm (MW = 56133.2 Da, ε280 = 82570 M-1cm-1). 
A.1.1.2.4 Expression of MOG-Fc  
MOG-Fc was expressed in a 1 L spinner flask and purified using a similar procedure 
described in the “Expression of PLP-Fc-LABL (spinner flask)” experimental section. The yield 
of purified protein obtained was measured to be 2.7 mg as determined by measuring the optical 
density of the solution at 280 nm (MW = 53634.8 Da, ε280 = 85550 M-1cm-1). 
A.1.1.2.5 Expression of LABL-Fc-ST (Spinner Flask) 
LABL-Fc-ST was expressed in a 1 L spinner flask and purified using a similar procedure 
described in the “Expression of PLP-Fc-LABL (spinner flask)” experimental section. The yield 
of purified protein obtained was measured to be 15 mg as determined by measuring the optical 
density of the solution at 280 nm (MW = 54006.8 Da, ε280 = 71570 M-1cm-1). 
A.1.1.3 Characterization 
A.1.1.3.1 Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Polyacrylamide gels for SDS-PAGE were prepared in house using a Bio-Rad Mini-
PROTEAN Tetra casting stand and clamps. First, the resolving layer was prepared by mixing 
12% acrylamide/Bis solution (29:1), 375 mM Tris pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) 
Ammonium Persulfate (APS), and 0.04% (v/v) N,N,N’,N’-Tetramethylethylenediamine 
(TEMED). The mixture was poured between a Mini-PROTEAN short plate and 0.75 mm spacer 
plate, topped with a layer of n-butanol, and allowed to sit for 30 minutes at room temperature. 
After which, the butanol was rinsed off. The stacking layer was prepared by mixing 5% 
acrylamide/Bis solution (29:1), 125 mM Tris pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, and 




inserted, and the gel was allowed to sit for 30 minutes at room temperature. The protein samples 
for SDS-PAGE were prepared by mixing each sample with a 1:1 ratio of 2X sample loading 
buffer (100 mM Tris pH 6.8, 4% (w/v) SDS, 20% (v/v) Glycerol, 100 mM DTT, 0.02% (w/v) 
Bromophenol Blue). The samples were placed in a heat block at 94°C for 5 minutes, then 2 µg of 
protein was loaded into each well. The gel was placed in a Mini-PROTEAN Tetra 
electrophoresis chamber containing electrophoresis running buffer (0.25 M Glycine, 0.025 M 
Tris Base, 0.1% (w/v) SDS, pH 8.3). The samples were electrophoresed at 200 V for 50 minutes. 
After which, the gel was stained in a staining solution (0.25% (w/v) Coomassie Blue R-250, 50% 
(v/v) Methanol, 40% Water, 10% (v/v) Acetic Acid) for 1 hour at room temperature on a rotary 
shaker. The staining solution was poured off, and the gel was destained in a destaining solution 
(50% (v/v) Methanol, 40% Water, and 10% (v/v) Acetic Acid) for 30 minutes at room 
temperature on a rotary shaker. The destaining solution was poured off, and the gel was further 
destained in a weaker destaining solution (10% (v/v) Methanol, 88% Water, and 2% (v/v) Acetic 








Figure A.1.1: Characterization of PLP peptide. (A) Analytical HPLC chromatogram of the PLP 
peptide monitored by UV absorbance at 220 nm. (B) MALDI mass spectrum. [M+H]+ mass 





Figure A.1.2: Characterization of MOG peptide synthesized for a sortase-mediated ligation. 







Figure A.1.3: Characterization of sortase A. (A) Mass spectrum of Sortase A after Ni2+-NTA 
purification. Sortase A MW (Da): Expected = 17719.0, Observed = 17719.3. (B) SDS-PAGE of 
Sortase A Ni2+-NTA purification fractions. Lanes: 1, 2-212 kDa MW marker; 2, cell lysate of E. 
coli Rosetta 2 that overexpressed sortase A; 3, Ni2+-NTA flow through of cell lysate; and 4-7, 
Ni2+-NTA elution fractions. Elution fractions shown in lanes 4-6 were pooled and used for the 







Figure A.1.4: Characterization of recombinant expression of PLP-Fc-LABL dual fusion protein 
in a spinner flask. (A) Mass spectrum of PLP-Fc-LABL expression products. Prior to 
characterization, the protein was de-glycosylated with PNGase F and reduced to its monomeric 
state using DTT. (B) Table showing peptide sequences and observed vs. expected molecular 
weights of expression products. PLP sequence = H3N+-HSLGKWLGHPDKF, LABL sequence = 
H3N+-ITDGEATDSG. (C) SDS-PAGE of PLP-Fc-LABL reduced with DTT. Lanes: 1, 2-212 
kDa MW marker and 2, PLP-Fc-LABL after purification by protein G affinity chromatography. 
(D) Representation of PLP-Fc-LABL dual fusion protein showing sites of proteolysis that were 






Figure A.1.5: Characterization of recombinant expression of PLP-Fc-LABL dual fusion protein 
in a fermentor. (A) Mass spectrum of PLP-Fc-LABL expression products. Prior to 
characterization, the protein was de-glycosylated with PNGase F and reduced to its monomeric 
state using DTT. (B) Table showing peptide sequences and observed vs. expected molecular 
weights of expression products. PLP sequence = H3N+-HSLGKWLGHPDKF, LABL sequence = 
H3N+-ITDGEATDSG. (C) SDS-PAGE of PLP-Fc-LABL reduced with DTT. Lanes: 1, 10-200 
kDa MW marker; 2, PLP-Fc-LABL after purification by protein G affinity chromatography; 3, 
PLP-Fc-LABL de-glycosylated with PNGase F; and 4, PNGase F. (D) Representation of PLP-







Figure A.1.6: Characterization of recombinant expression of PLP-Fc-LABL dual fusion protein 
in a spinner flask with a media change prior to induction. (A) Mass spectrum of PLP-Fc-LABL 
expression products. Prior to characterization, the protein was de-glycosylated with PNGase F 
and reduced to its monomeric state using DTT. The peak with the observed MW of 26498.0 Da 
was determined to be carryover from an unrelated protein sample and was excluded from the 
yield calculation. (B) Table showing peptide sequences and observed vs. expected molecular 
weights of expression products. PLP sequence = H3N+-HSLGKWLGHPDKF, LABL sequence = 
H3N+-ITDGEATDSG. (C) SDS-PAGE of PLP-Fc-LABL reduced with DTT. Lanes: 1, 2-212 
kDa MW marker; and 2, PLP-Fc-LABL after purification by protein G affinity chromatography. 
(D) Representation of PLP-Fc-LABL dual fusion protein showing sites of proteolysis that were 






Figure A.1.7: Characterization of recombinant expression of MOG-Fc single fusion protein in a 
spinner flask. (A) Mass spectrum of MOG-Fc expression products. Prior to characterization, the 
protein was de-glycosylated with PNGase F and reduced to its monomeric state using DTT. (B) 
Table showing peptide sequences and observed vs. expected molecular weights of expression 
products. MOG sequence = H3N+-GWYRSPFSRVVHL. (C) SDS-PAGE of MOG-Fc after 
purification from Protein G affinity chromatography. All samples were treated with DTT. Lanes: 
1, 2-212 kDa MW marker; 2, supernatant from culture media; 3, flow through from protein G 
affinity chromatography of supernatant from culture media; and 4-5 = elution fractions of MOG-
Fc from protein G affinity chromatography. (D) Representation of MOG-Fc single fusion protein 






Figure A.1.8: Characterization of recombinant expression of LABL-Fc-ST fusion protein in 
spinner flask. (A) Mass spectrum of LABL-Fc-ST from recombinant expression. Prior to 
characterization, the protein was de-glycosylated with PNGase F and reduced to its monomeric 
state using DTT. LABL-Fc-ST MW (Da): Expected = 27010.41, Observed = 27006.00. LABL 
sequence = H3N+-ITDGEATDSG and ST sequence = AAALPETGGG. (B) SDS-PAGE of 
LABL-Fc-ST after purification from protein G affinity chromatography. All samples were 
treated with DTT. Lanes: 1, 2-212 kDa MW marker; 2, supernatant from culture media; 3, flow 
through from protein G affinity chromatography of supernatant from culture media; 4-6, elution 
fractions of LABL-Fc-ST from protein G affinity chromatography; 7, LABL-Fc-ST treated with 






Figure A.1.9: LC-MS TIC overlay of LABL-Fc-ST-PLP before (black) and after (red) 
purification by protein G affinity chromatography and dialysis. Peaks corresponding to the 




















b-1,2-N-acetylglucosamine On The a-1,6-Arm Of The N-linked Glycan Of 
IgG1 Fc Increases Stability And FcgRIIIa Binding Affinity But Decreases 





A.2.1.1 Cloning, expression, and purification of glycotransferases and glycosidases 
The concentrations of the enzyme preps were determined using a Pierce BCA Protein 
Assay Kit (Thermo Scientific, Waltham, MA) according to manufacturer’s instructions. 
A.2.1.1.1 Mannosidase-I and endomannosidase 
An expression plasmid for mannosidase-I from Bacteroides thetaiotaomicron was 
provided by the Gilbert laboratory at New Castle University and expressed in E. coli Rosetta 2 
cells and purified in the Tolbert laboratory by Dr. Ishan Shah.1, 2 An endomannosidase (accession 
#: NM_080785) from rat was also cloned, expressed in E. coli Rosetta 2 (Novagen), and purified 
in the Tolbert laboratory by Dr. Shah.1  
A.2.1.1.2 GnT-I  
A GnT-I enzyme from human (MGC-2304) was cloned in the Tolbert laboratory by Dr. 
Mark Pawlicki, and it was expressed in E. coli Rosetta gami2(DE3) (Novagen) and purified by 
Dr. Khalid Al-Kinani as previously described.3  
A.2.1.1.3 Mannosidase-II 
A mannosidase-II from mouse was cloned and transformed into P. pastoris KM71H 
strain (Invitrogen) in the Tolbert laboratory by Dr. Hamilton (unpublished procedure, can be 
found in Hamilton dissertation). The cells were grown in a shake tube containing 2 mL YPD 
media and 100 µg/mL zeocin at 25ºC and shaken at 250 rpm. After 3 days, the culture was 
transferred to a 250 baffled Erlenmeyer flask containing 50 mL YPD media and 100 µg/mL 
zeocin and grown at 25ºC and shaken at 250 rpm. After 2 days, the culture was transformed to a 
1 L spinner flask containing 1% yeast extract, 2% tryptone, 2% glycerol, 100 mM potassium 
phosphate buffer pH 6.2, 1.34% yeast nitrogen base, 0.00004% biotin, 0.004% histidine, and 1 
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drop Antifoam 204. The culture was stirred on a stir plate at r.t. with an air flow of 3 L/min. 
After 2 days, the pH of the culture was adjusted to 6.2 using NH4OH. Also, an additional 0.004% 
histidine was added, and induction was started by adding 0.5% methanol. Induction was 
maintained by adding 0.5% methanol every 12 hours for 2.5 days. After induction, the cultures 
were harvested by centrifugation at 6693 x g for 20 min using a Beckman JLA 10.5 rotor and 
Beckman Avanti J-series centrifuge (USA).  
The pellet was resuspended in approximately 100 mL of 100 mM potassium phosphate 
buffer pH 7.5. The resuspension was then mixed with 50% (v/v) glass beads and subjected to 7 
cycles of the following: 1 min bead beating (Biospec Products, Bartlesville, OK) and 20 min 
cool down on ice. The lysate was filtered through a cheese cloth and centrifuged at 27,216 x g 
for 30 min at 4°C using a Beckman JA-20 rotor and Avanti J-series centrifuge. The supernatant 
was saturated to 50% with (NH4)2SO4 and slowly stirred overnight at 4ºC. The precipitate was 
centrifuged at 48,384 x g for 30 min at 4°C using a Beckman JA-20 rotor and Avanti J-series 
centrifuge. The pellet was resuspended in approximately 50 mL of 10 mM potassium phosphate 
buffer pH 7.5 and dialyzed in 4 L of 10 mM potassium phosphate buffer pH 7.5 at 4°C with 1 
buffer change. An anion exchange column containing 50 mL of Toyopearl DEAE-650M resin 
(King of Prussia, PA) was equilibrated with 10 CV of 10 mM potassium phosphate buffer pH 
7.5. The dialyzed protein was loaded, and then the proteins were separated using a linear gradient 
of 0-500 mM NaCl in 10 mM potassium phosphate buffer pH 7.5 over 10 CV at a flow rate of 
0.5 mL/min. The fractions were screened for mannosidase-II activity mixing each fraction with 
100 mM p-nitrophenol-mannose in 100 mM MES buffer pH 5.6 in a fraction:substrate volume 
ratio of 1:10. The fractions were incubated at 37°C for 1 hr. The fraction that showed the most 
intense yellow color was confirmed for mannosidase-II activity by mixing the fractions with 0.3 
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mg/mL M5H-IgG1 Fc in 20 mM MES buffer pH 6.0 at a fraction:M5H-Fc volume ratio of 1:10 
and checking for the presence of M3H-IgG1 Fc after 2 hrs using intact mass spectrometry.  
A.2.1.1.4 GnT-II 
The gene sequence for a mammalian GnT-II was codon optimized for expression in yeast 
by Dr. Tolbert, synthesized by GenScript (Piscataway, NJ), cloned into pPICzaA by Dr. Tolbert, 
and then expressed in glycosylation-deficient strain of P. pastoris (OCH1 deleted)4 and purified 
by Dr. Al-Kinani (unpublished procedure, can be found in Hamilton dissertation).  
A.2.1.1.5 FUT8 
An a1,6-fucosyltransferase (FUT8) from mouse was cloned into a pET30a expression 
plasmid and transformed into E. coli SHuffle strain (New England BioLabs, Ipswich, MA) in the 
Tolbert laboratory by Dr. Al-Kinani (unpublished procedure, can be found in Al-Kinani 
dissertation). FUT8 used in 3.2.3.6 and 3.2.10.5 was prepared as previously described 
(unpublished procedure, can be found in Al-Kinani dissertation). FUT8 used in 3.2.10.1-3.2.10.4 
was prepared as follows: The E. coli SHuffle strain containing pET30a-FUT8 and pRARE 
(Novagen) was inoculated in a shake tube containing 5 mL LB media, 35 µg/mL 
chloramphenicol, and 37 µg/mL kanamycin and grown at 30ºC overnight. The 5 mL culture was 
transferred to a shake flask containing 1 L of LB media, 25 µg/mL chloramphenicol, and 37 
µg/mL kanamycin and grown at 30ºC. After 6 hrs, 0.2 mM isopropyl b-d-1-thiogalacopyranoside 
was added, and the culture was grown at 16ºC overnight. The culture was centrifuged at 11,899 x 
g for 20 min at 4°C using a Beckman JLA 10.5 rotor and Avanti J-series centrifuge (USA). The 
supernatant was discarded, and the pellet was resuspended in 50 mM sodium phosphate buffer 
pH 7.5 and sonicated using a Fisher Scientific sonicator at 60% amplitude. Sonication was 
performed on ice, with 10 sec sonication followed by 50 sec of no sonication for a total of 30 
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min (5 min total sonication). The lysate was immediately centrifuged at 27,216 x g for 30 min at 
4°C using a Beckman Avanti J-series centrifuge. The supernatant was filtered through a cotton 
plug and then FUT8 was purified from the lysate using Ni-NTA affinity chromatography. First, 2 
mL of Ni-NTA-agarose resin was washed with 25 CV of sodium phosphate buffer pH 7.5. Next, 
the lysate was passed through. Then the column was washed with wash buffer (50 mM sodium 
phosphate buffer pH 7.5, 500 mM NaCl, 5% glycerol, 10 mM imidazole). The FUT8 was eluted 
using 50 mM sodium phosphate buffer pH 7.5 containing 250 mM imidazole. 1.5 mL fractions 
were collected and screened for fucosylation activity using intact mass spectrometry with the 
M3H-IgG1 Fc glycoform substrate (0.5 mg/mL M3H-Fc, 0.5 mM GDP-fucose, 1% (v/v) FUT8, 
20 mM MES buffer pH 7.0, r.t.). Additionally, the fractions were screened for background 
activity in the PK/LDH coupled enzyme assay as described in 3.2.10.1 (no glycan, 1%(v/v) 
FUT8). The fraction that showed the most M3HF-IgG1 Fc after 21 hrs with the least amount of 
background activity was pipetted into 6-8 kDa MWCO dialysis tubing and dialyzed in 2 L of 
TBS pH 7.5 at 4°C with 1 buffer change. The enzyme was then mixed with 50% glycerol and 
stored at -20°C.  
 
A.2.2 Results 
A.2.2.1 Production of FcgRIIIa 
FcgRIIIa was expressed in a glycosylation-deficient yeast strain of P. pastoris (deleted 
och1, pno1, and bmt 1&2 genes and inserted STT3D gene from L. major in order to improve N-
glycosylation site occupancy).1, 4, 5 The extracellular region contains 5 N-glycosylation sites 
(Figure A.2.7). Expression and purification by Ni-NTA affinity chromatography showed both 
tetra- and penta-N-glycosylation by SDS-PAGE analysis (Figure A.2.7A). In order to make the 
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receptor more homogenous, it was further purified using HIC. After polishing by HIC, fully 
penta-glycosylated FcgRIIIa was obtained as determined by the presence of a single band on 
SDS-PAGE. For use in receptor binding studies, the receptor was biotinylated on its C-terminus 
using a sortase-mediated ligation (Figure A.2.7B). A biotin compound containing an N-terminal 
triglycine was synthesized previously in the Tolbert laboratory by Dr. Shaofeng Duan.6 It was 
reacted with FcgRIIIa in the presence of sortase, which was also produced previously in the 
Tolbert laboratory.7 Sortase is a transpeptidase that has been used extensively in literature for the 
C-terminal ligation of a variety of molecules including proteins, peptides, molecular probes, 
nucleic acids, sugars, solid supports, and others.8-10 The ligation required that FcgRIIIa contain 
the C-terminal sortase recognition sequence (GGLPETGGG), and the biotin contain a glycine 
with the N-terminus exposed. After the ligation, FcgRIIIa-biotin was purified from the sortase as 
well as from any unbiotinylated FcgRIIIa using Ni-NTA affinity chromatography by collecting 






Figure A.2.1: Characterization of homogenous IgG1 Fc N-glycoforms under non-reducing 
conditions. Shown for each N-glycoform is an intact mass spectrum, representation of the N-
glycoform, and the expected MW of the N-glycoform. (A) M5, (B) M5H, (C) M3H, (D) G0, (E) 
M5HF, (F) M3HF, and (G) G0F.  
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Figure A.2.2: Characterization of IgG1 Fc after de-glycosylation using PNGase F. (A) Intact 
mass spectrum of IgG1 Fc after purification by Protein A affinity chromatography. (B) SDS-
PAGE of IgG1 Fc. Lanes: 1, 10-200 kDa MW protein marker; 2, IgG1 Fc after purification by 
protein A affinity chromatography; and 3, de-glycosylated IgG1 Fc. (C) Intact mass spectrum of 
de-glycosylated IgG1 Fc. (D) Representation of de-glycosylated IgG1 Fc. All samples were 
reduced with DTT prior to analysis. Expected MW of IgG1 Fc species (Da): non-glycosylated = 




Figure A.2.3: Analysis of the synthesis of GDP-fucose using IPC. Signal was observed using 
UV/VIS Spectrophotometry at 254 nm. (A) Before reaction: contains ATP and fucose but no 
FKP, (B) After completion of step 1, (C) After completion of step 2, (D) After treatment alkaline 
phosphatase, (E) After purification using SEC. (F) Reaction scheme showing FKP-mediated 




Figure A.2.4: IPC chromatograms of standards that were used to identify peaks during synthesis 
of GDP-fucose. Signal was observed using UV spectrophotometry at 254 nm. (A) ADP, (B) 




Figure A.2.5: Comparison of IgG1 Fc N-glycoforms using analytical SEC. The reported % 
Monomer and % Soluble Aggregate values are the average of triplicate runs ± standard error. 
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Figure A.2.6: Comparison of IgG1 Fc N-glycoforms using OD350. The reported Tonset values are 




Figure A.2.7: Characterization of the purification and biotinylation of FcgRIIIa. (A) SDS-PAGE 
of FcgRIIIa. Lanes: 1, FcgRIIIa after Ni-NTA affinity chromatography; 2, FcgRIIIa after HIC; 3, 
FcgRIIIa after C-terminal biotinylation using a sortase-mediated ligation and subsequent 
purification by Ni-NTA affinity chromatography; and 4, 10-200 kDa MW protein marker. (B) 




Figure A.2.8: Intact mass spectra of de-glycosylated IgG1 Fc N-glycoforms using PNGase F. 
Shown are de-glycosylated IgG1 Fc samples from starting substrates of (A) M5H, (B) M3H, and 
(C) G0. Expected MW of de-glycosylated IgG1 Fc = 25067.5 Da. All samples were reduced with 





Figure A.2.9: Fucosylation of IgG1 Fc-bound N-glycoforms vs. time. The fucosylation reactions 
were monitored by intact mass spectrometry, and the % fucosylated was determined by 
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Appendix 3  
 
Controlled Assembly Of Multivalent IgG1 Fc – Polyacrylamide Conjugates 





A.3.1.1 Cloning of His6-TEV-Gly3-IL1ra 
IL1ra (MGC: 10430) was PCR-amplified using primers (forward: 5'-
ggcccgggatccgaaaacctgtatttccagggcggtggcatgcgaccctctgggagaaaatcc and reverse: 5'-
gcgccgctcgagttactcgtcctcctggaagtagaatttg) that added a hexahistidine tag followed by a TEV 
recognition sequence followed by two additional glycine residues to the N-terminus. The PCR 
product was digested with the restriction endonucleases BamHI-HF and XhoI. A pET28a 
expression vector (Novagen) was digested with the same restriction endonucleases. The digested 
IL1ra construct and expression vector were ligated together using T4 DNA Ligase and 
transformed into electrocompetent E. coli Top10f’ cells using electroporation. The transformed 
cells were plated on LB agar containing 37 µg/mL of kanamycin and incubated at 37°C 
overnight. The DNA was extracted from the cells using the QIAprep Spin Miniprep Kit, and the 
sequence was confirmed by the UC-Berkeley DNA Sequencing Facility. The plasmid was then 
transformed into electrocompetent E. coli Rosetta 2 cells (Novagen) using electroporation and 
plated on LB agar containing 37 µg/mL of kanamycin and incubated at 37°C overnight. 
A.3.1.2 Expression and purification of His6-TEV-Gly3-IL1ra 
The His6-TEV-Gly3-IL1ra was expressed in E. coli Rosetta 2 cells and purified by Ni-
NTA affinity chromatography using a similar procedure as previously described.1 Also, an 
expression construct for TEV protease was prepared previously in the Tolbert laboratory, and it 
was expressed and purified as previously described.1 130 mg/L of His-TEV-Gly3-IL1ra was 
obtained. Lastly, His6-TEV-Gly3-IL1ra was reacted with TEV protease to produce Gly3-IL1ra 
using a similar procedure as previously described.1  
A.3.1.3 Sortase ligation of Gly3-IL1ra to AM-ST co-polymers 
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Several reactions were prepared on 50 µL scale which all contained following reaction 
conditions: 500 µM Gly3-IL1ra, 2 mM CaCl2, and 10 µM Sortase A in TBS pH 7.5. 
Additionally, they contained AM-ST co-polymers (Table 4.1) as follows: no co-polymer, 125 
µM #1, 125 µM #2, 5 µM #3, 25 µM #3, 125 µM #3, and 600 µM #3. The reactions were 
incubated at 37°C for 24 hrs and analyzed using SDS-PAGE. 
The two reactions containing 125 µM and 600 µM AM-ST co-polymer #3 were 
combined, and the Gly3-IL1ra-polymer conjugate was separated from the free Gly3-IL1ra using 
SEC. 20 mL of Bio-Rad Bio-Gel P100 was equilibrated with 5 CV H2O. Then the polymerized 
mixtures were pipetted onto the volume. Next, H2O was passed through the column at a flow rate 
of approximately 0.3 mL/min. 1.5 mL fractions were collected. Fractions that showed signal at 





Figure A.3.1: Characterization of Gly5-IgG1 Fc with the M5 N-glycoform under non-reducing 
conditions. (A) Intact mass spectrum of the Gly5-IgG1 Fc with the M5 N-glycoform. (B) Intact 
mass spectrum of Gly5-IgG1 Fc after digestion with PNGase F. (C) Table showing observed vs. 





Figure A.3.2: Characterization of de-glycosylated Gly5-IgG1 Fc. (A) Intact mass spectrum of 
Gly5-IgG1 Fc (originally containing M5 N-glycoform) after de-glycosylation using PNGase F. 
The sample was reduced with DTT before analysis. De-glycosylated Gly5-IgG1 Fc: Expected 
MW (Da) = 25352.7, Observed MW (Da) = 25348.7; M1-Gly5-IgG1 Fc: Expected MW (Da) = 
25514.8, Observed MW (Da) = 25510.7; M2-Gly5-IgG1 Fc: Expected MW (Da) = 25677.0, 





Figure A.3.3: SDS-PAGE of small-scale, sortase-mediated ligations of Fc to the AM-ST co-
polymer under non-reducing conditions. Lanes: 1, 10-200 kDa MW protein marker; 2, Fc; 3, 
sortase A; 4, AM-ST co-polymer; 5-9, sortase-mediated ligations of Fc to AM-ST co-polymer: 
[AM-ST co-polymer] (µM): Lane 5 = 0, Lane 6 = 0.02, Lane 7 = 0.04, Lane 8 = 1, Lane 9 = 5. In 
order to obtain resolution in different size ranges, the samples were analyzed on gels prepared 




Figure A.3.4: SDS-PAGE of fractions during purification of Fc-polymer conjugate by SEC. 
Lanes: 1-5 are SEC fractions from earliest to latest elution that contained polymer and very little 
monomer. These fractions were pooled and constituted the Fc-polymer conjugate sample. All 





Figure A.3.5: Representative equilibrium binding curve Fc to FcgRIIIa. Reported KD is the 





Figure A.3.6: Characterization of Gly3-IL1ra. (A) Representation of cleavage to expose N-
terminal tri-glycine by TEV protease. IL1ra was expressed with an N-terminal hexa-histidine tag 
(green), followed by a TEV protease (red) tag with a glycine residue at the P1’ position, 
followed by two additional glycine residues (yellow). Cleavage by TEV protease cleaves 
between the glutamine and glycine within the protease recognition sequence to expose a glycine 
on the N-terminus of IL1ra. (B) SDS-PAGE of Gly3-IL1ra before and after cleavage by TEV 
protease. Lanes: 1, 2-212 kDa MW protein marker; 2, His6-TEV-Gly3-IL1ra; 3, His6-TEV-
Gly3-IL1ra + TEV protease reaction mixture; 4, Gly3-IL1ra after purification by Ni-NTA 
affinity chromatography; 5, Elution fraction of the purification by Ni-NTA affinity 
chromatography of Gly3-IL1ra from TEV protease reaction; and 6, TEV protease. The SDS-
PAGE gel was prepared using 12% Acrylamide. (C) Intact mass spectrometry of Gly3-IL1ra. 





Figure A.3.7: SDS-PAGE of small-scale, sortase-mediated ligation of Gly3-IL1ra to AM-ST co-
polymers. In order to obtain resolution in different size ranges, the samples were analyzed on 
gels prepared with both (A) 6% and (B) 12% acrylamide. Lanes: 1, 2-212 kDa MW protein 
marker; 2, sortase A; 3, Gly3-IL1ra; 4-9, Sortase-mediated ligation of Gly3-IL1ra to AM-ST co-
polymer using: 4, no co-polymer; 5, 25 µM #3; 6, 125 µM #3; 7, 600 µM #3; 8, 125 µM #1; 9, 





Figure A.3.8: SDS-PAGE of fractions of Gly3-IL1ra-polymer conjugate purification by SEC. 
Lanes: 1 & 11, Sortase-mediated polymerization reaction of Gly3-IL1ra using 125 µM AM-ST 
co-polymer #3; 2 & 12, Gly3-IL1ra monomer; 3-10 & 13-20, SEC fractions of Gly3-IL1ra-
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